# Diagnósticos da América S.A.

*(Publicly-held company)*

**Individual and consolidated financial statements December 31, 2021**

*(A free translation of the original report in Portuguese, as filed with the Brazilian Securities Commission (CVM), containing individual and consolidated financial statements prepared in accordance with the accounting practices adopted in Brazil and in accordance with International Financial Reporting Standards (IFRS) issued by International Accounting Standards Board - IASB)*

KPDS 1023779

# Contents

| | |
|---|---|
| **Management Report** | **3** |
| **Independent auditors' report on the individual and consolidated financial statements** | **15** |
| **Balance sheets** | **22** |
| **Statements income** | **23** |
| **Statements of comprehensive income** | **24** |
| **Statements of changes in shareholders' equity** | **25** |
| **Statements of cash flows** | **26** |
| **Statements of value added** | **27** |
| **Notes to the financial statements** | **28** |
| **Audit Committee’s Opinion** | **127** |
| **Statement of the Executive Officers on the Financial Statements** | **128** |
| **Statement of the Executive Officers on the Independent Auditor’s Report** | **129** |

# FINANCIAL PERFORMANCE

## Gross operating revenue

The Dasa Group's consolidated gross revenue in the fourth quarter of 2021 reached R$ 2,902 million, representing an increase of 19.9% compared to 4Q20. In the 12-month period of 2021, gross revenue totaled R$ 11,231 million, an increase of 46.6% when compared to the same period in 2020, when we reached R$ 7,642 million. This growth in the twelve-month period reflects: recovery of patients' volume in the Company's business segments, which was strongly impacted by the COVID-19 pandemic in 2020; (ii) new acquisitions in the period; and (iii) revenue from the strategy of patient navigation within the ecosystem.

## Costs and gross income

In the fourth quarter of 2021, the costs of services provided totaled R$ 2,000 million, equivalent to 74.8% of net operating revenue, accounting for an increase of 26.4% when compared to the costs of the fourth quarter of the previous year. In the fourth quarter of 2021, gross income reached R$ 673 million, an increase of 4.2% compared to the same period of 2020, when we reached gross income of R$ 645 million.

In the twelve months of 2021, the costs of services provided totaled R$ 7,301 million, equivalent to 70.1% of net revenue, accounting for an increase of 38.3% compared to the same period of the previous year. Gross income reached R$ 3,117 million, representing an increase of 77.6% compared to the same period of previous year, which was R$ 1,775 million.

## General and administrative expenses

General and administrative expenses totaled R$ 721 million in the fourth quarter of 2021, representing 27.0% of net operating revenue. In relation to the fourth quarter of 2020, there was an increase of 23.1% and, in that quarter, expenses represented 26.3% of net operating revenue. In the twelve months of 2021, operating expenses totaled R$ 3,066 million, equivalent to 29.4% of net revenue, accounting for an increase of 87.6% compared to the same period of the previous year, which totaled R$ 1,634 million. The increase in expenses is explained by: (i) personnel expenses, (ii) provision for profit sharing and bonuses, and (iii) stock option plan. This last impact was negative by R$ 39 million in the fourth quarter of 2021 and by R$ 88 million in the twelve months of 2021.

## EBITDA

We reached an EBITDA of R$ 223 million in the fourth quarter of 2021, which accounts for a decrease of 23.1% in relation to the amount of R$ 290 million in the same period of the previous year. In this quarter of 2021, we reached a margin of 8.3%, compared to the 13.0% margin in the fourth quarter of previous year. In the twelve months of 2021, EBITDA reached R$ 1,018 million, which accounts for an increase of 9.2% in relation to the same period of the previous year.

**EBITDA**

Income before interest, taxes, depreciation and amortization.

| In millions of R$ | 4721 | 4720 | △ % | Accumulated 2021 | Accumulated 2020 | △ % |
|---|---|---|---|---|---|---|
| Net income (loss) for the period | **(166.8)** | **24.1** | N.A. | **(216.9)** | **(147.7)** | **46.8%** |
| (+) Income tax and social contribution | (43.9) | (35.6) | 23.3% | (157.3) | (71.7) | 119.4% |
| (+) Net financial | 171.5 | 71.9 | 138.5% | 462.7 | 385.8 | 19.9% |
| (+) Depreciation and amortization | 262.1 | 229.6 | 14.2% | 929.8 | 765.6 | 21.4% |
| EBITDA (R$ MLN) | **222.9** | **290.1** | **-23.1%** | **1,018.3** | **932.1** | **9.2%** |
| EBITDA margin (%) | **8.3%** | 13.0% | **-4,7D.D.** | **9.8%** | 13.2% | **-3.5 DD** |
| Acquired pro forma EBITDA | | | | 263.2 | 24.6 | - |
| Adjusted EBITDA (R$ MM)* | | | | **1,281,5** | **956,7** | |

** Acquirees' adjusted EBTDA as if acquisition date for business combination was at the beginning of the year.*

## Financial income (loss)

In the 4Q21, a net negative financial outcome of R$ 171 million was recorded, compared to negative outcome of R$ 72 million in the 4Q20, an increase of 138.2%. In the twelve months of 2021, the amount of R$ 463 million was recorded as net negative financial result, compared to R$ 386 million in the same period in 2020, a decrease of 19.9%.

## Income tax and social contribution

Income tax and social contribution was R$ 44 million in the fourth quarter of 2021, compared to R$ 36 million in the fourth quarter of prior year. In the twelve months of 2021, the taxes caption was positive by R$ 157 million, compared to a positive result of R$ 72 million in the same period of the previous year.

## Net income (loss)

In the fourth quarter of 2021, we had losses of R$ 167 million, compared to net income of R$ 24 million reported in the same period of prior year. In the twelve months of 2021, losses were R$ 217 million, compared to losses of R$ 148 million in the same period of prior year.

## Cash and interest earning bank deposits

We ended the fourth quarter of 2021 with a cash position and highly liquid interest earning bank deposits in the amount of R$ 3,614 million, an increase of 138.6% compared to December 31, 2020. The increase was justified by the subsequent public offering that took place in April 2021.

## Investments

Net CAPEX investments totaled R$ 397.2 in the fourth quarter of 2021. In the twelve months of 2021, net CAPEX investments totaled R$ 1,020.9 million. The investments for the period were mainly directed to: (i) implementation and development of the production and service systems and renovation of the technology park, in the amount of R$ 181.7 million in the quarter and R$ 392.7 million in the twelve-month period, (ii) renovation and expansion of existing care units and new units, in the amount of R$ 113.6 million in the quarter and R$ 401.0 million in the nine-month period and (iii) purchase of medical equipment and other in the amount of R$ 101.9 million in the quarter and R$ 227.2 million in the twelve-month period.

## Indebtedness

| *Dasa Group's net debt totaled R$ 3,998.8 million in 4Q21, compared to R$ 3,766.5 million in 4Q20.* | | | |
|---|---|---|---|
| | | *4Q21* | *4Q20* |
| CURRENT LIABILITIES | Loans and financing | 1,090,652 | 200,194 |
| | Debentures | 1,004,582 | 145,720 |
| | Derivative financial instruments | 12,364 | 1,856 |
| NON-CURRENT LIABILITIES | Loans and financing | 494,634 | 1,001,621 |
| | Debentures | 5,056,978 | 3,991,288 |
| | Derivative financial instruments | 7,934 | 5,603 |
| **CURRENT ASSETS** | (-) Derivative financial instruments | (22,626) | (26,201) |
| **NON-CURRENT ASSETS** | (-) Derivative financial instruments | (41,677) | (39,203) |
| Total gross debt = A | | **7,602,843** | **5,280,878** |
| Cash and Interest Earning Bank Deposits = B | | (3,614,058) | (1,514,423) |
| **Net Debt (A + B) =** | | **3,988,785** | **3,766,455** |

# RELEVANT EVENTS IN THE YEAR

## Election of Officer

On January 4, 2021, Dasa Group's Board of Directors elected Mr. Fabio Rose to serve as Chief People and Culture Officer at Dasa Group.

## Acquisition of Innova (completed)

On January 6, 2021, Dasa Group announced that on that date it had competed – through Ímpar Serviços Hospitalares S.A., a wholly-owned subsidiary of Dasa Group and a privately-held company – the acquisition of 100% (one hundred percent) of the shares representing the total capital of Innova Hospital Associados Ltda., a limited liability company; as a result, said Company is now wholly owned by Dasa.

## Acquisition of Gesto (completed)

On January 15, 2021, Dasa Group informed its shareholders and the market in general that it had concluded Dasa's acquisition of all of the shares held by the Sellers representing 100% (one hundred percent) of the capital of Gesto Saúde (Gesto Saúde Sistemas Informatizados, Consultoria Médica e Corretora de Seguros Ltda.).

## Director resignation

On January 27, 2021, the Dasa Group's Board of Directors was informed of the resignation request submitted by Mr. Diego Alvarez Araujo Correia, Information Technology Chief Officer of Dasa Group, and stated that his resignation was effective as of the end of December 18, 2020.

## Election of Director

On February 5, 2021, Dasa Group's Board of Directors elected Ms. Ana Elisa Alvares Correa de Siqueira to serve as Chief Officer of Integrated Care Operations; Ms. Andréa Rezende Dolabela as Chief Officer of Products and Marketing; Mr. Sérgio Ricardo Rodrigues de Almeida Santos as Chief Strategy Officer; and Mr. Adam Oliveira Alves as Chief Commercial Officer.

## Migration in the Novo Mercado

On February 23, 2021, the Extraordinary General Meeting of shareholders representing 98.5753% (ninety-eight point five-seven-five-three percent) of the voting capital of Dasa Group, decided – by unanimous vote of the attending shareholders, with no abstentions or votes against, and without reservations, with 473,873,274 (four hundred seventy-three million, eight hundred seventy-three thousand, two hundred seventy-four) votes in favor, corresponding to 98.5753% (ninety-eight point five-seven-five-three percent) of the voting capital of Dasa Group – approved the submission of Dasa Group's application for migration to the Novo Mercado of the B3 stock exchange.

## Seventh Issue of Promissory Note

On March 8, 2021, the 7th issue of PN was settled by Dasa Group, as the issuer of 500 (five hundred) commercial promissory notes of Dasa Group's seventh issue amounting to R$ 500 million. The term of promissory notes will be one hundred and eighty (180) days as of the date of issue.

## Acquisition of Hospital São Domingos (concluded)

On March 12, 2021, Dasa Group announced that on that date, by means of Ímpar Serviços Hospitalares S.A., a wholly-owned subsidiary of Dasa Group and a privately-held company – the acquisition of 100% (one hundred percent) of the shares representing the capital of São Domingos Group, including the shareholdings of Hospital São Domingos Ltda., Neuro imagens Ltda., and Clínica Solução Médica Ltda.

## Public Offering

On March 23, 2021, Dasa Group's Board of Directors conducted a public offering for primary and secondary distribution of up to 68,412,943 common shares, all registered, book-entry and without par value, unobstructed and clear of any liens or encumbrances ("Shares"), issued by Dasa Group, without prejudice to the Additional Shares (as defined in the Resolutions), with restricted placement efforts, to be conducted in the Federative Republic of Brazil ("Brazil"), under Brazilian Securities and Exchange Commission ("CVM") Instruction 476 of January 16, 2009, as amended ("CVM Instruction 476"), with efforts to place Shares abroad ("Restricted Offer"); such issue will be carried out within the limit of authorized capital provided for in Article 6, introductory paragraph, of the Articles of Organization.

## Acquisition of Grupo Carmo (completed)

On April 1, 2021, the Company announced that on that date it concluded – through Ímpar Serviços Hospitalares S.A., a wholly-owned subsidiary of the Company and a privately-held company – the acquisition of 70% (seventy percent) of the shares representing the capital of Nossa Senhora do Carmo Participações S.A.

## Acquisition of Allbrokers (completed)

On April 07, 2020, the Company announced the completion of the acquisition of equity interest in addition to the notice to the market dated February 17, 2020, representing 100% of the capital of Allbrokers Brasil Corretora de Seguros Ltda. As the acquisition price exceeds the limits provided for in item II of Article 256 of Law 6404/76, the Acquisition was ratified by DASA's shareholders at a general meeting held on July 1, 2020.

## Sixth Issue of Promissory Note

On April 7, 2020, the 6th issue of the Promissory Note was issued by the Company, as the issuer of 130 commercial promissory notes of the sixth issue of the Company, totaling R$ 650 million. Promissory notes will have a period of five years from the date of issue; thus, maturing on April 07, 2022.

## 13th issue of debentures

On April 13, 2020, the Company's 13th issue, in a single series, of 365,000 simple debentures, not convertible into shares, of the unsecured type in the amount of R$ 1,000 million was settled. Debentures will have a period of three years from the date of issue; thus, maturing on April 13, 2023.

## Election of Board Members

On April 28, 2020, the shareholders present at the Annual General Meeting unanimously approved the candidates presented on March 26, 2020 by the Controlling Shareholders, with the consequent election of the members of the Board of Directors appointed by them, namely: (a) Romeu Côrtes Domingues, as Co-Chairman of the Board of Directors; (b) Oscar de Paula Bernardes Neto, as Vice-Chairman of the Board of Directors; (c) Dulce Pugliese de Godoy Bueno, as Co-Chairman of the Board of Directors; (d) Alexandre de Barros; (e) Henrique Lourenço Grossi; and (f) George Schahin, as member of the Board of Directors.

The members of the Company's Board of Directors will exercise their terms of office until the Annual General Meeting that will examine the financial statements for the year 2022.

## Merger - Insitus

On May 3, 2021, DASA Group communicated to its shareholders and the market in general that it had completed the take-over of the entire ownership equity of DASA's subsidiary, Insitus Serviços Médicos e Laboratoriais Ltda., a limited liability company, with registered offices in the city of Sao Paulo.

## Acquisition of Grupo CASE (completed)

On May 25, 2021, Grupo DASA communicated that it concluded, on this date, through ALLBROKERS Brasil Corretora de Seguros Ltda., subsidiary of the Company, an Agreement for the Purchase and Sale of Quotas and Shares and Other Covenants for the acquisition of 100% (one hundred percent) of quotas or shares (as the case may be) of the total capital of the following companies ("Transaction"): Brasilidade Soluções Corporativas em Corretagem de Seguros Ltda., limited-liability company ("Brasilidade"), Dinâmica Administração e Corretagem de Seguros Ltda., limited-liability company ("Dinâmica"), Aeroseg Corretagem de Seguros Ltda., limited-liability company ("Aeroseg") "), Carvalho & Motta Corretora de Seguros Ltda., limited-liability company ("Carvalho & Motta"), Chase Assessoria Empresarial Ltda., limited-liability company ("Chase"), Case TBI Administração e Corretagem de Seguros Ltda., limited-liability company ("Case TBI"), GCSP Consultoria e Corretagem em Benefícios e Seguros Ltda., limited-liability company ("GCSP"), TBI Corretora de Seguros Ltda., limited-liability company ("TBI"), Case - Central de Administração de Planos de Saúde Ltda., company ("Case Administração" and, together with TBI, GCSP, Case TBI, Chase, Carvalho & Motta, Aeroseg, Dinâmica and Brasilidade are to be referred as "Grupo Case"), and Itech Care - Assessoria Empresarial em Tecnologia S.A., a business corporation ("Itech"). Grupo Case is focused on insurance brokerage in property and casualty lines.

## Acquisition of HBA (completed)

On June 1, 2021, Grupo DASA announced the acquisition, through Ímpar Serviços Hospitalares S.A. ("Ímpar"), wholly-owned subsidiary of Grupo DASA and privately-held corporation, of up to 100% (one hundred percent) of shares representing total capital of HBA S.A. - Assistência Médica e Hospitalar ("HBA") - Corporation. The completion of the transaction is subject to the fulfillment of some conditions precedent, among which the following are included: (i) the approval of the terms and conditions of the Transaction by the Administrative Council for Economic Defense (CADE), pursuant to Law 12529, of November 30, 2011; and (ii) the approval by the general meeting for the implementation of the operations provided for in the contract entered into, based on the terms of paragraph 1 of article 256 of Law 6404/76.

## B3 Approval - Novo Mercado

The Company informs that, on June 16, 2021, received B3's approval for the Migration Request and that signed on this date, the Agreement for Participation in Novo Mercado. As a result, all provisions of the Company's bylaws whose effectiveness was conditioned to the signature of this instrument became fully effective. As of June 23, 2021, the Company's shares began to be traded in the Novo Mercado segment under code DASA3. The last trading day of shares in the Basic segment was June 22, 2021.

## Acquisition of AMO, GEM and PAQUEÁ companies (completed in early 2022 as disclosed in subsequent events )

On June 30, 2021, Grupo DASA communicated, through Ímpar Serviços Hospitalares S.A. ("Ímpar"), wholly-owned subsidiary of Grupo DASA and a privately-held corporation, the acquisition of (i) shares representing up to 100% of the capital issued by Paquetá Participações S.A. ("Paquetá"), and (ii) shares representing up to 100% of the capital issued by AMO Participações S.A. ("AMO", and jointly with Paquetá, "Target Companies"), legitimate and sole holders, together, of shares representing 41,900,181 common shares, 41,900,177 class I preferred shares and 55,866,905 class II preferred shares issued by GEM, as defined below, representing 99.69% of total capital and 100% of voting capital of GEM Assistência Médica Especializada S.A. ("GEM", and together with AMO Societies, "Target Companies"), a company engaged in the provision of oncology services (chemotherapy treatment, including outpatient procedures and tests, medical consultations related to oncology care lines, oncological outpatient treatment and oncological surgeries) in the states of Bahia, Sergipe and Rio Grande do Norte ("Acquisition") corporation.

The completion of the transaction acquisition is subject to the fulfillment of some conditions precedent, among which the following are included: (i) the approval of the terms and conditions of the Transaction by the Administrative Council for Economic Defense (CADE), pursuant to Law 12529, of November 30, 2011; and (ii) the approval by the general meeting for the implementation of the operations provided for in the contract entered into, based on the terms of paragraph 1 of article 256 of Law 6404/76.

## Acquisition of Centro de Tomografia por Computador (concluded)

On July 7, 2021, Dasa Group announced that it had acquired, on that date, 100% (one hundred percent) of the shares representing the total capital of Centro de Tomografia por Computador Ltda. ("Clínica CT"), a limited liability company, headquartered in the City of São Paulo.

## Acquisition of Marimed Serviços Médicos ("Hospital Paraná") (completed in early 2022 as disclosed in subsequent events)

On July 9, 2021, Dasa Group announced the approval by Ímpar Serviços Hospitalares S.A. ("Ímpar"), a wholly-owned subsidiary of Dasa Group and a privately-held company – of the acquisition of 100% (one hundred percent) of the shares representing the capital of the corporation Marimed Serviços Médicos S.A. ("Hospital Paraná")

## Election of Director

On August 2, 2021, the Company's Board of Directors elected Mr. Andrew Thomas Campbell, to occupy the position of Chief Investor Relations and Value Capture Officer of the Company.

## Acquisition of Grupo Leforte (completed)

On September 3, 2021, Dasa Group announced, in addition to the information disclosed in the Material Fact of December 3, 2020, that, pursuant to the Agreement for the Purchase and Sale of Shares and Other Covenants ("Agreement") through which the Company, through its wholly-owned subsidiary, Ímpar Serviços Hospitalares S.A., agreed to acquire shares representing 100% (one hundred percent) of the capital issued by Biodínamo Empreendimentos e Participações Ltda. ("Biodínamo"), the company that controls the hospital, outpatient, clinical and diagnostic services businesses of Grupo Leforte, including the equity interests of hospitals Leforte Liberdade, Leforte Morumbi and Hospital e Maternidade Dr. Christóvão da Gama ("Operation"), the Transaction was concluded on September 3, 2021, through the implementation of the closing acts provided for in the Agreement.

## Market Maker

On October 1, 2021, Dasa Group announced to its shareholders and the market in general that it had entered into an agreement with BTG Pactual Corretora de Títulos e Valores Mobiliários S.A., a corporation headquartered in the city of São Paulo at Avenida Brigadeiro Faria Lima, nº 3.477, 14º andar, partial, CEP 04538-133, enrolled with the CNPJ [EIN] 43.815.158/0001-22 ("Market Maker" or "BTG Pactual CTVM"), to exercise the function of market maker of the common shares of the Company in the environment of B3 S.A – Brasil, Bolsa, Balcão.

## 15th issue of debentures

On October 30, 2021, the Company's 15th issue in three series of 2,000,000 simple debentures, not convertible into shares, of the unsecured type in the unit value of R$ 1,000 was settled. Debentures will have a term of five years from the date of issue of 1st Series; thus, maturing on November 10, 2025 and seven years from the date of issue of 2nd Series, maturing on November 10, 2028 and ten years from the date of issue of 3rd Series; thus, maturing on November 10, 2031.

## Acquisition of Laboratório de Medicina S.A. (completed)

On November 18, 2021, Grupo Dasa announced the acquisition carried out by Diagnósticos Maipú per Imágenes S.A., a subsidiary of the Company located in the Republic of Argentina ("Diagnosticos Maipú"), of shares representing 100% (one hundred percent) of total capital of Laboratorio de Medicina S.A., a company duly established and existing in accordance with the legislation of the Republic of Argentina.

## Acquisition of MO Holding and Mantris (in progress)

On November 18, 2021, the Dasa Group announced, on this date, the acquisition carried out by the Company of shares representing 100% of the total capital of MO Holding S.A., a joint stock company, and quotas representing 100% of the total capital of Matris – Gestão em Saúde Corporativa Ltda., a limited liability company.

## Independent auditors' replacement

As of December 15, 2021, the Company's Board of Directors, in compliance with Article 31 of CVM Resolution 23 and to meet the rotation of independent auditors, approved the replacement of KPMG Auditores Independentes Ltda., enrolled with CNPJ [EIN] under number 57.755.217/0003-90 ("KPMG") by PricewaterhouseCoopers Auditores Independentes Ltda., enrolled with CNPJ [EIN] under number 61.562.112/0001 -20 ("PwC"). In view of Article 28 of CVM Resolution 23, the Company states that KPMG agreed with the change informed herein, in view of the aforementioned instruction; and the Company finally informs that PwC will start its activities as the Company's independent auditor as of January 1, 2022.

## Payment of interest on own capital (JCP)

On December 21, 2021, the Dasa Group communicated, on this date, the Shareholders and the Market in general that the Board of Directors, as proposed by the Executive Board, approved, *ad referendum* of the Ordinary General Meeting that deliberates on the financial statements related to the year ended December 31, 2021 ("Year 2021"), the distribution of interest on own capital, subject to the following conditions: The value of the distribution will be R$ 165,044,010.00, corresponding to the gross amount per share of R$ 0.30124582748. It will be based on the shareholding structure at the end of December 27, 2021, including the negotiations carried out on that date. The shares will be traded in the "ex" interest condition on own capital as of December 28, 2021, inclusive. Payment to shareholders will take place up to April 30, 2022.

## Acquisition of SALL S.A. (completed)

On December 28, 2021, Grupo Dasa communicates to its shareholders and the market in general, on this date, the acquisition carried out by the Company of shares representing 100% of the total capital of SALL Participações S.A., a corporation, in the city of Recife, State of Pernambuco, and of, indirectly, 99% of Sall's equity interest in CENTRO DE DIAGNÓSTICO BORIS BERENSTEIN LTDA., a limited liability company headquartered in the city of Recife, State of Pernambuco, ("CDBB" and, together with Sall, "Companies").

## Mergers of HSD shares

On December 30, 2021, the Dasa Group informs its shareholders and the market in general, in compliance with the provisions of Article 157, Paragraph 4, of Law 6404, of December 15, 1976 ("Corporate Law"), and in Article 2, Sole Paragraph, item VII, of CVM Resolution 44, of August 23, 2021, in addition to the Material Facts disclosed on March 15, 2021, December 3, 2021 and December 27, 2021, that, on this date, the acquisition and merger of, respectively, (i) 100% of the shares representing the capital of Andrade da Silva Participações S.A. ("Andrade da Silva") and (ii) 100% of the shares representing the capital of Mendes da Silva Participações S.A. ("Mendes da Silva" and, together with Andrade da Silva, the "Companies"), companies controlling the business of hospital, outpatient, medical services, clinical and diagnostic imaging of Grupo São Domingos, including the equity interests of Hospital São Domingos Ltd., Neuro Imagens Ltda. and Clínica Soluções Médica Ltda. ("Transaction"), considering the fulfillment (or waiver, as the case may be) of the precedent conditions set forth in the agreement for the purchase and sale of shares, merger of shares and other agreements related to the Transaction, among them, the approval of the Transaction by the Administrative Council for Economic Defense (CADE). As a result, as of that date, all matters approved at the Company's Extraordinary Shareholders' Meeting held on December 27, 2021, including the Merger of Shares, become valid and fully effective.

# RELEVANT SUBSEQUENT EVENTS

## Acquisition of AMO, GEM and PAQUEÁ Companies (completed)

On January 3, 2022, Grupo Dasa communicated through its wholly-owned subsidiary, Ímpar Serviços Hospitalares S.A., that it agreed to acquire (i) shares representing 100% of the capital issued by Paquetá Participações S.A. ("Paquetá" ), and (ii) shares representing 100% of the capital issued by AMO Participações S.A. ("AMO"), and, indirectly, 100% of the capital of GEM Assistência Médica Especializada S.A. ("GEM", and, together with Paquetá and AMO, "Companies").

## Acquisition of Marimed Serviços Médicos ("Hospital Paraná") (concluded)

As of March 15, 2022, the Dasa Group communicated, through its wholly-owned subsidiary, Ímpar Serviços Hospitalares S.A., that it agreed to acquire up to 100% of the shares representing the total capital of Marimed Serviços Médicos S.A. ("Hospital Paraná"), a publicly held company.

## Capital increase

On January 31, 2022, Dasa Group communicated to its shareholders and the market in general the approval by the Board, unanimously and without any qualifications or restrictions, of the capital increase, within the limit of the authorized capital, in the total amount of R$ 1.03, with the consequent issuance of 67,384 new registered book-entry common shares with no par value, fully subscribed and paid in on this date, in accordance with the subscription bulletins that are filed at the Company's headquarters. In view of the aforementioned capital increase, the Company's capital stock will increase from R$ 16,359,198,783.91, divided by 560,510,880 common shares, all nominative, book-entry and with no par value, to R$ 16,359,198,784.94, divided into 560,578,264 common shares, all nominative, book-entry and with no par value.

## Issuance of commercial note

On February 15, 2022, the Dasa Group announced to its shareholders and the market in general the settlement of the First Book-Entry Commercial Notes by the Company in a single series, in the total amount of R$ 2,000,000,000.00, in the terms of Law 14195 and the Brazilian Securities and Exchange Commission ("CVM") Instruction 476, of January 16, 2009, as amended ("Offer" and "CVM Instruction 476", respectively);

## Independent Audit

In conformity with CVM (Brazilian Exchange and Securities Commission) Instruction 381/03, we inform you that the Company adopts the formal procedure of consulting independent auditors KPMG Auditores Independentes Ltda. (KPMG) to make sure that provision of other services does not affect its independence and objectivity required to perform independent audit services. The Company's policy of hiring independent auditors ensures that there is no conflict of interest, loss of independence or objectivity. In the year ended December 31, 2021, KPMG provided audit services of the financial statements, charging fees of R$ 2,457 thousand, audit-related services for the issuance of reports on previously agreed procedures in relation to the Company's public offering of shares with fees of R$ 1,746 thousand, which represented 71.1% of the fees for external audit services, as well as non-audit services, with fees of R$ 930 thousand, which represented 37.9% of the fees for external audit services. We understand that such services do not represent a conflict of interest, loss of independence or objectivity of our independent auditors.

## Projections and non-accounting data

The assertions contained in this document related to business prospects, projections of operating and financial results, as well as those related to the Dasa Group's growth prospects, are merely projections and, as such, are based exclusively on the management's expectations about the future of the businesses. This performance report includes non-accounting data and accounting data such as, operational, financial and projections based on the expectations of the Dasa Group's management. Non-accounting data was not subject to audit by the independent auditors of Dasa Group.

## Additional information

The financial information is presented in millions of reais, unless otherwise indicated. The individual financial statements of the Dasa Group were prepared in accordance with accounting practices adopted in Brazil and consolidated in accordance with International Financial Reporting Standards (IFRS), as well as in accordance with accounting practices adopted in Brazil.

# STATEMENT OF THE EXECUTIVE BOARD

## Commitment clause

DASA Group is subject to arbitration in the court of arbitration of the market, pursuant to an arbitration clause contained in Article 35 of its bylaws.

## Statement of the Executive Board

In compliance with the provisions contained in CVM Instruction 480 of December 7, 2009, the Executive Board hereby states that it discussed, reviewed and agreed with the individual and consolidated financial statements, as well as the audit report of the independent auditors' review issued as to the respective individual and consolidated financial statements for the year ended December 31, 2021.

KPMG Auditores Independentes Ltda.
Rua Arquiteto Olavo Redig de Campos, 105, 6º andar - Torre A
04711-904 - São Paulo/SP - Brasil
Caixa Postal 79518 - CEP 04707-970 - São Paulo/SP - Brasil
Telefone +55 (11) 3940-1500
kpmg.com.br

# Independent auditors' report on the individual and consolidated financial statements

*(A free translation of the original report in Portuguese, as filed with the Brazilian Securities Commission (CVM), containing parent company and consolidated financial statements prepared in accordance with the accounting practices adopted in Brazil and in accordance with International Financial Reporting Standards (IFRS) issued by International Accounting Standards Board - IASB)*

To the Directors and Shareholders of

Diagnósticos da América S.A.

Barueri - SP

## Opinion

We have examined the individual and consolidated financial statements of Diagnósticos da América S.A. ("Company"), identified as Parent Company and Consolidated, respectively, comprising the balance sheet as of December 31, 2021 and the related statements of income, comprehensive income, changes in shareholders' equity and cash flows for the year then ended, as well as the corresponding notes, comprising the significant accounting practices and other explanatory notes.

### Opinion on the individual financial statements

In our opinion, the individual aforementioned financial statements present fairly, in all material respects, the financial position of Diagnósticos da América S.A. as of December 31, 2021, the performance of its operations and its cash flows, for the year then ended, in accordance with the accounting practices adopted in Brazil.

### Opinion on the consolidated financial statements

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Diagnósticos da América S.A. as of December 31, 2021, the consolidated performance of its operations and its cash flows, consolidated for the year then ended, in conformity with accounting practices adopted in Brazil and International Financial Reporting Standards - IFRS issued by the International Accounting Standards Board (IASB).

## Basis for opinion

Our audit was conducted in accordance with Brazilian and international standards on auditing. Our responsibilities, in conformity with these standards, are described in the following section denominated "Auditor's responsibilities for the audit of the individual and consolidated financial statements". We are independent in relation to the Company and its subsidiaries, in accordance with the relevant ethical principles provided for in the Accountant's Code of Professional Ethics and in professional standards issued by the Federal Accounting Council, and we comply with other ethical responsibilities according to these standards. We believe that the audit evidence obtained is sufficient and appropriate to provide a basis for our opinion.

## Key audit matters

The main audit matters are those who, in our professional judgment, were the most significant in our audit of current year. These matters were addressed in the context of our audit of the individual and consolidated financial statements as a whole, and in forming our opinion thereon, and, therefore, we do not express a separate opinion on these matters.

### Measurement of identifiable assets acquired and liabilities assumed in a business combination - Parent Company and Consolidated

See Notes nº 2 and nº 13 to the individual and consolidated financial statements

| Key audit matter | How the matter was addressed in the audit |
| --- | --- |
| During the year ended December 31, 2021, the Company and its subsidiaries acquired interests in other companies, obtaining their control. The estimates associated with the recording of a business combination acquisition involve material assumptions in determining the fair value of the assets acquired and liabilities assumed. Due to the uncertainties related to the assumptions and estimates used to measure the acquired assets and assumed liabilities that may result in a material adjustment in the accounting balances, we consider this matter to be material for our audit. | Our audit procedures included, among others:<br><br>(i) Evaluation of purchase and sale contracts;<br><br>(ii) Evaluation, with the help of internal corporate finance experts, of the methodology and assumptions used to measure the fair value of assets acquired and liabilities, including the assumptions used by the Company and its subsidiaries;<br><br>(iii) Comparison of the amounts determined in the price allocation reports paid in the business combination with the respective accounting balances; and (iv) analysis of disclosures made by the Company in individual and consolidated financial statements.<br><br>During our audit, we identified adjustments that affected the measurement and disclosure of identifiable assets acquired and liabilities assumed in business combinations, and the adjustments were considered immaterial. Therefore, they were not recorded or disclosed.<br><br>As a result of the evidence obtained through the procedures summarized above, we consider the measurement and disclosure of the fair value of identifiable assets acquired and liabilities assumed in business combinations to be acceptable in the context of the individual and consolidated financial statements taken as a whole. |

| Recoverable amount of goodwill for future profitability - Parent Company and Consolidated | |
|---|---|
| See Notes nº 13 and nº 15 to the individual and consolidated financial statements | |
| **Key audit matter** | **How the matter was addressed in the audit** |
| As of December 31, 2021, the Company's individual and consolidated financial statements included goodwill on the acquisition of companies and goodwill on merged companies, whose recoverable amount is tested annually, as required by CPC 01/IAS 36 – Impairment of Assets.<br><br>For impairment tests, goodwill is grouped into Cash Generating Units (CGU), whose value in use is based on estimated future cash flows, discounted to present value, which involves assumptions such as: business growth rates and discount rates.<br><br>Due to the uncertainties related to the assumptions used to estimate the value in use of the CGU, which could result in a material adjustment to the accounting balances, we considered this matter to be material for our audit. | Our audit procedures included, among others:<br><br>(i) understanding on the preparation and review of technical studies and analyzes of recoverable value made available by the Company;<br><br>(ii) Analysis, with the assistance of our corporate finance experts, of the assumptions adopted by the Company, especially those related to business growth rates, cash flow projections and the respective discount rates, as well as the comparison of the assumptions used by the Company, when available, with data obtained from external sources, such as projected economic growth and discount rates; and<br><br>(iii) Analysis of disclosures made by the Company in individual and consolidated financial statements.<br><br>As a result of evidence from the procedures summarized above, we consider that the value in use of CGUs for which goodwill for future profitability is allocated, as well as respective disclosures are as acceptable in the context of individual and consolidated financial statements taken as a whole. |

| Revenue recognition - Parent Company and Consolidated | |
|---|---|
| See Notes nº 4.c and nº 25 to the individual and consolidated financial statements | |
| **Key audit matter** | **How the matter was addressed in the audit** |
| The revenues of the Company and its subsidiaries are derived from the provision of services and the recognition is made based on the services performed up to the balance sheet date, for which it is necessary to determine the amount of revenue to be recognized, considering the services provided, billed; however, not billed yet and the estimate of with procedures carried out, but not approved by plans and healthcare operators (certain "disallowances"). The Company and its subsidiaries periodically review the history of losses on disallowances with the purpose of measuring and recognizing these losses. Due to the relevance of the amounts in the process of recognizing revenues from services rendered, as well as the characteristics inherent to the process of calculating estimates related to the measurement of estimated losses with disallowances, we understand that these matters are material for our audit. | Our audit procedures included, among others:<br><br>(i) Understanding of the process and adequacy of the accounting policies adopted by the Company and its subsidiaries for revenue recognition, specifically those related to the billing of services provided and the measurement of services provided and not yet billed (unbilled revenue);<br><br>(ii) Reconciliation of the billing reports for the period from January to December 2021 with the book balance of revenue recognized in the financial statements;<br><br>(iii) Performance of documentary tests, on a sample basis, on the existence of revenue from services billed and unbilled at the end of the year, assessing the moment of revenue recognition and amounts recognized;<br><br>(iv) Analysis of assumptions related to disallowances of health care plans, as well as criteria for measuring estimated losses from disallowances and their compliance with the accounting policies of the Company and its subsidiaries;<br><br>(v) Recalculation of provisions for losses on disallowances on December 31, 2021; and (iv) analysis of disclosures made by the Company in individual and consolidated financial statements.<br><br>During our audit, we identified adjustments related to revenue recognition, and the adjustments were considered immaterial. Therefore, they were not recorded or disclosed.<br><br>As result of the evidences obtained through the procedures summarized above, we consider acceptable that the recognition of revenues from rendering of services, as well as the balances of provisions for estimated losses on disallowances and related disclosures are acceptable in the context of the individual and consolidated financial statements taken as a whole. |

## Other matters - Statements of value added

Individual and consolidated statements of value added (DVA) for the year ended December 31, 2021, prepared under responsibility of Company's Management, and presented as supplementary information for IFRS purposes, were submitted to audit procedures carried out together with the audit of Company's financial statements. To form our opinion, we evaluated whether these statements are reconciled with the financial statements and accounting records, as applicable, and whether their form and content are in accordance with the criteria defined in CPC 09 Technical Pronouncement - Statement of Value Added. In our opinion, these statements of value added were prepared, in all material respects, in accordance with the criteria defined in this Technical Pronouncement and are consistent in relation to the individual and consolidated financial statements taken as a whole.

## Other information accompanying individual and consolidated financial statements and the auditors' report

The Company's management is responsible for other information comprising Management Report.

Our opinion on the individual and consolidated financial statements does not include the Management Report and we do not express any form of audit conclusion on such report.

Regarding the audit of individual and consolidated financial statements, our responsibility is to read the Management Report and, in doing so, consider whether this report is, in a material way, inconsistent with the financial statements or with our knowledge gained in the audit or otherwise appears to be materially misstated. If, based on the works performed, we conclude that there is a material misstatement in the Management Report, we are required to disclose this fact. We do not have anything to report on this respect.

## Responsibilities of management and governance for the individual and consolidated financial statements

The Company's Management is responsible for the preparation and adequate presentation of the individual financial statements in accordance with the accounting practices adopted in Brazil and of the consolidated financial statements in accordance with the accounting practices adopted in Brazil and International Financial Reporting Standards (IFRS) issued by issued by the International Accounting Standards Board - IASB, as well as for the internal controls that it deemed necessary to enable the preparation of financial statements free of significant distortions, regardless of whether the latter were caused by fraud or error.

In the preparation of individual and consolidated financial statements, Management is responsible for assessing the ability of the Company and its subsidiaries to continue as a going concern, disclosing, where applicable, the matters relating to its going concern and the use of this basis of accounting in preparing the financial statements, unless Management intends to wind-up the Company and its subsidiaries or cease its operations, or has no realistic alternative to avoid the closure of operations.

Those charged with governance of the Company and its subsidiaries are the people responsible for overseeing the process of preparation of the financial statements.

## Auditors’ Responsibilities for the Audit of the Individual and Consolidated Financial Statements

Our purposes are to obtain reasonable assurance that the individual and consolidated financial statements, taken as a whole, are free from material misstatement, whether caused by fraud or error, and to issue audit report containing our opinion. Reasonable assurance means a high level of security, but not a guarantee that an audit conducted in accordance with Brazilian and international auditing standards always detects any existing material misstatements. Misstatements may be due to fraud or error and are considered material when, individually or taken as a whole, can influence, within a reasonable perspective, the economic decisions of users taken based on these financial statements.

As part of the audit conducted in accordance with Brazilian and international auditing standards, we exercise professional judgment and maintain our professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the individual and consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement due to fraud is higher than due to error, since a fraud can involve the act of circumventing internal controls, collusion, falsification, omission or intentional misrepresentations.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control of the Company and its subsidiaries.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company and its subsidiaries to continue as a going concern. If we conclude that a material uncertainty exists, then we are required to draw attention in our auditors’ report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on audit evidence obtained up to the date of our report. However, future events or conditions may lead the Company and its subsidiaries to no longer remain as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the individual and consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the individual and consolidated financial statements. We are responsible for directing, supervising and carrying out the group’s audit and, therefore, for the audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal controls that we identified during our audit.

We also provide to those responsible for governance a statement that we fulfilled the material ethical requirements, including the applicable independence requirements, and report all the possible relationships or issues that could considerably affect our independence, including, when applicable, the respective disclaimers.

Of the issues that were subject of communication with those charged with governance, we determine those that were considered the most significant in the audit of the financial statements for the current year and, thus, represent the main audit issues. We describe these issues in our audit report, unless a law or regulation has prohibited the public disclosure of the issue, or when, under extremely rare circumstances, we determine that the issue shall not be reported in our report, because the adverse consequences from such report may, from a reasonable perspective, exceed the benefits from the report for public interest.

São Paulo, March 28, 2022

KPMG Auditores Independentes Ltda.
CRC 2SP014428/O-6
*(Original report in Portuguese signed by)*
Danielle Rezende Suzano
Accountant CRC 1SP-276876/O-4

## Diagnósticos da América S.A.

### Balance sheets at December 31, 2021 and 2020

*(In thousands of Reais)*

| ASSETS | Note | Parent company 2021 | Parent company 2020 | Consolidated 2021 | Consolidated 2020 |
|---|---|---|---|---|---|
| **CURRENT ASSETS** | | | | | |
| Cash and cash equivalents | 7 | 193,762 | 143,045 | 1,143,026 | 753,607 |
| Interest earning bank deposits | 8 | 2,434,350 | 740,916 | 2,471,032 | 760,816 |
| Trade accounts receivable | 9 | 708,971 | 903,728 | 2,305,316 | 1,743,233 |
| Inventories | 10 | 140,935 | 169,841 | 367,124 | 357,800 |
| Recoverable taxes | 11 | 186,691 | 116,742 | 392,908 | 260,035 |
| Prepaid expenses | | 10,454 | 10,159 | 26,536 | 12,178 |
| Derivative financial instruments | 32 | - | - | 22,626 | 26,201 |
| Call option obtained from non-controlling shareholders | 21 | - | 6,147 | - | 6,147 |
| Other receivables | 12 | 159,314 | 89,588 | 138,965 | 290,854 |
| **TOTAL CURRENT ASSETS** | | **3,834,477** | **2,180,166** | **6,867,533** | **4,210,871** |
| **NON-CURRENT RECEIVABLES** | | | | | |
| Interest earning bank deposits | 21 | 29,353 | 38,386 | 29,477 | 38,505 |
| Trade accounts receivable | 9 | 5,637 | 881 | 6,961 | 2,653 |
| Recoverable taxes | 11 | 40,922 | - | 61,167 | 20,275 |
| Prepaid expenses | | - | 4 | 433 | 607 |
| Derivative financial instruments | 32 | - | - | 41,677 | 39,203 |
| Call option obtained from non-controlling shareholders | 21 | 1,969 | 1,322 | 14,482 | 1,322 |
| Judicial deposits | 22 | 50,842 | 81,081 | 84,287 | 100,303 |
| Deferred taxes | 30 | 602,121 | 319,799 | 859,478 | 448,790 |
| Related parties | 33 | 40,072 | 13,586 | - | - |
| Other receivables | 12 | 7,299 | 8,992 | 308,371 | 13,414 |
| **TOTAL LONG-TERM ASSETS** | | **778,215** | **464,051** | **1,406,333** | **665,072** |
| Investments | 13 | 7,129,930 | 3,408,761 | 1,030 | 4,332 |
| Property, plant and equipment | 14 | 1,170,582 | 1,083,675 | 3,778,971 | 2,608,954 |
| Right to use | 18 | 946,919 | 796,876 | 1,964,337 | 1,384,934 |
| Intangible assets | 15 | 2,749,472 | 2,616,003 | 9,231,700 | 4,469,333 |
| | | **11,996,903** | **7,905,315** | **14,976,038** | **8,467,553** |
| **TOTAL NON-CURRENT ASSETS** | | **12,775,118** | **8,369,366** | **16,382,371** | **9,132,625** |
| **TOTAL ASSETS** | | **16,609,595** | **10,549,532** | **23,249,904** | **13,343,496** |

| LIABILITIES | Note | Parent company 2021 | Parent company 2020 | Consolidated 2021 | Consolidated 2020 |
|---|---|---|---|---|---|
| **CURRENT LIABILITIES** | | | | | |
| Suppliers | 16 | 601,993 | 535,942 | 1,230,833 | 893,175 |
| Loans and financing | 17 | 652,611 | 46,211 | 1,090,652 | 200,194 |
| Debentures | 19 | 801,277 | 145,133 | 1,004,583 | 145,720 |
| Taxes and contributions payable | | 60,928 | 96,573 | 216,451 | 185,333 |
| Income tax and social contribution payable | | - | 4,365 | 79,566 | 19,210 |
| Social charges and labor legislation obligations | | 217,167 | 258,610 | 581,226 | 495,668 |
| Taxes in installments | 20 | 2,084 | 2,627 | 116,469 | 23,150 |
| Accounts payable from acquisition of subsidiaries | 21 | 383,387 | 116,638 | 1,077,631 | 121,408 |
| Interest on own capital | 24 | 159,241 | 116,627 | 212,346 | 224,146 |
| Derivative financial instruments | 32 | - | - | 12,364 | 1,856 |
| Provision for negative shareholders' equity | 13 | 20,653 | 46,798 | - | - |
| Lease liabilities | 18 | 525,039 | 294,843 | 699,264 | 427,238 |
| Share-based payment | 23 | 25,889 | 32,581 | 25,889 | 32,581 |
| Put option granted to non-controlling shareholders | 21 | 30,504 | 33,768 | 30,504 | 33,768 |
| Other accounts payable and provisions | | 142,524 | 126,244 | 571,889 | 209,665 |
| **TOTAL CURRENT LIABILITIES** | | **3,623,297** | **1,856,960** | **6,949,667** | **3,013,112** |
| **NON-CURRENT LIABILITIES** | | | | | |
| Suppliers | 16 | 10,075 | 13,712 | 12,620 | 15,461 |
| Loans and financing | 17 | 16,177 | 629,180 | 494,634 | 1,001,621 |
| Debentures | 19 | 4,657,504 | 3,392,076 | 5,056,978 | 3,991,288 |
| Taxes in installments | 20 | 2,984 | 4,596 | 268,547 | 61,926 |
| Accounts payable from acquisition of subsidiaries | 21 | 78,620 | 408,218 | 776,480 | 415,395 |
| Derivative financial instruments | 32 | - | - | 7,934 | 5,603 |
| Tax, social security, labor and civil provisions | 22 | 125,404 | 123,941 | 255,341 | 201,418 |
| Lease liabilities | 18 | 489,897 | 562,640 | 1,419,773 | 1,058,275 |
| Share-based payment | 23 | 38,913 | 7,181 | 38,913 | 7,181 |
| Put option granted to non-controlling shareholders | 21 | 20,722 | 5,691 | 90,814 | 5,691 |
| Deferred taxes | 30 | - | - | 21,327 | 8,502 |
| Other accounts payable and provisions | | 3,714 | 9,106 | 308,358 | 21,495 |
| **TOTAL NON-CURRENT LIABILITIES** | | **5,444,010** | **5,156,341** | **8,751,719** | **6,793,856** |
| **TOTAL LIABILITIES** | | **9,067,307** | **7,013,301** | **15,701,386** | **9,806,968** |
| Capital | 24 | 16,302,238 | 12,326,706 | 16,302,238 | 12,326,706 |
| Capital reserves | 24 | 913,708 | 431,487 | 913,708 | 431,487 |
| Equity valuation adjustment | 24 | (9,612,292) | (9,552,209) | (9,612,292) | (9,552,209) |
| Profit reserves | 24 | - | 330,247 | - | 330,247 |
| Accumulated loss | | (61,366) | - | (61,366) | - |
| **TOTAL SHAREHOLDERS' EQUITY** | | **7,542,288** | **3,536,231** | **7,542,288** | **3,536,231** |
| Non-controlling interest | | - | - | 6,230 | 297 |
| **TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY** | | **16,609,595** | **10,549,532** | **23,249,904** | **13,343,496** |

See the notes to the individual and consolidated interim financial information.

## Diagnósticos da América S.A.

### Statements of income

**Year ended December 31, 2021 and 2020**

***(In thousands of reais, except for earnings per share, expressed in Reais)***

| | | Parent company | | Consolidated | |
|---|---|---|---|---|---|
| | **Note** | **2021** | **2020** | **2021** | **2020** |
| Net operating revenue | 25 | 4,686,672 | 3,550,870 | 10,418,674 | 7,039,331 |
| Cost of services rendered | 26 | (3,116,829) | (2,514,798) | (7,301,851) | (5,283,623) |
| **Gross income** | | **1,569,843** | **1,036,072** | **3,116,823** | **1,755,708** |
| Administrative and general expenses | 27 | (1,965,775) | (974,911) | (3,066,248) | (1,634,545) |
| Other operating revenues | 28 | 10,492 | 19,483 | 58,320 | 54,508 |
| Other operating expenses | 28 | (3,970) | (4,285) | (20,380) | (9,121) |
| **Income (loss) before net financial expenses, equity in net income of subsidiaries and taxes** | | **(389,410)** | **76,359** | **88,515** | **166,550** |
| Financial revenues | 29 | 132,124 | 38,407 | 206,450 | 176,305 |
| Financial expenses | 29 | (429,981) | (333,759) | (669,192) | (562,297) |
| **Financial expenses, net** | | **(297,857)** | **(295,352)** | **(462,742)** | **(385,992)** |
| Equity in net income of subsidiaries | 13 | 200,023 | (4,022) | - | - |
| **Equity in net income of subsidiaries** | | **200,023** | **(4,022)** | **-** | **-** |
| **Loss before income tax and social contribution** | | **(487,244)** | **(223,015)** | **(374,227)** | **(219,442)** |
| Deferred income tax and social contribution | 30 | 260,675 | 104,767 | 302,154 | 154,347 |
| Income tax and social contribution | 30 | - | (32,554) | (144,864) | (82,644) |
| **Loss for the year** | | **(226,569)** | **(150,802)** | **(216,937)** | **(147,739)** |
| **Income (loss) attributable to:** | | | | | |
| Controlling shareholders | | (226,569) | (150,802) | (226,569) | (150,802) |
| Non-controlling shareholders | | - | - | 9,632 | 3,063 |
| **Loss for the year** | | **(226,569)** | **(150,802)** | **(216,937)** | **(147,739)** |
| **Earnings per share** | | | | | |
| Basic earnings per common share (in R$) | 24 | (0.40429) | (0.31370) | (0.38710) | (0.30733) |
| Diluted earnings per share (in R$) | 24 | (0.38803) | (0.30123) | (0.37154) | (0.29511) |
| Number of shares - Basic | 24 | 560,419 | 480,722 | 560,419 | 480,722 |
| Number of shares - diluted | 24 | 583,892 | 500,624 | 583,892 | 500,624 |

See the accompanying notes to the individual and consolidated financial statements.

## Diagnósticos da América S.A.

### Statements of comprehensive income

**Year ended December 31, 2021 and 2020**

***(In thousands of Reais)***

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **2021** | **2020** | **2021** | **2020** |
| Loss for the year | (226,569) | (150,802) | (216,937) | (147,739) |
| Effect on translation of financial statements of foreign subsidiaries | (35,451) | 31,145 | (35,451) | 31,145 |
| Effect of the adoption of CPC 42 / IAS 29 - Hyperinflation | (8,341) | (6,507) | (8,341) | (6,507) |
| Comprehensive income for the year | **(270,361)** | **(126,164)** | **(260,729)** | **(123,101)** |
| **Comprehensive income attributable to:** | | | | |
| Controlling shareholders | | | (270,361) | (126,164) |
| Non-controlling shareholders | | | 9,632 | 3,063 |
| Comprehensive income for the year | | | **(260,729)** | **(123,101)** |

See the accompanying notes to the individual and consolidated financial statements.

**Diagnósticos da América S.A.**

**Statements of changes in shareholders' equity**

**Years ended December 31, 2021 and 2020**

***(In thousands of Reais)***

| | | Parent company | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Capital reserve | | Profit reserve | | | | | | |
| | **Note** | **Capital** | **Goodwill reserve and other** | **Transactions with stock-based payments** | **Legal reserve** | **Profit retention** | **Accumulated loss** | **Equity valuation adjustment** | **Total parent company** | **Non-controlling interest** | **Total consolidated** |
| **Balance at December 31, 2019** | 24 | **2,326,423** | **430,348** | **-** | **62,204** | **556,042** | **-** | **(102,788)** | **3,272,229** | **(8,846)** | **3,263,383** |
| Capital increase | 24 | 10,000,283 | - | - | - | - | - | (9,243,944) | 756,339 | - | 756,339 |
| Disposal of treasury shares | | | 1,140 | - | - | | | | 1,140 | 0 | 1,140 |
| Shareholders' transaction | | - | - | - | - | - | - | (230,116) | (230,116) | 6,080 | (224,036) |
| Loss for the year | | - | - | - | - | - | (150,802) | - | (150,802) | 3,063 | (147,739) |
| Effect on translation of financial statements of foreign subsidiaries | | - | - | - | - | - | - | 31,145 | 31,145 | - | 31,145 |
| Effect of the adoption of CPC 42 / IAS 29 - Hyperinflation | | - | - | | | - | - | (6,507) | (6,507) | - | (6,507) |
| Allocations: | | | | | | | | | - | | - |
| Absorption of losses | | - | - | | | (150,802) | 150,802 | - | - | - | - |
| Interest on own capital | 24 | - | - | | | (137,197) | - | - | (137,197) | - | (137,197) |
| **Balance at December 31, 2020** | 24 | **12,326,706** | **431,487** | **-** | **62,204** | **268,043** | **-** | **(9,552,209)** | **3,536,231** | **297** | **3,536,528** |
| **Saldo em 31 de dezembro de 2019** | | **2,326,423** | **430,347** | **-** | **62,204** | **556,042** | **-** | **(102,787)** | **3,272,229** | **(8,846)** | **3,263,383** |
| Aumento de capital | 24 | 10,000,283 | - | - | - | - | - | (9,243,944) | 756,339 | - | 756,339 |
| Alienação de ações em tesouraria | | | 1,140 | - | | | | | 1,140 | - | 1,140 |
| Transação de acionistas | | - | - | - | - | - | - | (230,116) | (230,116) | 6,080 | (224,036) |
| Prejuízo do exercício | | - | - | - | - | - | (150,802) | - | (150,802) | 3,063 | (147,739) |
| Efeito na conversão de demonstrações financeiras de controladas do exterior | 24 | - | - | - | - | - | - | 31,145 | 31,145 | - | 31,145 |
| Efeito da aplicação do CPC42 / IAS29 - Hiperinflação | 24 | - | - | - | - | - | - | (6,507) | (6,507) | - | (6,507) |
| Destinações: | | | | | | | | | - | | |
| Reserva de retenção de lucros | | - | - | - | - | (150,802) | 150,802 | - | - | - | - |
| Juros sobre capital próprio | | - | - | - | - | (137,197) | - | - | (137,197) | - | (137,197) |
| **Balance at December 31, 2020** | 24 | **12,326,706** | **431,487** | **-** | **62,204** | **268,043** | **-** | **(9,552,209)** | **3,536,231** | **297** | **3,536,528** |
| Capital increase | 24 | 4,032,493 | - | - | - | - | - | - | 4,032,493 | - | 4,032,493 |
| Costs with issue of shares | 24 | (56,961) | - | - | - | - | - | - | (56,961) | - | (56,961) |
| Shareholders' transaction | | - | - | - | - | - | - | (16,291) | (16,291) | (3,699) | (19,990) |
| Loss for the year | | - | - | - | - | - | (226,569) | - | (226,569) | 9,632 | (216,937) |
| Effect on translation of financial statements of foreign subsidiaries | | - | - | - | - | - | - | (35,451) | (35,451) | - | (35,451) |
| Effect of the adoption of CPC 42 / IAS 29 - Hyperinflation | | - | - | - | - | - | - | (8,341) | (8,341) | - | (8,341) |
| Stock option plan | 23 | - | - | 482,221 | - | - | - | - | 482,221 | - | 482,221 |
| Allocations: | | - | - | - | - | - | - | - | - | - | - |
| Absorption of losses | | - | - | - | (62,204) | (102,999) | 165,203 | - | - | - | - |
| Interest on own capital | 24 | - | - | - | - | (165,044) | - | - | (165,044) | - | (165,044) |
| **Balance at December 31, 2021** | 24 | **16,302,238** | **431,487** | **482,221** | **-** | **-** | **(61,366)** | **(9,612,292)** | **7,542,288** | **6,230** | **7,548,518** |

See the accompanying notes to the individual and consolidated financial statements.

## Diagnósticos da América S.A.

### Statements of cash flows

**Years ended December 31, 2021 and 2020**

***(In thousands of Reais)***

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **2021** | **2020** | **2021** | **2020** |
| **Cash flow from operating activities** | | | | |
| **Loss for the year** | **(226,569)** | **(150,802)** | **(216,937)** | **(147,739)** |
| Adjustments for: | | | | |
| Depreciation and amortization | 584,752 | 504,899 | 929,761 | 765,586 |
| Tax, social security, labor and civil provisions | 54,781 | 37,730 | 38,292 | 40,997 |
| Current and deferred taxes | (260,675) | (72,213) | (157,290) | (71,703) |
| Restatement of interest and exchange-rate change from loans and accounts payable due to | 290,145 | 201,748 | 289,900 | 313,909 |
| Income from derivative financial instruments | - | - | (3,463) | (57,345) |
| Residual write-off of property, plant and equipment and intangible assets | 6,985 | (16,213) | 17,918 | (325) |
| Update of option plan | 656,299 | (87,863) | 695,242 | (87,863) |
| Equity in net income of subsidiaries | (200,023) | 4,022 | - | - |
| Expected losses for doubtful accounts | (8,368) | 14,654 | (131) | (9,568) |
| Provision for disallowance | 4,012 | (7,615) | 13,116 | 2,658 |
| Restatement of interest and exchange-rate change from interest earning bank deposits | (102,217) | (9,482) | (102,707) | (15,392) |
| (Reversal) of provision for loss on inventories | (1,290) | 14,342 | (1,454) | 19,422 |
| Interest on lease | 81,836 | 85,590 | 156,246 | 129,239 |
| **(Increase) decrease in assets** | | | | |
| Accounts receivable | 195,313 | (131,905) | (237,392) | (124,496) |
| Inventories | 30,196 | (102,535) | 46,231 | (200,875) |
| Other current assets | (83,716) | (14,560) | 224,918 | (33,676) |
| Other noncurrent assets | (50,628) | 2,779 | (4,060) | (19,997) |
| **Increase (decrease) in liabilities** | | | | |
| Suppliers | (90,862) | 203,068 | 16,026 | 219,661 |
| Accounts payable and provisions | (131,411) | 132,956 | (140,208) | 161,377 |
| Payment of stock option plan | (187,981) | (83,979) | (187,981) | (83,979) |
| Income tax and social contribution | - | (15,421) | (77,848) | (33,387) |
| **Cash flow from operating activities** | **560,579** | **509,200** | **1,298,179** | **766,504** |
| **Cash flow from investment activities** | | | | |
| Acquisition of fixed assets | (253,229) | (281,011) | (647,858) | (553,669) |
| Acquisition of intangible assets | (189,369) | (148,979) | (257,947) | (202,064) |
| Capital increase in subsidiaries | (751,000) | - | - | - |
| Advances for future capital increase | - | (465,389) | - | - |
| Dividends and interest on own capital received from subsidiaries | - | 19,369 | - | - |
| PP&E sale | - | 88,910 | - | 88,910 |
| Cash fro acquisition of subsidiaries | - | - | - | 566,705 |
| Acquisition of subsidiary less net cash | (105,815) | (246,918) | (2,423,350) | (206,724) |
| Interest earning bank deposits | (9,216,514) | (2,283,461) | (9,267,140) | (2,849,886) |
| Redemption of interest earning bank deposits | 7,609,417 | 1,845,882 | 7,644,577 | 2,415,525 |
| Loans with related parties | - | 32,001 | - | - |
| Dividends received | 47,947 | - | - | - |
| Advance for acquisition of subsidiaries | (2,362,100) | - | - | (200,000) |
| Cash from merger of subsidiary | 178 | 10,968 | - | - |
| **Cash flow used in investment activities** | **(5,220,485)** | **(1,428,628)** | **(4,951,718)** | **(941,203)** |
| **Cash flow from financing activities** | | | | |
| Loans obtained and debentures | 2,499,908 | 1,613,485 | 2,557,630 | 1,761,942 |
| Payment of loans and debentures | (679,064) | (210,388) | (947,958) | (509,401) |
| Interest paid on loans and debentures | (167,441) | (115,580) | (225,885) | (142,063) |
| Payments of derivative financial instruments | - | - | (2,871) | (40,187) |
| Receipt of derivative financial instruments | - | - | 20,274 | 72,897 |
| Dividends and interest on own capital paid | (122,430) | (177,450) | (220,250) | (204,450) |
| Capital increase from issuance of shares | 3,666,273 | - | 3,666,273 | - |
| Expenditures from issue of shares | (86,304) | - | (86,304) | - |
| Capital increase | - | 283 | - | 283 |
| Acquisition of non-controlling interest | - | (127,010) | - | (127,010) |
| Payments of accounts payable from acquisition of subsidiaries | (177,331) | (126,465) | (276,919) | (126,465) |
| Payment of lease | (222,988) | (207,471) | (441,032) | (325,049) |
| **Cash flow from financing activities** | **4,710,623** | **649,404** | **4,042,958** | **360,497** |
| **Net increase (decrease) in cash and cash equivalents** | **50,717** | **(270,024)** | **389,419** | **185,798** |
| **Statement of increase (decrease) in cash and cash equivalents** | | | | |
| At the beginning of the year | 143,045 | 413,069 | 753,607 | 567,809 |
| At the end of the year | 193,762 | 143,045 | 1,143,026 | 753,607 |
| | **50,717** | **(270,024)** | **389,419** | **185,798** |

See the accompanying notes to the individual and consolidated financial statements.

## Diagnósticos da América S.A.

### Statements of added value

**Years ended December 31, 2021 and 2020**

***(In thousands of Reais)***

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | 2021 | 2020 | 2021 | 2020 |
| **Revenues** | | | | |
| Sale of merchandise, products and services | 5,059,736 | 3,879,855 | 11,231,324 | 7,642,318 |
| Other revenues | 10,492 | 19,483 | 58,320 | 54,508 |
| Expected losses for doubtful accounts | 8,368 | (14,654) | (47,521) | 1,382 |
| **Inputs acquired from third parties** | | | | |
| (Include the tax amounts - ICMS, IPI, PIS and COFINS) | | | | |
| Cost of products and goods sold and services provided | (1,453,730) | (1,550,726) | (4,253,165) | (3,201,959) |
| Materials, energy, outsourced services and other | (605,397) | (407,283) | (1,078,573) | (967,345) |
| **Gross added value** | 3,019,469 | 1,926,675 | 5,910,385 | 3,528,904 |
| **Depreciation and amortization** | (584,752) | (504,899) | (929,761) | (765,586) |
| **Net added value produced** | 2,434,717 | 1,421,776 | 4,980,624 | 2,763,318 |
| **Added value received as transfer** | | | | |
| Equity income (loss) | 200,023 | (4,022) | - | - |
| Financial revenues | 132,124 | 38,407 | 206,450 | 176,305 |
| **Total added value payable** | 2,766,864 | 1,456,161 | 5,187,074 | 2,939,623 |
| **Distribution of added value** | 2,766,864 | 1,456,161 | 5,187,074 | 2,939,623 |
| **Personnel** | 1,916,821 | 770,341 | 3,577,359 | 1,626,356 |
| **Taxes, duties and contributions** | 314,980 | 304,235 | 851,790 | 675,887 |
| **Third-party capital remuneration** | | | | |
| Interest and rentals | 596,588 | 532,387 | 809,818 | 785,119 |
| **Remuneration of own capital** | | | | |
| Interest on own capital | 165,044 | 137,197 | 165,044 | 137,197 |
| Loss for the year | (226,569) | (287,999) | (226,569) | (287,999) |
| Non-controlling interests in loss for the year | - | - | 9,632 | 3,063 |

See the accompanying notes to the individual and consolidated financial statements.

# Notes to the financial statements

***(In thousands of Reais)***

## 1 Operations

Diagnósticos da América S.A. "Parent Company" or "Company" and, jointly with its subsidiaries, "DASA Group") is headquartered at Avenida Juruá, nº 434, Alphaville, CEP 06455-010, city of Barueri, State of São Paulo, is a publicly-held corporation located in the city of Barueri, State of São Paulo, with its registration granted by the Brazilian Securities and Exchange Commission (CVM) for the trading of its securities on the stock market on November 5, 2004 and also registered at Novo Mercado of B3 S.A. - Brasil, Bolsa, Balcão ("B3"), that characterizes the highest level of corporate governance in the Brazilian capital market, for the trading of its securities on the stock market, under ticker DASA3.

The public offering for the primary distribution of common shares, all registered, book-entry and without par value, free and clear of any liens or encumbrances ("Shares"), issued by the Company was completed on April 6, 2021, with restricted placement efforts, pursuant to CVM Instruction nº 476 ("Restricted Offer"). The price per share was set at R$ 58.00 ("Price per Share"), totaling R$ 3,306,626, and the effective increase in the Company's capital in the total amount of R$ 3,306,626, upon the issuance of 57,010,786 new shares, as well as their ratification (- 24).

The capital increase was approved on May 10, 2021, with the issuance of 6,200,817 new common shares, in the total amount of R$ 359,647 due to the partial exercise of option for supplementary shares in the scope of the offer (- 24).

At the Extraordinary General Meeting held on December 27, 2021, the Company's capital increase was approved, with the issuance of 12,547,692 new common, nominative and book-entry shares with no par value of the Company, in the amount of R$ 366,220. The capital increase was recorded as a contra entry for the Company's investment, as a result of the exchange of shares with its subsidiary - Hospital Impar, for payment of part of the acquisition price of the São Domingos Group (- 24).

The Company, through its own operations as well as through its subsidiaries, is engaged in the provision of the following services:

(i) Outpatient physicians for telemedicine appointments or in person, outpatient procedures, outpatient procedures with resources to perform surgical procedures and complementary exams and medicine administration (therapies) for private patients or covered companies, insurance companies, medical-hospital assistance entities or other health care costing modalities.

(ii) Auxiliary diagnostic support services to private patients or covered companies, insurance companies, medical and hospital assistance entities, other types of health care, including clinical analyzes and vaccination, directly or in a supplementary manner, through contracted laboratories; and other auxiliary diagnostic support services, exclusively through specialized clinics, mainly in the following areas: (i) cytology and pathological anatomy; (ii) diagnosis by images and graphic methods; and (iii) nuclear medicine.

(iii) Provide hospital services; provide medical and outpatient services in its facilities; work as a development field for doctors, nurses and other professionals related to such activities; and provide means for research and scientific investigation. The services are provided through Ímpar, a Company's subsidiary, in the following hospitals: Hospital 9 de Julho, Complexo Hospitalar Niterói, Hospital São Lucas Copacabana, Hospital Brasília, Maternidade Brasília, Hospital Santa Paula, Hospital Águas Claras, Innova Hospitais, Grupo Carmo, Grupo Leforte, Hospital Bahia and São Domingos Group.

(iv) Provision of services related to care coordination, remote monitoring, population health management, service home medical and paramedical services, and outpatient medical activity restricted to medical consultations. Development of consultancy for companies and healthcare operators in the development of healthcare management models, new remuneration models, risk control, and healthcare network management. The services are performed through Santa Celina, the Company's subsidiary.

(v) Development and licensing of software, digital products including applications, data processing and handling, Internet services, hosting, provider developments and other related activities, consulting, support, maintenance and other IT-related services. The services are provided by the Company through its Nexa brand.

(vi) Development and licensing of predictive models using information technology and data science. The services are carried out through the subsidiaries Genia, Nobeloy, and Optiren.

(vii) Provision of brokerage services, sales of health care plans, data analysis, consultancy for loss reduction, and health management for companies. The services are provided by the Company through its brands Dasa Empresas (Allbrokers), Gesto Saúde, and Grupo Case.

(viii) The Company also explores activities related to: (i) (iii) elaboration, edition, publication and distribution of newspapers, books, magazines, periodicals and other vehicles of written communication, intended for scientific dissemination or for the activities included within the scope of the Company's activities (ii) granting and administration of business franchising including advertising and publishing fund, training and selection of labor, supplying of equipment and research material suppliers (iii) tests in food and substances to evaluate risks for the human being; and (iv) import, for its own use, of medical-hospital equipment, sets for diagnostics and related material in general.

For the purposes of analysis and decision making by Management, the DASA Group's operations are managed by three segments: (i) outpatient care and care coordination - specifically in relation to economic characteristics, provision of services and production processes, type of client, suppliers and logistics process, comprised of service units and technical operations centers, (ii) hospitals and oncology - through Ímpar Serviços Hospitalares S.A., a subsidiary of the Company, formed by hospitals located in the states of São Paulo, Rio de Janeiro, Bahia, Pernambuco and Federal District, and (iii) International Operations - auxiliary diagnostic support services, formed by a unit service and technical operations centers located in Argentina, Uruguay, Chile and Colombia. The Board of Directors reviews the reports at least quarterly.

**COVID-19 impacts on DASA Group's operations**

In March 2020, the World Health Organization (WHO) announced that the coronavirus (COVID-19) is a global health emergency and declared pandemic status. The outbreak triggered major decisions by governments and private sector entities, which coupled with the potential impact of the outbreak, increased the degree of uncertainty for economic agents.

Management is constantly evaluating the impact of the outbreak on DASA Group's operations and financial position, with the purpose of implementing appropriate measures to mitigate the impacts of the outbreak on its operations and in individual and consolidated financial statements. As of the authorization date for the issuance of these individual and consolidated financial statements, the following main measures were taken:

- DASA Group assembled a Crisis Committee and has been managing several action plans with the purpose of minimizing the impacts on operation.

- Management performed an annual analysis of the recoverable amount of goodwill and assets allocated to the Cash Generating Units (CGU), considering its projections made on the base date of December 31, 2021, as disclosed in - 15. As a result, there is no need to record a provision for impairment for any of the related assets.

- DASA Group reviewed the impact of the crisis on its accounts receivable, due to the possible increase in credit risk, but have not identified any relevant impacts arising from this issuance for the year ended December 31, 2021. In relation to inventories, DASA Group reviewed its inventory position for the year ended December 31, 2021, as well as its provision for losses, and there was no significant impact.

- Regarding the realization of deferred tax credits, Management performed the annual recovery analysis, considering its projections made on the base date of December 31, 2021. As a result, no need for derecognition of deferred income tax and social contribution was identified.

# 2 Acquisitions of subsidiaries

Identifiable assets acquired and liabilities assumed at fair value on the acquisition date, as well as other information necessary to assess the accounting and financial effect of the business combination are shown in the table at the end of this -.

## 2.1 Acquisitions in the year 2021

### *Innova Hospitais Associados Ltda. ("Innova")*

As of January 6, 2021, the DASA Group announced that it concluded the acquisition of control on that date through its subsidiary Ímpar Serviços Hospitalares S.A., acquiring 100% of the quotas representing the total capital of Innova.

The acquisition was concluded for R$ 98,237, R$ 61,286 paid on the date the agreement was signed and R$ 36,951 will be paid in five annual installments beginning on January 6, 2022, recorded in the statement of financial position under Accounts payable from the acquisition of subsidiaries.

The subsidiary Ímpar Serviços Hospitalares S.A. engaged an independent appraiser to allocate the purchase price and assess the acquired intangible assets and, based on the recognition criteria of CPC 04, no potential intangible assets were identified. The goodwill of R$ 71,091 is mainly attributed to the geographic expansion and increase in the number of beds in DASA's hospital network, as well as the synergies expected to be obtained with the integration of the acquired company into the DASA Group's business. No goodwill recognized will be deductible for tax purposes until the acquisition of the acquiree.

### *Gesto Saúde Sistemas Informatizados, Consultoria Médica e Corretora de Seguros Ltda. ("Gesto Saúde").*

On January 15, 2021, the Company informed its shareholders and the market in general that it had concluded the acquisition of all of the quotas held by the sellers representing 100% (one hundred percent) of the capital of Gesto Saúde, thus obtaining its control.

Gesto Saúde's purpose is to provide brokerage services, sales of health care plans, data analysis, consultancy in loss reduction, and management of health plans for companies.

The acquisition was concluded for R$ 68,120, of which R$ 64,870 was paid in cash on the data the agreement was signed and R$ 3,250 will be paid in January 2023, recorded in the statement of financial position under Accounts payable from the acquisition of subsidiaries.
There was no contingent consideration as part of the purchase agreement and contingencies.

The Company engaged an independent appraiser to allocate the purchase price and assess the acquired intangible assets. The fair value of the identified intangible assets (Customer Relationship, Non-Competition Agreement and Software) is R$ 28,921. The goodwill of R$ 55,806 is mainly related to the expansion of the provision of health care plan brokerage services and the synergies expected to be obtained from the integration of the acquired company into the Company's business. No goodwill recognized will be deductible for tax purposes until the acquisition of the acquiree.

### *Nossa Senhora do Carmo Participações S.A. ("Grupo Carmo")*

At a Board of Directors meeting held on September 15, 2020, the acquisition by Ímpar Serviços Hospitalares S.A., a wholly-owned subsidiary of the Company, of the equity interest representing 70% of the capital of Nossa Senhora do Carmo Participações Ltda. was approved, thus obtaining its control. The company develops the provision of medical, outpatient, hospital, clinical and surgical services in the State of Rio de Janeiro, including medium and high complexity procedures, diagnostic imaging and laboratory services.

After compliance with the applicable suspensive conditions and approvals, the transaction was submitted for ratification by the shareholders at the time of the General Meeting, pursuant to paragraph 1º of article nº 256 of Law nº 6,404/76.

The acquisition was completed on April 1, 2021, after CADE [Administrative Council for Economic Defense] approval and compliance with suspensive conditions and applicable approvals for the amount of R$ 115,728, divided into: i) R$ 40,604 in cash as of April 3, 2021, ii) R$ 18,346 in four payments throughout 2021; R$ 25,243 to be paid on April 1, 2022, iii) R$ 24,881 to be paid on April 1, 2023, and iv) R$ 6,654 to be paid on April 1, 2024, the installments are recorded in the statement of financial position under Accounts payable from acquisitions of subsidiaries.

There was no contingent consideration as part of the purchase agreement and contingencies.

The subsidiary Ímpar Serviços Hospitalares S.A. engaged an independent appraiser to allocate the purchase price paid and valuate the acquired intangible assets and, based on the recognition criteria of CPC 04, no potential intangible assets were identified. The goodwill of R$ 118,242 is mainly attributed to the geographic expansion and increase in the number of beds in DASA's hospital network, as well as the synergies expected to be obtained with the integration of the acquired company into the business of the subsidiary Ímpar Serviços Hospitalares S.A.. No goodwill recognized will be deductible for tax purposes until the acquisition of the acquiree.

Should new information obtained within one year as of the acquisition date, on facts and circumstances existing on the acquisition date, point to adjustments in the above-mentioned sums or to any additional provision existing on the acquisition date, the acquisition's bookkeeping will be reviewed.

*Call and put option*

As part of the agreement to acquire equity interest, a put option was issued by the subsidiary Ímpar Serviços Hospitalares S.A. in favor of the non-controlling shareholders and a call option was issued by the Sellers in favor of the subsidiary Ímpar Serviços Hospitalares S.A., which may result in an acquisition by the subsidiary Ímpar Serviços Hospitalares S.A. of the remaining 30% shares of Grupo Carmo.

The call option is calculated at an amount equivalent to a multiple (1x) of the acquiree's gross operating revenue, and the minimum is the gross operating revenue of 2019, equivalent to R$ 178,125. The result of this calculation will be divided by the total shares of Grupo Carmo and multiplied by the total shares held by the Sellers. The fair value of the call option as of December 31, 2021, was R$ 12,513, recorded in "call option obtained from non-controlling shareholders" caption (- 21).

For the exercise of the put option, it will be calculated at the fixed value of the shares, on the date of the first acquisition, plus the DI rate up to the option exercise date. Both put or call options are exercisable from April 1, 2024, to April 2025, and are recorded in the statement of financial position under "call option obtained from controlling shareholders (assets) and put option granted to non-controlling shareholders (liabilities)" caption.

As the put option granted to non-controlling shareholders provides for cash settlement, the subsidiary Ímpar Serviços Hospitalares S.A. recognized a liability at the present value of the option strike price in the amount of R$ 70,092, recorded in the "Put option granted to non-controlling shareholders" caption (- 21).

The subsidiary Ímpar has determined that non-controlling shareholders still have current access to returns associated with Grupo Carmo's underlying equity interests. The subsidiary Ímpar Serviços Hospitalares S.A. opted to account for the put option under the current access method under which the non-controlling shareholder continues to be recognized and the amount was debited to "Equity valuation adjustments". The policy of subsidiary Ímpar Serviços Hospitalares S.A. is to recognize subsequent changes in the value of this instrument in shareholders' equity.

### *Grupo Case*

On May 25, 2021, the Company announced that it acquired 100% of the shares representing the capital of Grupo Case on that date, through Allbrokers Brasil Corretora de Seguros Ltda., a wholly-owned subsidiary of the Company and a privately-held company and obtaining its control. Grupo Case is formed by: Brasilidade Soluções Corporativas em Corretamente de Seguros Ltda., Dinâmica Administração e Corretagem de Seguros Ltda., Aeroseg Corretagem de Seguros Ltda., Carvalho & Motta Corretora de Seguros Ltda., Chase Assessoria Empresarial Ltda., Case TBI Administração e Corretagem de Seguros Ltda., GCSP Consultoria e Corretagem em Benefícios e Seguros Ltda., TBI Corretora de Seguros LTDA, CASE- Central de Administração de Planos de Saúde Ltda., and Itech Care Assessoria Empresarial em Tecnologia S.A.

Grupo Case is engaged in:

(a) Provision of P&C and life insurance brokerage services, sales of capitalization and health care plans;

(b) Provision of technical advisory services in the insurance field;

(c) Assistance in health care plans and related matters, technical assistance for companies in the areas of health care and private pension;

(d) Development and licensing of health programs, on demand, with data processing, internet hosting service providers, portals, content providers, and other internet services, as well as activities in support of health management and teleservice; and

(e) Management of health care benefits.

The acquisition value of Grupo Case recorded by Allbrokers was R$ 216,863 of which R$ 142,544 on the agreement date, R$ 44,485 by the end of 2021, R$ 10,052 in 2024, R$ 10,052 in 2025, and R$ 9,730 in 2026, installments recorded in the statement of financial position under Accounts payable from acquisition of subsidiaries.

The subsidiary Allbrokers Brasil Corretora de Seguros Ltda. engaged an independent appraiser to allocate the price paid and valuate the acquired intangible assets. The fair value of the identified intangible assets (customer relationship) is R$ 67,945. The goodwill of R$ 151,360 is mainly related to the expansion of the provision of health care plan brokerage and the synergies expected to be obtained from the integration of the acquired company into the Company's business. No goodwill recognized will be deductible for tax purposes until the acquisition of the acquiree.

#### *Contingent consideration*

In addition to the acquisition price, the sellers will be entitled to the possible and eventual receipt of an earn-out in the maximum amount of R$ 59,144, related to the total or partial achievement of certain targets established by the parties in the business plan for the period between the date of the first closing and December 31, 2023. The targets are related to the achievement of 160,000 lives insured in the health care industry by the group and the achievement of EBITDA change calculated on an accrued basis in each of the years until December 31, 2023.

As of May 25, 2021, the closing date, the Company advanced the partial payment of the earn-out in the amount of R$ 29,144 and recorded the installment of R$ 30,000 to be paid as on December 31, 2023. Also according to the contract, if the additional price is not confirmed as due or if it is confirmed as partially due at the end of the period, the amount must be returned by the sellers. As of December 31, 2021, the projections demonstrate the achievement of the agreed targets.

***Centro de Tomografia por Computador Ltda. ("Clinica CT").***

On July 7, 2021, the Company announced to its shareholders and the market in general that it acquired all the shares held by the sellers representing 100% of the capital of Clínica CT.

Clínica CT aims to provide specialized medical services, specifically related to medical imaging exams.

The acquisition was concluded for R$ 1,500, of which R$ 60 was paid in cash on the date the agreement was signed and R$ 1,440 in 24 installments of R$ 60, recorded in the statement of financial position under Accounts payable from the acquisition of subsidiaries.

There was no contingent consideration as part of the purchase contract.

The Company engaged an independent appraiser to determine the consideration transferred and to valuate the identified intangible assets and goodwill. The company provisionally presented a negative goodwill of R$ 1,759 in the financial statements.

***Biodínamo Empreendimentos e Participações Ltda. ("Biodínamo")***

At a meeting of the Board of Directors held on September 3, 2021, the acquisition by Ímpar Serviços Hospitalares S.A., a wholly-owned subsidiary of the Company, of the equity interest representing 100% of the capital of Biodínamo Empreendimentos e Participações Ltda. was approved, obtaining its control. The company controls the hospital and outpatient medical care, clinical and diagnostic services businesses of Grupo Leforte, including the equity interests in the hospitals Leforte Liberdade, Leforte Morumbi, and Hospital e Maternidade Dr. Christóvão da Gama.

After compliance with the applicable suspensive conditions and approvals, the transaction was submitted for ratification by the shareholders at the time of the General Meeting, pursuant to paragraph 1º of article nº 256 of Law nº 6,404/76.

The acquisition was concluded after approval by CADE and compliance with suspensive conditions and applicable approvals for the amount of R$ 1,806,396, of which: i) R$ 200,000 as of December 03, 2020 and R$ 100,427 as of February 26, 2021 as downpayment; ii) R$ 1,188,290 in cash on the date the contract was signed; and iv) R$ 317,679 to be paid on September 3, 2027, the installments are recorded in the statement of financial position under Accounts payable from acquisition of subsidiaries.

There was no contingent consideration as part of the purchase contract.

The subsidiary Ímpar Serviços Hospitalares S.A. engaged an independent appraiser to allocate the purchase price paid and valuate the acquired intangible assets and, based on the recognition criteria of CPC 04, no potential intangible assets were identified. The goodwill of R$ 1,911,607 is mainly attributed to the geographic expansion and increase in the number of beds in the hospital network, as well as the synergies expected to be obtained with the integration of the acquired company into the business of the subsidiary Ímpar Serviços Hospitalares S.A. No goodwill recognized will be deductible for tax purposes until the acquisition of the acquiree.

Should new information obtained within one year as of the acquisition date, on facts and circumstances existing on the acquisition date, point to adjustments in the above-mentioned sums or to any additional provision existing on the acquisition date, the acquisition's bookkeeping will be reviewed.

### *Laboratório de Medicina S.A.*

As of November 18, 2021, the Company informed its shareholders and the market in general that it concluded, on that date, the acquisition of 100% of the quotas representing the total capital of Laboratório de Medicina S.A by Diagnósticos Maipú por Imágenes S.A., wholly-owned subsidiary of the Company.

Laboratório de Medicina S.A. is engaged in providing clinical analysis laboratory services and its operational technical center adds greater processing capacity, complementing the activities of Diagnósticos Maipú.

Pursuant to SEP Official Letter 02/21, the Company and its subsidiary Diagnósticos Maipú por Imágenes S.A. clarify to their shareholders and the market in general that article nº 256 of Law nº 6,404/76 does is not applicable to the acquisition. They also clarify that the acquisition was carried out fully with local funds from the subsidiary Diagnósticos Maipú por Imágenes S.A., without the need for any additional capital contribution from the Company.

The acquisition was concluded for the amount of US$ 5,000 thousand, equivalent to R$ 27,735 thousand translated on the acquisition date, of which US$ 4,500 thousand (R$ 24,962 thousand) was paid in cash and US$ 500 thousand (R$ 2,774 thousand) will be held as collateral for three years as of the closing date.

There was no contingent consideration as part of the purchase contract.

The subsidiary Diagnósticos Maipú por Imágenes S.A. did not identify potential intangible assets and provisionally presented the amount of R$ 3,692 as goodwill in these consolidated financial statements.

### *HBA S.A - Assistência Médica e Hospitalar*

On November 30, 2021, it communicated to its shareholders and the market in general that it concluded, on that date, the acquisition by Ímpar Serviços Hospitalares S.A., a wholly-owned subsidiary of the Company, of the equity interest representing 100% of the capital of HBA S.A. - Assistência Médica e Hospitalar, thus obtaining its control. The company owns and operates the business of hospital and outpatient medical care, clinical services and diagnostic imaging in the "Hospital da Bahia" hospital complex.

The acquisition was completed on November 30, 2021, after CADE's approval and compliance with suspensive conditions, as well as applicable approvals for the amount of R$ 828,497, of which R$ 539,385 will be paid in cash on the date the agreement is signed, and R$ 289,112 will be paid on May 31, 2023.

There was no contingent consideration as part of the purchase contract.

The subsidiary Ímpar Serviços Hospitalares S.A. engaged an independent appraiser to allocate the purchase price paid and valuate the acquired intangible assets and, based on the recognition criteria of CPC 04, no potential intangible assets were identified. The goodwill of R$ 804,293 is mainly attributed to the geographic expansion and increase in the number of beds in the hospital network, as well as the synergies expected to be obtained with the integration of the acquired company into the business of the subsidiary Ímpar Serviços Hospitalares S.A. No goodwill recognized will be deductible for tax purposes until the acquisition of the acquiree.

Should new information obtained within one year as of the acquisition date, on facts and circumstances existing on the acquisition date, point to adjustments in the above-mentioned sums or to any additional provision existing on the acquisition date, the acquisition's bookkeeping will be reviewed.

***Sall Participações S.A.***

As of December 28, 2021, the Company communicated to its shareholders and the market in general the acquisition, on that date, of shares representing 100% of the total capital of Sall Participações S.A., and indirectly, 99% of the equity interest held by Sall at Centro de Diagnóstico Boris Berenstein Ltda.

Centro de Diagnóstico Boris Berenstein provides medical services in radiology, computed tomography and diagnostic imaging methods, in addition to complementary activities, while Sall Participações is a pure holding company that holds a majority interest in the capital of Centro de Diagnóstico Boris Berenstein.

The acquisition was concluded as of December 28, 2021 for the amount of R$ 90,500, of which R$ 67,875 was paid on January 3, 2022, R$ 11,312 will be paid on December 28, 2022 and R$ 11,313 will be paid on December 28, 2023.

Considering that the acquisition completion date was on December 28, 2021, the Company did not identify potential intangible assets. Due to the non-conclusion of the report on the fair value of property, plant and equipment, the subsidiary Sall Participações S.A. provisionally presented property, plant and equipment and goodwill in the financial statements in the amount of R$ 43,093 and R$ 59,017, respectively.

*Contingent consideration*

As part of the purchase and sale contract, a contingent consideration was agreed. The Sellers will be entitled to a possible and eventual receipt of an additional price proportional to the growth of the Investee's gross operating revenue in the calendar year 2022, which must be understood as the revenue generated based on the Investee's production according to the accrual basis of accounting, provided that the revenue for the 2022 calendar year was equal to or greater than the amount of R$ 60,000, limited to the amount of R$ 30,000.

As of December 31, 2021, the earnings projections of the Centro de Diagnóstico Boris Berenstein did not indicate the achievement of the stipulated target and no contingent liability was recognized, as the fair value of the contingent consideration was considered zero.

### *Hospital São Domingos Ltda.*

At a meeting of the Board of Directors held on March 12, 2021, a binding agreement was approved for the acquisition of (a) 100% of the capital issued by Andrade da Silva Participações S.A. and (b) 100% of the capital issued by Mendes da Silva Participações S.A ("Mendes da Silva" and, together with Andrade da Silva, the "Companies"), thus obtaining its control. The Companies are the controlling shareholders of the São Domingos Group's hospital and outpatient medical care business, clinical services and diagnostic imaging, including the equity interests of Hospital São Domingos Ltda., Neuro Imagens Ltda. and Clínica Soluções Médica Ltda. (the "Operation").

The acquisition was concluded on December 30, 2021, after CADE [Administrative Council for Economic Defense] approval and compliance with suspensive conditions and applicable approvals for the amount of R$ 1,236,424.

The transaction format considers two components for the formation of the price paid:

- Acquisition of 100% of the capital of Andrade da Silva, through payment of R$ 153,738 as of December 30, 2021, R$ 659,327 as of January 3, 2022; and

- Acquisition of 100% of the capital of Mendes da Silva through the exchange of 58,369,839 shares of Ímpar and subsequent exchange of 12,547,692 shares of DASA. The share amount was calculated based on the DASA3 share price as of December 30, 2021, in the amount of R$ 33.74, and the EBITDA multiple implied in the negotiation of the same was 17.44x the EBITDA. As a result, the measurement of Ímpar's shares, considering the same DASA trading multiple, was equal to R$ 423,359. The exchange of shares at Ímpar and DASA took place simultaneously on the closing date and, therefore, the measurement of Ímpar's shares at fair value was calculated based on the market value of DASA's shares.

There was no contingent consideration as part of the purchase contract.

Considering that the completion date of the acquisition was on December 30, 2021, based on valuations carried out previously in similar transactions, in the acquiree's business and in the purchase agreement, there is no expectation of identifying potential intangible assets. Due to the non-conclusion of the report on the fair value of property, plant and equipment, the subsidiary Ímpar Serviços Hospitalares S.A. provisionally presented property, plant and equipment and goodwill in the financial statements in the amount of R$ 301,100 and R$ 1,388,455, respectively.

## *Fair value of identifiable assets acquired and liabilities assumed*

The fair value of assets acquired and liabilities assumed at the acquisition date is as follows:

| | **Innova** | **Gesto** | **Grupo Carmo** | **Grupo Case** | **Clínica CT** | **Biodinamo** | **Laboratório Medicina** | **Hospital da Bahia** | **Sall Partic.** | **Hospital São Domingos** | **Total** |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Acquisition date** | 01/06/2021 | 01/15/2021 | 04/01/2021 | 05/25/2021 | 07/07/2021 | 09/03/2021 | 11/18/2021 | 11/30/2021 | 12/28/2021 | 12/30/2021 | |
| **Interest acquired** | 100% | 100% | 70% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | |
| **Assets** | | | | | | | | | | | |
| Cash and cash equivalents | 850 | 4,345 | 35,143 | 8,536 | 2,709 | 7,467 | 14,652 | 10,653 | 11,574 | 15,570 | 111,499 |
| Trade accounts receivable | 1,560 | 944 | 9,340 | 897 | 526 | 164,498 | 13,611 | 77,117 | 1,161 | 72,330 | 341,984 |
| Inventories | 2,168 | - | 6,566 | - | - | 16,249 | 1,972 | 3,965 | 254 | 22,927 | 54,101 |
| Recoverable taxes | - | 476 | 785 | 132 | 172 | 15,297 | 1,075 | 3,023 | 11 | 24,338 | 45,309 |
| Indemnifiable asset | - | 3,250 | - | - | - | - | - | 33,680 | - | 45,400 | 82,330 |
| Prepaid expenses | - | 518 | - | 203 | - | 7,032 | | 237 | 181 | 23 | 8,194 |
| Deferred tax assets | - | | - | - | | 68,761 | 160 | - | - | 17,088 | 86,009 |
| Other receivables | 3,687 | 97 | 91,014 | 95 | 3 | 23,047 | 776 | 39,768 | 122 | 224,188 | 382,797 |
| Property, plant and equipment (d) | 31,661 | 1,361 | 18,486 | 767 | 3 | 234,714 | 946 | 216,011 | 43,093 | 301,100 | 848,142 |
| Intangible assets (e) | - | 38 | 3 | 450 | 1 | 4,907 | 691 | 499 | 173 | 509 | 7,271 |
| Right of use | - | 2,244 | 52,302 | - | - | 90,522 | - | 43,452 | - | 2,965 | 191,485 |
| Intangible assets - Non-contractual relationship with client | - | 8,259 | - | 67,945 | - | - | - | - | - | - | 76,204 |
| Intangible assets – Non-competition agreement | - | 5,243 | - | - | - | - | - | - | - | - | 5,243 |
| Intangible assets - Software | - | 15,419 | - | - | - | - | - | - | - | - | 15,419 |
| **Total identifiable assets acquired** | **39,926** | **42,194** | **213,639** | **79,025** | **3,414** | **632,494** | **33,883** | **428,405** | **56,569** | **726,438** | **2,255,987** |
| **Liabilities** | | | | | | | | | | | |
| Suppliers | (3,442) | (275) | (8,492) | (1,199) | - | (76,229) | (6,147) | (19,962) | (1,136) | (44,913) | (161,795) |
| Loans and financing | - | (4) | (46,790) | (7,336) | - | (299,500) | (9) | (115,311) | (21,492) | (139,889) | (630,331) |
| Income tax and social contribution payable | (233) | (1,246) | - | - | - | (1,728) | (81) | - | (208) | - | (3,496) |
| Taxes and contributions payable | (7,081) | (244) | (18,544) | (2,988) | (33) | (133,188) | (320) | (44,210) | (310) | (217,830) | (424,748) |
| Deferred tax liabilities | - | (7,698) | - | - | - | - | - | - | - | - | (7,698) |
| Lease liabilities | - | (2,244) | (53,379) | - | - | (106,196) | - | (66,740) | - | (3,852) | (232,411) |
| Contingent liabilities | - | - | - | - | - | - | - | (33,680) | - | (45,400) | (79,080) |
| Tax, social security, labor and civil provisions | (1,995) | (16,809) | (2,507) | - | - | (17,544) | - | (11,327) | - | (27,093) | (77,275) |
| Accounts payable from acquisition of subsidiaries | - | - | (75,728) | - | - | - | - | - | - | | (75,728) |
| Accounts payable from subsidiaries | - | - | - | - | - | - | - | - | - | (200,002) | (200,002) |
| Other accounts payable and provisions | (29) | - | (12,946) | (1,999) | (122) | (103,662) | (3,283) | (112,971) | (1,940) | (199,490) | (436,442) |
| **Total liabilities assumed** | **(12,780)** | **(28,520)** | **(218,386)** | **(13,522)** | **(155)** | **(738,047)** | **(9,840)** | **(404,201)** | **(25,086)** | **(878,469)** | **(2,329,006)** |
| **Total assets, net** | **27,146** | **13,674** | **(4,747)** | **65,503** | **3,259** | **(105,553)** | **24,043** | **24,204** | **31,483** | **(152,031)** | **(73,019)** |
| Goodwill (negative goodwill) on acquisition | 71,091 | 55,806 | 118,242 | 151,360 | (1,759) | 1,911,607 | 3,692 | 804,293 | 59,017 | 1,388,455 | 4,561,804 |

| | Innova | Gesto | Grupo Carmo | Grupo Case | Clínica CT | Biodinamo | Laboratório Medicina | Hospital da Bahia | Sall Partic. | Hospital São Domingos | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt agreed | - | (1,360) | - | - | - | - | - | - | - | - | (1,360) |
| Interest of non-controlling shareholders (a) | - | - | 2,233 | - | - | 342 | - | - | - | - | 2,575 |
| **Total consideration transferred** | **98,237** | **68,120** | **115,728** | **216,863** | **1,500** | **1,806,396** | **27,735** | **828,497** | **90,500** | **1,236,424** | **4,490,000** |
| Amount paid in cash | 61,286 | 64,870 | 59,288 | 142,543 | 60 | 1,488,717 | 24,962 | 539,385 | - | 153,738 | 2,534,849 |
| Payment with delivery of shares | - | - | - | - | - | - | - | - | - | 423,359 | 423,359 |
| Balance payable (- 21) | 36,951 | 3,250 | 56,440 | 15,176 | 1,440 | 317,679 | 2,773 | 289,112 | 90,500 | 659,327 | 1,472,648 |
| Balance payable of contingent consideration (- 21) | - | - | - | 59,144 | - | - | - | - | - | - | 59,144 |
| **Total** | **98,237** | **68,120** | **115,728** | **216,863** | **1,500** | **1,806,396** | **27,735** | **828,497** | **90,500** | **1,236,424** | **4,490,000** |

| | Innova | Gesto | Grupo Carmo | Grupo Case | Clínica CT | Biodi-namo | Labora-tório Medicina | Hospital da Bahia | Sall Partic. | Hospital São Domingos |
|---|---|---|---|---|---|---|---|---|---|---|
| Contribution to the DASA Group - Net revenues since the acquisition (b) | 28,267 | 12,975 | 165,017 | 29,000 | 4,415 | 294,599 | 7,846 | 20,650 | - | - |
| Contribution to the DASA Group – Profit or loss since the acquisition (b) | (16,595) | (8,167) | 23,889 | 4,708 | (1,269) | (30,330) | (4,070) | (3,149) | - | - |
| Contribution to the DASA Group - Net revenues since the beginning of the year (c) | 28,267 | 14,096 | 207,414 | 40,523 | 8,436 | 871,541 | 74,242 | 236,732 | 47,506 | 639,452 |
| Contribution to the DASA Group - Profit or loss since the beginning of the year (c) | (16,595) | (9,492) | 19,541 | 4,636 | 2,394 | 4,746 | 3,561 | (50,502) | 42 | 136,444 |

(a) The non-controlling interest was estimated based on the proportional interest granted by the equity instruments in the recognized amounts of the acquiree's identifiable net assets.

(b) The acquiree's revenues and profit or loss for the period from the acquisition date that were included in the consolidated statement of profit or loss.

(c) The acquiree's revenues and profit or loss for the period as if the acquisition date for the combination occurred was the beginning of the year.

(d) Property, plant and equipment: Market comparison and cost technique: evaluation model considers the market prices for similar items, when available, and the depreciated replacement cost, when appropriate. The depreciated replacement cost reflects wear and tear adjustments, as well as functional and economic obsolescence.

(e) Intangible assets: Relief-from-royalty method and multi-period excess earnings method: the relief-from-royalty method considers the discounted payments of estimated royalties that should be avoided as a result of patents acquired. The multi-period excess earnings method considers the present value of the expected net cash flows from relationships with clients, excluding any cash flow related to contributory assets

## 2.2 Acquisitions in the year 2020

### *Ímpar Serviços Hospitalares S.A.*

On November 7, 2019, the Company's Board of Directors approved the proposal to increase the Company's capital to be paid-up by the transfer of all the shares issued by Ímpar Serviços Hospitalares S.A., a company operating in the hospital segment of the same economic group of the Company's controlling shareholder. The Transaction was approved by shareholders at the general meeting held on November 22, 2019. After complying with the legal and regulatory procedures imposed by the Brazilian Securities and Exchange Commission ("CVM"), the capital increase was approved on January 23, 2020, and Ímpar became a wholly-owned subsidiary of the Company. The Transaction aims to facilitate and streamline the development of new businesses by both parties, accelerate technological innovations and offer services in a differentiated remuneration model, besides identifying opportunities for better optimization of its resources, meeting the interests of both companies and their shareholders.

Considering the minimum subscription amount of the Capital Increase of R$ 10,000,000, determined through an appraisal report at Ímpar's market value, with the issuance of 165,755,015 common shares, all nominative, book-entry and with no par value, the Board Members resolved, by unanimous vote and without qualifications, to approve the partial ratification of the Capital Increase, in the amount of R$ 10,000,000, by issuing 165,759,713 new common shares, all nominative, book entry and with no par value, as subscribed during the period to exercise the preemptive right and apportionment of the remaining shares, having canceled 3,826,543 unsubscribed shares. This process for issuing new shares, as well as the allocation of the remaining shares ("leftovers"), were approved by the Brazilian Securities and Exchange Commission (CVM) and disclosed to the market on January 24, 2020.

The assets transferred to Company's capital through Ímpar's shares were valued in accordance with article nº 8 of the Brazilian Corporation Law, by an independent appraiser engaged by the Company to carry out said valuation of the economic value of these shares. There was no cash contribution from Company's controlling shareholders.

The accounting standards, CPC 36 / IFRS 10 - Consolidated Financial Statements, address the business combination between companies under common control and determine the recognition of the transaction at its book value, which determines that the transaction must be based on the cost method of the predecessor, which considers the measurement of the assets and liabilities of the subsidiary that became controlled by the Company at their historical book values on the transaction date. Therefore, for accounting purposes, the transaction shall not result in the recognition of goodwill or any increase in shareholders' equity other than at cost as shown below: Therefore, after the acquisition, to reconcile the effects of the transaction considering both the Brazilian accounting practices adopted in Brazil, including the provisions of the CVM and IFRSs, the amount of R$ 9,243,944 was recorded as an equity valuation adjustment, reducing Shareholders' Equity, thus resulting in an increase in Shareholders' Equity at book value at cost.

Transactions with third parties:

***Allbrokers Brasil Corretora de Seguros Ltda.***

The intention and agreement occurred on February 17, 2020 and on April 01, 2020, the Company acquired 100% of the capital of Allbrokers Brasil Corretora de Seguros Ltda., a company headquartered in the city of São Paulo, State of São Paulo. The company is engaged in providing brokerage services involving property and casualty insurance, life insurance, capitalization, pension and health care plans, business management advisory, intermediation and agencing of services and businesses in general, as well as auxiliary activities for insurance, supplementary pension and health care plans.

The acquisition price of Allbrokers recorded by the Company was R$ 7,708, of which R$ 1,542 was paid as a downpayment on the date of signature, and R$ 6,166 was paid on the closing date, on April 01, 2020.

***Cromossomo Participações V S.A. ("Nexa")***

On May 11, 2020, the Company acquired 100% of the equity capital of Cromossomo Participações V S.A., a company headquartered in the city of São Paulo, State of São Paulo, as approved at a meeting of the Company's Board of Directors held on May 11, 2020. The company is engaged in the development and licensing of software, data processing and handling, Internet services, hosting, provider developments and other related activities, consulting, support, maintenance and other IT-related services. Nexa's technical skills and expertise will be applied by the Company to provide more customized and efficient healthcare services through the use of data analytics and artificial intelligence, as well as platforms (patient and physician appointments and journey/care coordination programs).

The acquisition value of Nexa recorded by the Company was R$ 43,700, the fixed price fully paid in cash upon the signing of the contract.

There was no contingent consideration as part of the purchase agreement and contingencies.

***São Marcos - Saúde e Medicina Diagnóstica S.A***

At a meeting of the Board of Directors held on June 5, 2020, the acquisition of a 100% equity interest of the capital of São Marcos – Saúde e Medicina Diagnóstica S.A., headquartered in the city of Belo Horizonte, State of Minas Gerais, was approved. The transaction for the acquisition of equity interest representing 100% of São Marcos capital was concluded on October 30, 2020. Moreover, the Company clarifies that the acquisition was made directly and fully in cash, therefore, without any right to withdraw under the terms of article nº 252 of Law nº 6,404/76.

Since the acquisition price exceeds the limits referred to in item II, article nº 256 of Law nº 6,404/76, the acquisition was submitted for ratification by the shareholders at the Extraordinary General Meeting. The meeting was held on November 12, 2020 and the acquisition was approved by the shareholders.

The acquisition was completed for the amount of R$ 130,000, as follows: i) R$ 125,000 paid in cash and fully settled on October 30, 2020; ii) R$ 5,000 to be paid in October 2025, monetarily restated by the change of 100% of the CDI for the period.

There was no contingent consideration as part of the purchase agreement and contingencies.

### *Santa Celina Participações S.A.*

On June 8, 2020, the Company acquired 60% of the equity capital of Santa Celina Participações S.A., a company headquartered in the city of São Paulo, State of São Paulo, as approved at a meeting of the Company’s Board of Directors held on June 08, 2020. Santa Celina is engaged at providing solutions and health care management with excellence and innovation, building an integrated, coordinated and sustainable health system, unifying data and generating information that support the decisions of doctors and multidisciplinary teams, in addition to continuous access to care, operational and financial indicators. Its clients are health care plan operators, self-management companies, companies from the most diverse segments, hospitals, brokers and health care insurers. The acquisition was carried out for R$ 70,510 in cash, fully paid upon execution of the contract.

*Acquisition of additional interest in Santa Celina Participações S.A.*

The accounting standards, CPC 36 / IFRS 10 - Consolidated Financial Statements, address the business combination between companies under common control and determine the recognition of the transaction at its book value, which determines that the transaction must be based on the cost method of the predecessor, which considers the measurement of the assets and liabilities of the subsidiary that became controlled by the Company at their historical book values on the transaction date. Therefore, for accounting purposes, the transaction shall not result in the recognition of goodwill or any increase in shareholders’ equity other than at cost.

As of October 5, 2020, the Company acquired the remaining 40% of the capital of Santa Celina Participações S.A. The acquisition was carried out for the amount of R$ 107,966, as follows: i) 43,186 in cash and fully settled upon execution of the agreement, ii) R$ 43,186 to be paid on March 31, 2022 duly adjusted by the change of 100% of the CDI for the period iii) R$ 21,594 to be paid on March 31, 2025, adjusted according to the change, positive or negative, of the appreciation/depreciation of the shares issued by the Company on the date of actual payment, and considering the base value per share issued by the Company of R$ 55.00 (390,545 shares). As of December 31, 2020, the base amount per share was R$ 72.50. Therefore, the fair value of the share was R$ 28,315 (- 21) and the change in the initial value, in the amount of R$ 6,721, was recognized in profit or loss for the year.

The book value of net assets (excluding goodwill on the original acquisition) at that date was R$ 3,604.

There was no contingent consideration as part of the purchase contract.

Santa Celina Participações contributed with revenues of R$ 56,984 and R$ 17,534 of loss from the acquisition date to December 31, 2020 to the Company’s profit or loss for the year. If the combination had taken place at the beginning of that year, the contribution with revenues would have totaled R$ 97,333 and the loss would have totaled R$ 25,768.

### *Laboratório Nobel S.A. (“Grupo Exame”)*

As of December 17, 2020, the acquisition of a 90% equity interest in Laboratório Nobel S.A., headquartered in the city of Novo Hamburgo, State of Rio Grande do Sul, was approved. Laboratório Nobel S.A. operates under the brands Exame, Antonello, Senhor dos Passos and CEC with a focus on clinical analysis.

Acquisition was carried out at the amount of R$ 70,417, divided into: i) R$ 27,559 in cash and fully settled on January 4, 2021, ii) R$ 27,558 over 2022, 2023 and 2024, restated by 100% of the CDI change for the period and iii) R$ 15,300 as contingent consideration (see disclosure of contingent consideration below) is also paid over 2022, 2023 and 2024 (- 21).

*Call and put option*

As part of the agreement to acquire equity interest, a put option was issued by the Company in favor of the non-controlling shareholders and a call option was issued by the Sellers in favor of the Company, which may result in an acquisition by the Company of the remaining 10% shares of Exame.

The call option is calculated at an amount equivalent to a multiple of recurring net operating income, plus net non-recurring income, less net debt. The result of this calculation will be divided by the total shares of Exames and multiplied by the total shares held by the Sellers. The fair value of the call option as of December 31, 2020, was R$ 1,000 and there was no balance as of December 31, 2021, recorded as a call option obtained from non-controlling shareholders (- 21).

For the exercise of the put option, it will be calculated at the fixed value of the shares, on the date of the first acquisition, plus the DI rate up to the option exercise date. Both put or call options are exercisable from January 1, 2021 to December 2022.

As the put option granted to non-controlling shareholders provides for cash settlement, the Company recognized a liability at the present value of the option strike price in the amount of R$ 16,552 as of December 31, 2020 and R$ 14,762 as of December 31, 2021. (- 21).

The Company has determined that non-controlling shareholders still have current access to returns associated with Exame's underlying equity interests. The Company opted to account for the put option under the current access method under which the non-controlling shareholder continues to be recognized and the amount was debited to "Equity valuation adjustments". The Company's policy is to recognize subsequent changes in the value of this instrument in shareholders' equity.

Contingencies, when they exist, are recorded at fair value and are sufficient to meet the requirements of CPC 15 / IFRS 3 - Business Combinations.

As part of the purchase contract, a contingent consideration was agreed. Additional payments will be made as follows:

(a) R$ 15,300, if the acquired company generates a 18% growth in gross operating revenue, equivalent to R$ 65,000 as of December 31, 2020.

On the acquisition date, the fair value of the contingent consideration was estimated at R$ 15,300 based on discounted cash flows considering the present value of expected future payments, through projections of results based on the maximum amount. As of December 31, 2021, the main performance indicators of Laboratório Nobel S.A. evidenced the fulfillment of the stipulated goal.

***Instituto de Hematologia de São José do Rio Preto Ltda. ("Hemat")***
As of December 18, 2020, the acquisition of equity interest representing 80% of the capital of Instituto de Hematologia de São José do Rio Preto Ltda. was approved. The Institute was founded in 1990 and serves the city of São José do Rio Preto and region, counting on a staff of approximately 130 employees. Hemat was acquired so that the Company could operate in the city of São José do Rio Preto, an important medical center in the State of São Paulo, and expand its operations through several initiatives.

Acquisition was carried out at the amount of R$ 19,550, divided into: i) R$ 7,820 in cash and fully paid on January 4, 2021, ii) R$ 5,865 to be paid on December 18, 2021, and iii) R$ 5,865 to be paid on December 18, 2022, corrected by 100% of the CDI variation for the period. (- 21).

*Call and put option*
As part of the agreement to acquire equity interest, a put option was issued by the Company in favor of the non-controlling shareholders and a call option was issued by the Sellers in favor of the Company, which may result in an acquisition by the Company of the remaining 20% shares of Hemat.

The call option is calculated at an amount equivalent to a multiple of recurring net operating income, plus net non-recurring income, less net debt. The result of this calculation will be divided by the total shares of Hemat and multiplied by the total shares held by the Sellers. The fair value of the call option as of December 31, 2021, was R$ 610 (R$ 1,270 in 2020), recorded as a call option obtained from non-controlling shareholders (- 21).

For the exercise of the put option, it will be calculated at the fixed value of the shares, on the date of the first acquisition, plus the DI rate up to the option exercise date. Both put or call options are exercisable from January 2021 to December 2023.

As the put option granted to non-controlling shareholders provides for cash settlement, the Company recognized a liability at the present value of the option strike price in the amount of R$ 7,884 (R$ 5,694 in 2020) (- 21).

The Company has determined that non-controlling shareholders still have present access to the returns associated with the underlying equity interests of Hemat. The Company opted to account for the put option under the current access method under which the non-controlling shareholder continues to be recognized and the amount was debited to "other reserves - equity valuation adjustment". The Company's policy is to recognize subsequent changes in the value of this instrument in shareholders' equity.

There was no contingent consideration as part of the purchase agreement, and contingencies, if any, are recorded at fair value and are sufficient to meet the requirements of CPC 15 / IFRS 3 - Business Combinations.

*Acquisition of additional interest in Laboratório Santa Luiza*
On October 15, 2020, the Company acquired the remaining 49.99% of the common shares of Laboratório Santa Luzia, totaling 100% of the equity interest. The consideration transferred was R$ 91,601 - as follows: R$ 90,461 paid in full on the acquisition date and R$ 1,140 in shares (17,534 shares) from the Company's treasury.

The table that follows summarizes the fair value on the acquisition date of transferred consideration:

| | |
|---|---:|
| Cash | 90,461 |
| Equity instruments (17,534 common shares) (a) | 1,140 |
| **Total consideration transferred:** | **91,601** |

(a) The fair value of the common shares was measured based on the market value of the share price on the acquisition date of R$ 65.02 per share.

The opening of the additional interest obtained is as follows:

| | |
|---|---:|
| Consideration paid to non-controlling shareholders | 84,963 |
| Book value of the additional interest acquired (49.99% of R$ 13,279) | 6,638 |
| Difference recognized in retained earnings | 91,601 |

The book value of net assets (excluding goodwill on the original acquisition) at that date was R$ 13,279.

*Fair value of identifiable assets acquired and liabilities assumed*
The fair value of assets acquired and liabilities assumed at the acquisition date is as follows:

| | **Ímpar (f)** | **Allbrokers** | **Nexa** | **São Marcos** | **Santa Celina** | **Exame** | **Hemat** |
|---|---:|---:|---:|---:|---:|---:|---:|
| **Acquisition date** | 01/23/2020 | 02/17/2020 | 05/11/2020 | 06/05/2020 | 06/08/2020 | 12/17/2020 | 12/18/2020 |
| **Interest acquired** | 100% | 100% | 100% | 100% | 60% | 90% | 80% |
| Call option obtained from non-controlling shareholders - updated on September 30, 2021 | - | - | - | - | - | 144 | 652 |
| Put option granted to non-controlling shareholders - updated on September 30, 2021 | - | - | - | - | - | 17,731 | 7,984 |
| **Assets** | | | | | | | |
| Cash and cash equivalents | 566,705 | 170 | 2,076 | 22,603 | 8,083 | 4,431 | 2,831 |
| Interest earning bank deposits | 1,101 | - | - | - | - | - | - |
| Trade accounts receivable | 529,161 | - | - | 52,921 | 21,047 | 18,607 | 1,792 |
| Inventories | 65,870 | - | - | 4,839 | 601 | - | 399 |
| Recoverable taxes | 26,972 | 123 | 37 | 10,355 | 4,204 | 254 | 5 |
| Prepaid expenses | 22,030 | - | - | 491 | 189 | 118 | 828 |
| Deferred taxes | 65,962 | - | - | 67 | 858 | - | - |
| Derivative financial instruments | 41,552 | - | - | 4,185 | - | - | - |
| Judicial deposits | 12,501 | - | - | 2,203 | 431 | 98 | - |
| Other receivables | 20,915 | 76 | 2,532 | 270 | 2,132 | 142 | - |
| Investment | - | - | - | 436 | - | - | 59 |
| Property, plant and equipment **(g)** | 1,166,249 | - | 510 | 36,065 | 5,047 | 6,209 | 235 |
| Intangible assets **(h)** | 15,806 | - | 24,002 | 4,164 | 4,510 | 1,025 | 4,602 |
| Right of use | 469,304 | - | - | 37,415 | 4,831 | 6,118 | - |
| Intangible assets - Trademark | - | 1,481 | - | 44,282 | 31,477 | 22,290 | 3,610 |
| Intangible assets - Non-contractual relationship with client | - | 705 | - | 14,110 | 28,400 | 10,472 | 1,696 |
| **Total identifiable assets acquired** | **3,004,128** | **2,555** | **29,157** | **234,406** | **111,810** | **69,764** | **16,057** |
| **Liabilities** | | | | | | | |
| Suppliers | (245,331) | - | - | (16,297) | (5,135) | (3,756) | (1,082) |
| Loans and financing | (440,923) | (3,867) | - | (81,506) | (18,941) | (25,588) | (4,322) |
| Debentures | (601,571) | - | - | - | - | - | - |
| Social charges and labor legislation obligations | (127,294) | (740) | (1,309) | (8,061) | (7,594) | (3,573) | (558) |
| Income tax and social contribution payable | (28,667) | - | - | - | - | - | - |
| Taxes and contributions payable | - | - | (24) | (7,982) | (3,611) | (2,440) | (163) |
| Taxes in installments | (77,833) | - | - | (6,492) | - | (1,758) | - |
| Deferred taxes | | - | - | - | - | (230) | - |
| **Deferred tax liabilities** | | | | | | | |
| Interest on own capital | (125,157) | - | - | - | (2,480) | | - |
| Accounts payable from acquisition of subsidiaries | - | - | - | (2,810) | - | (9,216) | - |
| Lease liabilities | (489,138) | - | - | (40,016) | (5,556) | (6,117) | - |

| | Ímpar (f) | Allbrokers | Nexa | São Marcos | Santa Celina | Exame | Hemat |
|---|---|---|---|---|---|---|---|
| Derivative financial instruments | (12,427) | - | - | - | - | - | - |
| Tax, social security, labor and civil provisions | (51,206) | - | - | (2,621) | (391) | (61) | - |
| Other accounts payable and provisions | (48,525) | (208) | (3,226) | (26,414) | (244) | (648) | (860) |
| **Total liabilities assumed** | **(2,248,072)** | **(4,815)** | **(4,559)** | **(192,208)** | **(44,550)** | **(53,387)** | **(6,985)** |
| **Total assets, net** | **756,056** | **(2,260)** | **24,598** | **42,198** | **67,260** | **16,377** | **9,072** |
| Goodwill on acquisition **(a)** | - | 9,968 | 19,102 | 106,925 | 27,696 | 52,401 | 11,279 |
| Non-controlling interest **(b)** | - | - | - | - | (2,953) | 1,639 | (801) |
| **Total consideration transferred (c)** | **-** | **7,708** | **43,700** | **149,123** | **92,003** | **70,417** | **19,550** |
| **Breakdown of consideration:** | | | | | | | |
| Contingent consideration (- 21) | - | - | - | - | - | 15,300 | - |
| Cash | - | 7,708 | 43,700 | 130,000 | 70,510 | 55,117 | 19,550 |
| Total assets, net | 756,056 | (2,206) | 24,598 | 55,530 | 41,670 | 16,377 | 9,072 |
| Total goodwill | - | 9,968 | 19,102 | 74,470 | 31,793 | 52,401 | 11,279 |
| Contribution to the DASA Group - Revenues since the acquisition date **(d)** | 2,690,793 | 3,347 | - | 40,050 | 56,984 | - | - |
| Contribution to the DASA Group - (loss) profit since the acquisition date **(d)** | (43,378) | (6,997) | - | 908 | (17,534) | - | - |
| Contribution to the DASA Group - Revenues since the beginning of the year **(e)** | 2,740,256 | 4,342 | - | 175,569 | 97,333 | 96,336 | 18,930 |
| Contribution to the DASA Group - (loss) profit since the beginning of the year **(e)** | (39,387) | (7,885) | (6,875) | (600) | (25,768) | 32,427 | 1,875 |

**(a)** Goodwill is mainly attributed to the qualification and technical talent of the workforce and the synergies expected to be obtained with the integration of the acquiree into DASA Group. No goodwill recognized is expected to be deductible for tax purposes until the merger.

**(b)** The non-controlling interest was estimated based on the proportional interest granted by the equity instruments in the recognized amounts of the acquiree's identifiable net assets.

**(c)** In 2021, São Marcos and Santa Celina had adjustments in the consideration transferred in the amount of R$ 19,392 and R$ 21,493, respectively, totaling R$ 40,885. The adjustment is within the measurement period and directly affected the goodwill recognized in the business combination, therefore, the total consideration transferred was R$ 149,123 and R$ 92,003, respectively.

**(d)** The acquiree's revenues and profit or loss for the period from the acquisition date that were included in the consolidated statement of profit or loss.

**(e)** The acquiree's revenues and profit or loss for the period as if the acquisition date for the combination occurred was the beginning of the year.

**(f)** The accounting standards, CPC 36 / IFRS 10 - Consolidated Financial Statements, address the business combination between companies under common control and determine the recognition of the transaction at its book value, which determines that the transaction must be based on the cost method of the predecessor, which considers the measurement of the assets and liabilities of the subsidiary (Impar) that became controlled by the Company at their historical book values on the transaction date. Therefore, for accounting purposes, the transaction did not result in the recognition of goodwill or any increase in shareholders' equity other than at cost.

**(g)** Property, plant and equipment: Market comparison and cost technique: evaluation model considers the market prices for similar items, when available, and the depreciated replacement cost, when appropriate. The depreciated replacement cost reflects wear and tear adjustments, as well as functional and economic obsolescence.

**(h)** Intangible assets: Relief-from-royalty method and multi-period excess earnings method: the relief-from-royalty method considers the discounted payments of estimated royalties that should be avoided as a result of patents acquired. The multi-period excess earnings method considers the present value of the expected net cash flows from relationships with clients, excluding any cash flow related to contributory assets.

# 3 Preparation basis

## 3.1 Statement of conformity (regarding the Accounting Pronouncement Committee (CPC) standards)

The individual financial statements were prepared according to accounting practices adopted in Brazil and consolidated financial statements were prepared according to accounting practices adopted in Brazil and International Financial Reporting Standards - IFRS issued by the International Accounting Standards Board (IASB).

The issuance of individual and consolidated financial statements was authorized by the Board of Directors during a meeting held on March 28, 2022.

All material information proper to the individual and consolidated financial statements, and only it, is being evidenced, and corresponds to those used by Management for administration.

## 3.2 Statement of value added ("DVA")

The presentation of the Individual and Consolidated Statement of Value Added is required by Brazilian corporate law and the accounting practices adopted in Brazil applicable to publicly-held companies.

International Financial Reporting Standards ("IFRS") do not require presentation of this statement. For IFRS purposes, this statement is presented as supplementary information, and not as part of the required set of individual and consolidated interim financial information.

## 3.3 Functional and presentation currency

Individual and consolidated financial statements are being presented in reais, functional currency of the Company and its subsidiaries. All financial information presented in reais (R$) has been rounded to the nearest value, except otherwise indicated. For the subsidiaries in Argentina, the functional currency is the Argentine Peso (ARS), for the subsidiary in Uruguay, the functional currency is the Uruguayan Peso (UYU), and for the Chilean subsidiary, the functional currency is the Chilean Peso (CHL) and for the subsidiary in Colombia is the Colombian Peso (COP) which have been converted to Real (R$).

### *Transactions and balances:*

Transactions in foreign currency are initially recorded at the exchange rate of the functional currency in force on the date of transaction. Monetary assets and liabilities denominated in foreign currency are translated at the closing exchange rate prevailing at the statement of financial position date. All differences are reported in the statement of profit or loss.

Non-monetary items measured at the historical cost in foreign currency are translated using the exchange rate in force on the transaction date. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rate on the dates that the fair value was measured.

The Company tracks goodwill and any fair value adjustments made to the book values of assets and liabilities arising from the acquisition as assets and liabilities of subsidiaries. Accordingly, these assets and liabilities will be translated into the presentation currency of the individual and consolidated financial statements.

### *Subsidiaries:*

The assets and liabilities of foreign subsidiaries are translated into Reais (R$) at the exchange rate on the respective statement of financial position date, and the corresponding statements of profit or loss are translated based on foreign exchange rates in force on the transaction date, as well as the statements of cash flows. Foreign exchange differences derived from this translation are accounted for in other comprehensive income.

Any goodwill and adjustments to the fair value of the book values of assets and liabilities arising from the acquisition are treated as assets and liabilities of the foreign subsidiary and translated at the exchange rate on the reporting date.

## 3.4 Use of estimates and judgments

In the preparation of these individual and consolidated financial statements, Management used judgments and estimates that affect the application of DASA Group's accounting policies and the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from these estimates.

Estimates and assumptions are reviewed on a continuous basis. Reviews of estimates are recognized on a prospective basis.

### *Judgments*

Information about judgment referring to the adoption of accounting policies which impact significantly the amounts recognized in the individual and consolidated financial statements are included in the following -s:

- 13 - Investments: determine if the parent company and its subsidiaries in fact holds control over an investee.

### *Uncertainties on assumptions and estimates*

Information on uncertainties as to assumptions and estimates as of December 31, 2021 that pose a high risk of resulting in a material adjustment in book balances of assets and liabilities in the next fiscal year are included in the following -s:

- 2 - Acquisition of subsidiary (business combination): fair value of identifiable intangible assets (non-competition agreement, non-contractual relationship with customers and brands) and goodwill, measured on a provisional basis when specified;
- 9 - Analysis of expected losses due to bad debt and variable consideration;
- 15 – Review of the useful life of intangible assets and impairment test of intangible assets and goodwill;
- 18 – Determination of discount rate on lease;
- 22 - Recognition and measurement of provision for tax, social security, labor and civil claims, main assumptions on the probability and volume of outflows;
- 25 - Revenue recognition: estimation of expected variable considerations (disallowances);
- 30 - Recognition of deferred tax assets: availability of future taxable income against which tax losses may be used; and
- 32 - Assumptions used to calculate the fair value of financial instruments.

### *Measurement of fair value*

A series of DASA Group's accounting policies and disclosures requires the measurement of fair value, for financial and non-financial assets and liabilities.

DASA Group established a control structure for measuring fair value. This includes the responsibility of reviewing all significant fair value measurements, including Level 3 fair values, and directly report to the Financial Executive Board and Top Management of DASA Group.

If third-party information, such as brokerage firms' quotes or pricing services, is used to measure fair value, then the management assesses the evidence obtained from the third parties to support the conclusion that such valuations meet the requirements of the terms of the technical pronouncement CPC / IFRS requirements, including the level in the fair value hierarchy in which such valuations should be classified.

When measuring fair value of an asset or liability, the DASA Group uses observable data as much as possible. Fair values are classified at different levels according to hierarchy based on information (inputs) used in valuation techniques as presented in - 32 - Financial instruments.

The DASA Group recognizes transfers between fair value hierarchic levels at the end of individual and consolidated financial statements year in which changes occurred.

### 3.5 Measuring basis

The individual and consolidated financial statements were prepared based on the historical cost, except for the following items recognized in the statements of financial position:

- Non-derivative financial instruments measured at fair value through profit or loss;
- Contingent payments assumed in a business combination are measured at fair value; and
- Liabilities for share-based payment transactions settled in cash measured at fair value.

## 4 Significant accounting policies

The accounting practices described in detail below have been consistently applied by the Company and its subsidiaries to all the years presented in these individual and consolidated financial statements. We present below the significant accounting policies, whose details are available in the following -s:

### a. Basis of consolidation

***Business combinations***

Business combinations are recorded using acquisition method when control is transferred to the Company and its subsidiaries. The consideration transferred is usually measured at fair value, as well as the identifiable net assets acquired. Any goodwill arising in the transaction is tested annually for impairment. Gains in a bargain purchase are immediately recognized in profit or loss. Transaction costs are recorded in profit or loss as incurred, except the costs related to the issuance of debt or equity instruments.

Transferred consideration does not include amounts referring to payment of pre-existing relations.

These amounts are usually recognized in profit or loss for the year.

Any contingent consideration payable is measured at its fair value on acquisition date. If the payment is classified as an equity instrument, it is not remeasured and the liquidation is recorded in shareholders' equity. The remaining contingent consideration is remeasured at fair value on each reporting date, and subsequent changes in fair value are recorded in the statement of profit and loss for the year.

***Subsidiaries***

The Company controls a company when it is exposed to, or has a right over the variable returns arising from its involvement with the company and has a significant influence of affecting those returns exerting its power over the company.

The financial information of subsidiaries is recognized under the equity method in the individual financial statements of the parent company.

The consolidated financial statements include the financial information of the Company and its subsidiaries. Information on subsidiaries is presented in - 13.

***Interest of non-controlling shareholders***

The Company decided to measure non-controlling interests at their proportion interest in identifiable net assets of the acquiree on the acquisition date.

Changes to the Company’s interest in a subsidiary that do not result in loss of control are accounted for as transactions from shareholders’ equity.

***Loss of control***

When the entity loses control over a subsidiary, the Company derecognizes the assets and liabilities and any non-controlling interests and other items recorded in the shareholders’ equity related to this subsidiary. Any gain or loss resulting from loss of control is recognized in profit or loss. If the Company holds any in interest in former subsidiary, this interest is measured at fair value on the date control is lost.

***Investments in entities accounted for at the equity method***

The Company’s investments in entities accounted for at the equity method include interests in subsidiaries.

Such investments are initially recognized by the cost, which includes expenses with transactions. After initial recognition, financial statements include the Company’s interest in profit or loss for the year and other comprehensive income of the investee up to the date in which significant influence or joint control no longer exists.

***Transactions eliminated in the consolidation***

Balances and transactions between the companies of the group and any unrealized revenues or expenses derived from intragroup transactions, are eliminated. Unrealized gains originating from transactions with investees recorded using the equity method are eliminated against the investment in the proportion of the Company's interest in the investee. Unrealized losses are eliminated in the same way as unrealized gains, but only up to the point where there is no evidence of loss due to impairment.

## b. Foreign currency

### *Foreign currency transactions*

Transactions in foreign currency are translated into the respective functional currencies of the Company and its subsidiaries at the exchange rates on the dates of the transactions.

### *Foreign operations*

Foreign transactions' assets and liabilities, including goodwill and adjustments to fair value resulting in the acquisition, are translated into reais (R$) at the exchange rate prevailing on statement of financial position date. Foreign transactions' income and expenses are translated into Reais at exchange rates prevailing on transaction dates. The differences in foreign currencies generated for the translation into the presentation currency are recognized in other comprehensive income and accumulated in the equity valuation adjustments in shareholders' equity account. For subsidiaries whose economy is considered hyperinflationary, as in the case of Maipú and Genia in Argentina, the exchange rate at the statement of financial position date is used when translating the statement of financial position and statement of profit or loss to the presentation currency. If the subsidiary is not a wholly-subsidiary, the corresponding portion of the translation difference is allocated to the non-controlling shareholders.

In July 2018, considering that the inflation accumulated in the last three years in Argentina was above 100%, the adoption of the accounting and reporting standard in a hyperinflationary economy (CPC 42 / IAS 29) became mandatory.

In accordance with CPC 42 / IAS 29, non-monetary assets and liabilities, shareholders' equity, and statements of profit or loss of subsidiaries operating in hyperinflationary economies are adjusted according to the change in the general purchasing power of currency, applying a general price index.

The financial statements of an entity whose functional currency is the currency of a hyperinflationary economy should be expressed in terms of the current measurement unit at the statement of financial position date and translated into Reais at the closing exchange rate for the period.

In view of the above, the Company applied the hyperinflationary economy accounting for its subsidiary in Argentina, adopting the rules of CPC 42 / IAS 29 as follows:

- Non-monetary assets and liabilities recorded at historical cost (e.g., property, plant and equipment, intangible assets, inventories, etc.) and the subsidiary's equity in Argentina were adjusted based on an inflation index. The impacts of hyperinflation arising from the change in general purchasing power up to the date of acquisition of the Companies were reported in equity under "Other comprehensive income". The impacts of the general purchasing power from the acquisition were reported in the statement of profit or loss in a specific hyperinflation adjustment account, in the financial income. In CPC 42 / IAS 29, there is no general price index defined, but it allows the use of judgment when updating the financial statements is necessary. Therefore, used indices were based on Resolution 539/18 of the Argentinian Federation of the Council of Economic Sciences' Professionals: i) from January 1, 2017 onwards, domestic IPC (national index of prices to consumer; ii) up to December 31, 2016, IPIM (wholesale prices' domestic index).

- The statement of profit or loss is adjusted at the end of each reporting period by the change of the general price index and, subsequently, converted by the exchange rate at the end of each period (instead of the average), resulting, in the year to date, in the accounts of the statement of profit or loss, the effects of the inflation index and exchange rate conversion.

## c. Operating revenue

### *Service revenues*

Operating revenues correspond substantially to the amount of considerations received or receivable for the sale of services in the regular course of activities of the Company and its subsidiaries.

IFRS 15 establishes a five-step model, applicable to the calculation of revenues from contracts with customers. The Company's and its subsidiaries' revenues derive from the provision of diagnostic and hospital services. Revenue is recognized in profit or loss for the year based on contracted amounts to the extent that it is probable that economic benefits will be generated for the Company and its subsidiaries, revenue can be measured reliably and considering that control and all rights and rewards arising from the services provided flow to the customer. Revenue is not recognized if there are uncertainties as to its realization.

The contracts signed between the Company and its subsidiaries and their respective customers are commercial by nature, as they are approved by the parties and have rights for each of the parties, as well as the payment conditions identified.

Revenue is recognized at a point in time at an amount that reflects the consideration that an entity expects to be entitled to in exchange for services provided to a customer, net of related taxes, and variable consideration, such as estimated trade discounts and disallowances.

Contracts with health plan payers include variable consideration and, therefore, the Company and its subsidiaries estimate the corresponding revenue considering contractual prices and historical disallowances. The Company and its subsidiaries use the expected value method to estimate the variable consideration due to the large number of insurance companies that have similar characteristics and based on statistics of historical percentages of disallowances for the last 3 years. The Company and its subsidiaries reassess the accuracy of the percentage on a quarterly basis. As of December 31, 2021, the average of disallowances on the parent company's gross revenue was 0.8% (1.9% as of December 31, 2020) and the consolidated was 1.1% (1.7% as of December 31, 2020).

There are no return or refund obligations, nor a significant funding component.

## d. Financial revenues and costs

Financial revenues basically comprise revenue from interest on Interest earning bank deposits, foreign exchange gain and receivables. Interest revenue is recognized in profit or loss using the effective interest method.

Financial expenses include mainly expenses with interest on debentures, bank loans and financing. This balance also includes foreign exchange loss, bank charges, tax on financial transactions, income tax paid on remittance of interest abroad, interest on tax installment payment, financial discounts granted to clients and monetary updating of contingencies.

### e. Income tax and social contribution

The income tax and social contribution for the year, both current and deferred, are calculated using 15% rate and an additional charge of 10% on taxable income of R$ 240 for income tax and 9% on taxable income for social contribution on net income, and consider the offsetting of tax losses and negative basis of social contribution, limited to 30% from the taxable income for the year.

***Current income and social contribution tax expenses***

Current tax expense is the tax payable or receivable on the taxable profit or loss for the year and any adjustments to taxes payable in relation to prior years. The amount of current taxes payable or receivable is recognized in the statement of financial position as an asset or tax liability under the best estimate of the expected amount of taxes to be paid or received reflecting the uncertainties related to its calculation (if any), measured based on tax rates in force on the statement of financial position date.

***Expenses with deferred income tax and social contribution***

Deferred tax assets and liabilities are recognized in relation to the temporary differences between the book values of assets and liabilities for financial statement purpose and the related amounts used for taxation purposes. The changes in deferred tax assets and liabilities for the year are recognized as deferred income tax and social contribution expense. Deferred taxes are not recognized for:

- Temporary differences on the initial recognition of assets and liabilities in a transaction that is not a business combination, and not affecting the taxable, accounting profit or loss;

- Temporary differences related to investments in subsidiaries, associated companies and joint ventures to the extent that the Company is able to control the timing of the reversal of the temporary difference and it is probable that it will not be reversed in the foreseeable future; and

- Taxable temporary differences arising from the initial recognition of goodwill.

A deferred tax asset is recognized for unused tax losses, tax credits and unused deductible temporary differences, to the extent that it is probable that future taxable income will be available against which the credits will be utilized. Future taxable income is determined based on the reversal of relevant taxable temporary differences. If the amount of the taxable temporary differences is insufficient to fully recognize a deferred tax asset, the future taxable income, adjusted for reversals of the existing temporary differences, will be considered, based on the business plans of the parent company and of its subsidiaries, individually.

Deferred tax assets and liabilities are measured at tax rates expected to be applied to temporary differences when they are reversed, based on rates decreed up to the statement of financial position date. Deferred tax assets and liabilities are offset only if certain criteria are met.

### f. Inventories

Inventories are valued at historical cost less the lower amount between the cost and net realizable value. The inventories are fully used in the process of performing clinical analysis tests, imaging diagnostics, hospital supplies items, medications, and consumables to be used with the patients treated at the hospital.

Pharmaceutical, clinical and medical supplies have an expiration date assigned by the manufacturer. The expiration date is established based on the results of stability tests obtained on the primary packaging and secondary packaging. A provision for obsolescence was set up for items that have not changed for more than 180 days and for those that will expire in the same period. All expired items are written off.

## g. Property, plant and equipment

### *Recognition and measurement*

Property, plant and equipment items are stated at historical acquisition or construction cost, including loan cost capitalized, net of accumulated depreciation and impairment losses.

When significant parts of a property, plant and equipment item have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

### *Subsequent costs*

Subsequent costs are capitalized only when it is probable that associated future benefits may be earned by the Company and its subsidiaries.

### *Depreciation*

Depreciation is calculated to amortize the cost of items of property, plant and equipment, net of their estimated residual values, using the straight-line method based on estimated useful lives of such items. Leased assets are depreciated over the shorter of the estimated useful life of the asset and the contractual term, unless it is certain that the Company and its subsidiaries will become the owner of the asset at the end of the lease term.

Depreciation methods, useful lives and residual values are reviewed on each fiscal year and adjusted if appropriate. The estimated useful lives for property, plant and equipment are disclosed in - 14.

## h. Intangible assets

### *Recognition and measurement*

*Goodwill*

Goodwill arising from the acquisition of subsidiaries is included in investments in subsidiary's financial statements. On the acquisition date, the acquisition cost is considered at the purchase price, representing the fair value of assets and liabilities assumed or incurred, and including any costs related to contingent or deferred additional payments. The transaction costs are recognized in profit or loss when incurred. The acquisition cost is allocated to the acquired assets, liabilities and contingent liabilities assumed based on their respective fair values, including assets and liabilities that were not previously recognized in the acquired entity's statement of financial position, such as intangible assets, as trademark and contracts.

*Research and development*
Research and development expenditures are recognized in profit or loss as incurred. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company and its subsidiaries intend to and has sufficient resources to complete development and use or sell the asset. Other development expenses are recognized in the profit or loss as incurred. After the initial recognition, capitalized development expenditures are measured at cost less accumulated amortization and any accumulated impairment losses.

*Subsequent expenses*
Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate.

*Amortization*
Amortization is calculated using the straight-line method based on estimated useful lives of such items, net of estimated residual values and amortization recognized in profit or loss. Goodwill is not amortized. The estimated useful lives are disclosed in - 15.

Amortization methods, useful lives and residual values are reviewed on each fiscal year and adjusted if appropriate.

## i. Financial instruments

***Financial assets and liabilities - Recognition and derecognition***
The Company and its subsidiaries initially recognize the trade accounts receivable and debt instruments on the date that they were originated. All other financial assets and liabilities are recognized on the date of the negotiation when the Company becomes a party to the contractual provisions of the instrument. The Company and its subsidiaries derecognize a financial asset when the contractual rights to the cash flow of the asset expire, or when the Company and its subsidiaries transfer the rights to the reception of contractual cash flows on a financial asset. The Company and its subsidiaries derecognize a financial liability when its contractual obligations are discharged or canceled or expire.

***Financial assets - Classification, subsequent measurement and gains and losses***
All financial assets not classified as measured at amortized cost or at fair value through other comprehensive income (FVTOCI), as described above, are classified at fair value through profit or loss (FVTPL). At initial recognition, the Company and its subsidiaries may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortized cost or at fair value through other comprehensive income (FVTOCI), as fair value through profit or loss (FVTPL) if it eliminates or significantly reduces an accounting mismatch that would otherwise arise.

A financial asset is measured at amortized cost if it meets both conditions below and is not designated as measured at fair value through profit or loss (FVTPL): (i) it is maintained within a business model whose purpose is to maintain financial assets to receive contractual cash flows; and (ii) its contractual terms generate, on specific dates, cash flows only related to the payment of principal and interest on outstanding principal value.

A debt instrument is measured at fair value through other comprehensive income (FVTOCI) if it meets both conditions below and is not designated as measured at fair value through profit or loss (FVTPL): (i) it is maintained within a business model whose purpose is achieved by both the receipt of contractual cash flows and the sale of financial assets; and (ii) its contractual terms generate, on specific dates, cash flows which are only payments of principal and interest on outstanding principal value.

- Any gain or loss on derecognition is recognized in profit or loss.

***Non-derivative financial liabilities - classification, subsequent measurement and gains and losses***

Financial liabilities were classified as measured as amortized cost or at fair value through profit or loss (FVTPL). A financial liability is classified as measured at fair value through profit or loss if it is classified as held-for-trading it is a derivative or it is designated as such on initial recognition. Financial liabilities measured at fair value through profit or loss (FVTPL) are measured at fair value and net profit or loss, plus interest, is recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense, foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss.

## j. Employee benefits

***Short-term employee benefits***

Employee short-term benefits are measured on a non-discounted basis and incurred as expenses as the related service is rendered. The liability is recognized at the amount expected to be paid under the cash bonus plans or short-term profit sharing if the Company and its subsidiaries have a legal or constructive obligation to pay this amount as a result of prior service rendered by the employee, and the obligation can be reliably estimated.

***Share-based payment agreements***

The current Plan is part of the Company's remuneration policy to foster the performance of the beneficiaries and encourage their commitment to the Company's results in the short, medium and long term, as well as aligning their interests with those of the shareholders.

The fair value of grants to beneficiaries is recognized as an expense in the profit or loss in proportion to the period incurred from the contracts entered into until the statement of financial position dates.

## k. Capital

***Common shares***

When applicable, additional costs directly attributable to the issuance of shares and share options are recognized as reducers of shareholders' equity. Tax effects related to the costs of these transactions are calculated in accordance with terms of the Technical Pronouncement CPC 32 / IAS 12.

***Repurchase and re-issuance of shares (treasury shares)***
When shares recognized as net assets are repurchased, the value of the consideration paid which includes any costs directly attributable is recognized as a deduction from net assets. The repurchased shares are classified as treasury shares and presented as a deduction from net assets. When treasury shares are sold or reissued subsequently, the amount received is recognized as an increase in net assets, and the resulting gain or loss from the transaction is shown as capital reserve.

***Earnings per share – Basic and diluted***
Basic earnings per share are calculated by dividing profit for the year assigned to the Company's shareholders by the weighted average of the number of paid-up capital and outstanding shares in respective year.

The diluted earnings per share are calculated by adjusting the profit or loss and the weighted average of the number of shares, taking into account the conversion of all potential shares with dilution effect. Potential shares are equity instruments or contracts capable of resulting in the issuance of shares, such as convertible securities and options, including employee stock options, which have a dilutive effect for the years presented, pursuant to technical pronouncement CPC 41 / IAS 33.

## l. Impairment

***Non-derivative financial assets***
Financial assets not classified as financial assets at fair value through profit or loss, including investments accounted for under the equity method, are evaluated at each statement of financial position date to determine if there are objective impairment evidence.

***Financial assets measured at amortized cost***
The Company and its subsidiaries consider as evidence of impairment of assets measured at amortized cost both individually and on an aggregate basis. All individually significant receivables are assessed for impairment. Those non-impaired on an individual basis are collectively assessed for any impairment loss not yet identified. Assets that are not individually significant are assessed on an aggregate basis in relation to impairment by grouping the assets with similar risk characteristics.

When assessing impairment loss on an aggregate basis the Company and its subsidiaries make use of historical trends of the recovery term and the amounts of losses incurred, adjusted to reflect the Management's judgment if the current economic and credit conditions are such that the actual losses will probably be higher or lower than those suggested by historical trends.

***Investees accounted for under the equity method***
An impairment loss referring to an investee valued under the equity method is measured by comparing the investment's recoverable value to its book value. An impairment loss is recognized in the statement of profit or loss and is reversed if there has been a favorable change in the estimates used to determine the recoverable value.

### *Non-financial assets*

The book values of the non-financial assets of the Company and its subsidiaries, except for inventories and deferred tax assets are reviewed at each statement of financial position date for indication of impairment. If such indication exists, the asset's recoverable amount is estimated. In case of goodwill, recoverable value is tested on an annual basis.

For impairment tests, assets are grouped into CGUs, that is, the smallest identifiable group of assets that can generate cash inflows by continuous use, which are highly independent from cash inflows referring to other assets or cash generating units. Goodwill in a business combination is allocated to cash generating units or groups of cash generating units that are expected to benefit combination synergy. Recoverable value of an assets or CGU is the higher of value in use and fair value less selling costs. Value in use is based on estimated future cash flows discounted to present value using a discount rate before taxes that reflects current market evaluations of times value of money and the specific risks of the assets or CGU. An impairment loss is recognized when the carrying amount of an asset or its CGU exceeds its recoverable value. An impairment loss related to goodwill is not reversed. Regarding other assets, impairment losses are reversed only with the condition that the new book value of the asset does not exceed the book value that would have been calculated, net of depreciation or amortization, if the value loss had not been recognized.

## m. Provisions

If the Company and its subsidiaries have a legal obligation as a result of a past event, which can be reliably estimated, and it is probable that an outflow of funds will be required to settle the obligation. Effects from derecognition of discount for elapsing of time are recognized in profit or loss as financial expense.

## n. Leases

At the inception of an agreement, the Company and its subsidiaries evaluate whether the agreement is for or contains a lease. A contract is, or contains, a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company and its subsidiaries follow the definition of lease under CPC 06 (R2) / IFRS 16 to assess whether an agreement transfer the right to control the use of an identified asset.

### *As a lessee*

At the inception or amendment of an agreement containing a lease component, the Company and its subsidiaries allocate the lease consideration to each lease and non-lease component based on its individual prices.

The Company and its subsidiaries recognize a right-of-use asset and a lease liability on the lease inception date. The right-of-use asset is initially measured at cost, which comprises the value of initial measurement of the lease liability adjusted to any lease payments made to the initial date, plus any initial direct costs incurred by the lessee and an estimate of the costs to be incurred by the lessee to disassemble and remove the underlying asset, by returning it to the place where it is located or returning the underlying asset to the state required under the lease terms and conditions, less any lease incentives received accordingly.

The right-of-use asset is subsequently depreciated using the straight-line method from the start date to the end of the lease term, unless the lease transfers ownership of underlying asset to the lessee at the end of lease term, or if the cost of the right-of-use asset reflects that the lessee will exercise the call option. In this case, the right-of-use asset will be depreciated over the useful life of the underlying asset, which is determined on the same basis as that of property, plant and equipment. Moreover, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the inception date, and discounted using the interest rate implied in the lease or, if that rate cannot be immediately determined, the incremental loan rate of the Company and its subsidiaries. The Company and its subsidiaries use their incremental loan nominal rate as discount rate.

***Low-value and short-term leases***

The Company and its subsidiaries chose to use some practical expedients when adopting CPC 06 (R2) / IFRS 16 to leases previously classified as operating leases, particularly: (i) not recognize right-of-use assets and lease liabilities for low-value assets; and (ii) short-term leases, including printers, forklifts, coffee machines, vehicles and other equipment. The Company and its subsidiaries record lease payments in connection with these leases as expenses on a straight-line basis based on the term of the lease.

***As a lessor***

The Company and its subsidiaries do not have any lease transactions as lessor. Therefore, any effects arising from the adoption of said standard were identified.

## o. Measurement of fair value

Fair value is the price that would be received upon the sale of an asset or paid for the transfer of a liability in an orderly transaction between market participants at the measurement date, on the primary market or, in the absence thereof, on the most advantageous market to which the Company and its subsidiaries have access on such date. The fair value of a liability reflects its risk of non-performance. Non-compliance risk includes the own credit risk of the Company and its subsidiaries, among others.

When available, the Company and its subsidiaries measure the fair value of a security using the price quoted on an active market for such securities. A market is considered as active if the transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

If there is no price quoted on an active market, the Company and its subsidiaries use valuation techniques that maximize the use of relevant observable data and minimize the use of unobservable data. The chosen valuation technique incorporates all the factors market participants would take into account when pricing a transaction.

# 5 Corporate restructuring

At an extraordinary general meeting held on May 3, 2021, the Merger Protocol and Justification signed on May 03, 2021 between the managements of the Company and the merged company - Insitus Serviços Médicos e Laboratoriais Ltda. was approved, with its extinction and succession by the Company, with no continuity solution, in all its rights and obligations. The merger took place on May 3, 2021, whose net assets in the amount of R$ 1,118 were appraised by a specialized company on the base date of April 30, 2021.

The analytical breakdown of the balances taken-over is as follows:

| | **Insitus** |
|---|---|
| **Assets** | |
| Cash and cash equivalents | 178 |
| Trade accounts receivable | 956 |
| Recoverable taxes | 40 |
| Prepaid expenses | 127 |
| Other receivables | 11 |
| Property, plant and equipment | 717 |
| Intangible assets | 79 |
| **Total assets** | **2,108** |
| **Liabilities** | |
| Suppliers | (508) |
| Income tax and social contribution payable | (31) |
| Taxes and contributions payable | (48) |
| Social charges and labor legislation obligations | (401) |
| Other accounts payable and provisions | (2) |
| **Total liabilities assumed** | **(990)** |
| **Net assets** | **1,118** |

# 6 New standards and interpretations not yet effective

Several new standards will become effective for the years started after January 1, 2021. The DASA Group did not adopt these standards in advance for preparation of these individual and consolidated financial statements.

## a. Onerous Contracts – Costs of Fulfilling a Contract (amendments to CPC 25 / IAS 37)

These amendments specify which costs an entity must include to determine the cost of fulfilling a contract to assess if the contract is onerous. The amendments apply to annual periods beginning on or after January 01, 2022 for existing contracts, on the date such changes are adopted for the first time. On the date of initial application, the cumulative effect of applying the changes is recognized as an adjustment to the opening balance in retained earnings or other components of equity, as appropriate. The comparisons are not restated. The DASA Group has determined that all existing contracts as of December 31, 2021 will be concluded before the changes take effect.

**b. Disclosure of Accounting Policies (Amendments to CPC 26 / IAS 1 and IFRS Practice Statement 2)**

In February 2021, the IASB issued amendments to IAS 1 (standard related to CPC 26 (R1)) and IFRS Practice Statement 2 Making Materiality Judgments, in which it provides guides and examples to help entities apply materiality judgment to the disclosure of accounting policies. The amendments aim to assist entities in disclosing accounting policies that are most useful by replacing the requirement for disclosure of significant accounting policies with material accounting policies and adding guidance on how entities should apply the concept of materiality when making decisions about the disclosure of accounting policies. The amendments to IAS 1 are applicable for periods beginning on or after January 1, 2023, with early adoption permitted. Since the amendments to Practice Statement 2 provide non-mandatory guidance in applying the material definition to accounting policy information, an adoption date for this amendment is not required. The DASA Group is currently evaluating the impacts of these changes in the accounting policies disclosed.

**c. Definition of Accounting Estimates (Amendments to CPC 23 / IAS 8)**

In February 2021, the IASB issued amendments to IAS 8 (standard related to CPC 23), in which it introduces the definition of "accounting estimates". The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and correction of errors. In addition, they clarify how entities use measurement and input techniques to develop accounting estimates. The amendments will be effective for periods beginning on or after January 1, 2023, and will apply to changes in accounting policies and estimates that occur on or after the beginning of that period. Early adoption is allowed if disclosed. Amendments are not expected to have a significant impact on the DASA group's financial statements:

**d. Other standards**

New and amended standards are not expected to have a significant impact on DASA Group's consolidated financial statements:

- Annual review of IFRS 2018-2020 standards
- Property, plant and equipment: Revenues before intended use (amendments to CPC 27 / IAS 16)
- Reference to Conceptual Framework (amendments to CPC 15 / IFRS 3)
- Classification of Liabilities in Current or Non-Current (amendments to CPC 26 / IAS 1)
- Insurance Contracts (CPC 50 / IFRS 17)

# 7 Cash and cash equivalents

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| Cash and banks | 45,557 | 31,060 | 310,337 | 80,339 |
| Interest earning bank deposits (a) | 148,205 | 111,985 | 832,689 | 673,268 |
| | **193,762** | **143,045** | **1,143,026** | **753,607** |

(a) Interest earning bank deposits are remunerated at a percentage of the CDI interest rate of 92.35% as of December 31, 2021 (95.26% as of December 31, 2020), have immediate liquidity, and they can be used according to the needs of DASA Group without any penalty.

Bank balances and interest earning bank deposits have immediate liquidity and are not subject to any restrictions or penalties on their use.

# 8 Interest earning bank deposits

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| Fixed income investment fund - non-exclusive (a) | 19 | 555 | 19 | 555 |
| Domestic repurchase and resale commitments (a) | 2,434,331 | 740,361 | 2,435,034 | 760,261 |
| Repurchase and resale agreement abroad (b) | - | - | 35,979 | - |
| | **2,434,350** | **740,916** | **2,471,032** | **760,816** |

(a) Domestic interest earning bank deposits are remunerated as a percentage of the CDI interest rate, with an investment fund as of December 31, 2021 at the rate of 102.39% (90.58% as of December 31, 2020), and repurchase agreement - Fixed-income Interest earning bank deposit at the rate of 170.56% (108.40% as of December 31, 2020).

(b) Interest earning bank deposits abroad are remunerated at the BADLAR interest rate (interest rate used with reference in Argentina), with a repo operation at the rate of 50.9% p.a.

# 9 Trade accounts receivable

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| Trade accounts receivable: | | | | |
| Domestic | 784,356 | 978,713 | 2,526,950 | 1,843,777 |
| Foreign | - | - | 71,166 | 53,551 |
| | 784,356 | 978,713 | 2,598,116 | 1,897,328 |
| Less: | | | | |
| Expected losses for doubtful accounts | (36,693) | (45,061) | (165,342) | (106,098) |
| Expected losses from variable consideration (disallowance) | (33,055) | (29,043) | (120,497) | (45,344) |
| | (69,748) | (74,104) | (285,839) | (151,442) |
| Total trade accounts receivable, net | **714,608** | **904,609** | **2,312,277** | **1,745,886** |
| Current | 708,971 | 903,728 | 2,305,316 | 1,743,233 |
| Non-current | 5,637 | 881 | 6,961 | 2,653 |
| **Breakdown of trade accounts receivable:** | | | | |
| Falling due | 331,997 | 501,635 | 1,547,292 | 1,181,992 |
| Overdue (b) | 254,815 | 193,229 | 351,450 | 279,401 |
| Related parties overdue | 15,996 | 27,406 | - | - |
| Related parties - overdue (c) | 15,453 | 27,127 | - | - |
| Returned checks | 749 | 1,032 | 1,247 | 3,513 |
| Unbilled agreements (a) | 165,346 | 228,284 | 698,127 | 432,422 |
| Total trade accounts receivable | **784,356** | **978,713** | **2,598,116** | **1,897,328** |

(a) The caption “unbilled agreements” refers to the amounts of services performed and not billed until the end of the year.

(b) Summary of trade -s overdue (trades -s receivable):

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| **Days:** | | | | |
| up to 120 | 151,199 | 105,818 | 211,517 | 160,190 |
| 121–180 | 22,448 | 10,252 | 29,548 | 13,043 |
| 181–360 | 43,416 | 29,079 | 57,176 | 38,858 |
| >360 | 37,752 | 48,080 | 53,209 | 67,310 |
| | **254,815** | **193,229** | **351,450** | **279,401** |

(c) Summary of expired trade bills (related parties):

| | Parent company | |
|---|---|---|
| | **12/31/2021** | **12/31/2020** |
| **Days:** | | |
| up to 120 | 8,446 | 25,832 |
| 121–180 | 3,580 | 1,295 |
| >180 | 3,427 | - |
| | **15,453** | **27,127** |

DASA Group developed a methodology for assigning ratings to its clients, the histories of receipts were analyzed, dividing them into two groups: rating A and B, respectively: rating A – clients considered as having a low risk of default, supported by historical receipts, and rating B – which DASA Group analyzes the history of receipts, considers different provisioning methodology and percentages, and analyzes overdue balances by category.

Changes in the year of expected losses for doubtful accounts:

| | **Parent company** | **Consolidated** |
|---|---|---|
| **Balance at December 31, 2019** | **(30,407)** | **(67,143)** |
| **Changes:** | | |
| Expected losses for doubtful accounts | (80,428) | (192,669) |
| Expected losses for doubtful accounts at cost - acquisition of subsidiaries | - | (48,523) |
| Reversal of expected losses for doubtful accounts | 65,774 | 202,237 |
| **Balance at December 31, 2020** | **(45,061)** | **(106,098)** |
| **Changes:** | | |
| Expected losses for doubtful accounts | (68,382) | (117,294) |
| Expected losses for doubtful accounts at cost - acquisition of subsidiaries | - | (59,375) |
| Reversal of expected losses for doubtful accounts | 76,750 | 117,425 |
| **Balance at December 31, 2021** | **(36,693)** | **(165,342)** |

Changes in the year of expected losses of variable consideration:

| | Parent company | Consolidated |
|---|---|---|
| **Balance at December 31, 2019** | **(36,658)** | **(36,701)** |
| **Changes:** | | |
| Expected losses from variable consideration (disallowance) | (10,145) | (40,319) |
| Expected losses from variable consideration at cost value - acquisition of subsidiaries (a) | - | (5,985) |
| Reversal of expected losses from variable consideration (disallowance) | 17,760 | 37,661 |
| **Balance at December 31, 2020** | **(29,043)** | **(45,344)** |
| **Changes:** | | |
| Expected losses from variable consideration (disallowance) | (20,147) | (47,265) |
| Expected losses from variable consideration at cost value - acquisition of subsidiaries (a) | | (62,037) |
| Reversal of expected losses from variable consideration (disallowance) | 16,135 | 34,149 |
| **Balance at December 31, 2021** | **(33,055)** | **(120,497)** |

(a) Refers to the acquisition of Ímpar Serviços Hospitalares.

# 10 Inventories

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| National direct material (a) | 84,259 | 107,154 | 267,553 | 272,576 |
| Imported direct material (a) | 4,730 | 7,704 | 12,060 | 7,821 |
| National secondary material (b) | 34,192 | 33,320 | 43,971 | 40,682 |
| Consumption material | 17,754 | 21,663 | 26,394 | 30,205 |
| Inventories held by third-parties | - | - | 17,146 | 6,516 |
| | **140,935** | **169,841** | **367,124** | **357,800** |

(a) Laboratory and hospital materials for clinical analyses, tests, imaging diagnoses, and for use in patients cared for by hospitals.

(b) Disposable materials used in the process of item (a).
Decrease in net realizable value - To reflect the best loss estimate of DASA Group in relation to its inventories, a reduction in net realizable value was recorded in the individual interim financial information in the amount of R$ 1,061 (R$ 2,351 as of December 31, 2020) and in the consolidated in the amount of R$ 1,581 (R$ 3,035 as of December 31, 2020) for items that are dormant for more than 180 days and for those that will mature in the same period. The balances above are shown net of the provision amount individually for each inventory category. The effect of the reduction to the net realizable value generated a reversal of R$ 1,290 in the parent company and R$ 1,454 in the consolidated. This provision was recognized in profit or loss in 2021.

# 11 Recoverable taxes

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| IRPJ/CSLL - credit recoverable on negative balance | 190,991 | 79,873 | 336,039 | 190,596 |
| PIS/COFINS/CSLL - withholding tax on billing | 8,849 | 33 | 21,145 | 5,670 |
| ISS recoverable | 1,590 | 12,569 | 13,034 | 4,725 |
| Withholding INSS | 12,833 | 10,899 | 50,131 | 55,723 |
| Other | 13,350 | 13,368 | 33,726 | 23,596 |
| | **227,613** | **116,742** | **454,075** | **280,310** |
| Current | 186,691 | 116,742 | 392,908 | 260,035 |
| Non-current | 40,922 | - | 61,167 | 20,275 |

DASA Group intends to consume most of the credits during the fiscal year and the remainder in the following years covered by federal taxes, under the terms of the Brazilian tax rules.

# 12 Other receivables

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| Advance for acquisition of subsidiary (a) | - | - | - | 200,000 |
| Advance to employees | 15,763 | 9,045 | 58,257 | 30,601 |
| Credit with previous management (b) | 6,468 | 6,036 | 22,087 | 10,131 |
| Credit with franchisees (c) | 4,917 | 7,289 | 5,121 | 7,308 |
| Business partnerships (d) | 4,098 | 9,786 | 4,098 | 9,786 |
| Advance of dividends and interest on own capital | - | - | 5,424 | 3,087 |
| Dividends and interest on own capital receivable | 81,294 | 52,042 | - | - |
| Shared services | 40,515 | 5,603 | - | - |
| Rents | - | - | 948 | 2,024 |
| Credit receivables (e) | - | - | 200,002 | - |
| Contingent assets | | - | 79,080 | - |
| Other | 13,558 | 8,779 | 72,319 | 41,331 |
| | **166,613** | **98,580** | **447,336** | **304,268** |
| Current | 159,314 | 89,588 | 138,965 | 290,854 |
| Non-current | 7,299 | 8,992 | 308,371 | 13,414 |

(a) Advance made to sellers of Hospital Leforte Liberdade S.A. as a down payment for the acquisition. The advance was written off with the acquisition of the hospital on September 3, 2021.

(b) Credit with former partners of acquirees, basically these are lawsuits from the time of the former Management that were rejected after the sale of the company.

(c) Advances for commission to franchisees.

(d) Assignment of credits with business partners.

(e) Between 2012 and 2017, Hospital São Domingos acquired credit rights from the Federal Government based on legal proceedings originating and drawn up in public deeds in the amount of R$ 219,000 thousand, which underwent a discount arising from the operation, thus the balance as of December 31, 2021, was R$ 200,002 (R$ 182,409 as of December 31, 2020). The Company hired a law firm to analyze these credit rights, which issued an opinion dated March 11, 2022, whose conclusion ratifies: the legitimacy of the credits; the criteria for updating and interest of the final and unappealable decision; the existence of the deeds and a breakdown of the amounts contained in each public deed acquired.

# 13 Investments

## 13.1 Information of investments in subsidiaries

The main information on the subsidiaries for the year ended December 31, 2021 is presented below. This information was adjusted by the percentage of interest held by the Company:

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| DASA Real Estate Empreendimentos Imobiliários Ltda. | 27,480 | 32,210 | - | - |
| CientíficaLab Produtos Laboratoriais e Sistemas Ltda. | 167,604 | 146,063 | - | - |
| Previlab - Análises Clínicas Ltda. | 47,902 | 44,449 | - | - |
| Clínica de Ressonância e Multi Imagem Petrópolis Ltda. | 2,123 | 2,493 | - | - |
| Antônio P. Gaspar Laboratórios Ltda. | 50,743 | 47,694 | - | - |
| Salomão e Zoppi Serviços Médicos e Participações S.A. | 134,259 | 146,115 | - | - |
| Laboratório Médico Santa Luzia S.A. | 44,714 | 24,557 | - | - |
| Laboratório Deliberato de Análises Clínicas Ltda. | 9,185 | 7,398 | - | - |
| Insitus Serviços Médicos e Laboratoriais Ltda. | - | 1,939 | - | - |
| Valeclin Laboratório de Análises Clínicas Ltda. | 12,844 | 12,415 | - | - |
| Ruggeri & Piva Ltda. | 1,595 | - | - | - |
| Maringá Medicina Nuclear Ltda. | 25,929 | 9,050 | - | - |
| Laboratório de Anatomia Patológica e Citopatologia São Camilo Ltda. | 1,915 | 839 | - | - |
| Aliança Biotecnologia Ltda. | 239 | 311 | - | - |
| Laboratório Chromatox Ltda. **(a)** | 26,862 | 11,403 | - | - |
| Diagnóstico Maipú por Imágenes S.A. **(a)** | 135,241 | 91,536 | - | - |
| CPCLIN - Centro de Pesquisas Clínicas Ltda. **(a)** | 2,061 | 1,802 | - | - |
| Genia S.A. **(a)** | 3,127 | 1,107 | - | - |
| Nobeloy S.A. **(a)** | 21,142 | 7,352 | - | - |
| Optiren S.A **(a)** | 20,789 | 1,624 | - | - |
| Laboratório Bioclínico MS Ltda. **(a)** | 10,610 | 6,153 | - | - |
| Ímpar Serviços Hospitalares S.A. **(b)** | 4,159,299 | 1,011,089 | - | - |
| Allbrokers Brasil Corretora de Seguros Ltda. **(b)** | 195,625 | - | - | - |
| Santa Celina Participações S.A. **(b)** | 129,453 | 37,471 | - | - |
| São Marcos - Saúde e Medicina Diagnóstica S/A **(b)** | 25,724 | - | - | - |
| Instituto de Hematologia de S.J.R. Preto Ltda. **(b)** | 6,960 | 3,012 | - | - |
| Laboratório Nobel S.A – Grupo Exame **(b)** | 1,434 | - | - | - |
| Gesto Saúde Sistemas Informatizados Ltda. **(e)** | 6,214 | - | - | - |
| Centro de Tomografia por Computador Ltda. | 1,990 | - | - | - |
| SALL Participações S.A. | 32,932 | - | - | - |
| Total investments in subsidiaries | 5,305,995 | 1,648,082 | - | - |
| Other investments | 322 | 329 | 1,030 | 4,332 |
| Goodwill in the acquisition of interest | 1,241,462 | 1,207,064 | - | - |
| Intangible asset identified in the acquisition of interest | 756,294 | 762,879 | - | - |
| Effect on translation of financial statements of foreign subsidiaries | (174,143) | (209,593) | - | - |
| Goodwill, intangible asset identified in the acquisition of interest and other investments | 1,823,935 | 1,760,679 | 1,030 | 4,332 |
| Overall total | **7,129,930** | **3,408,761** | **1,030** | **4,332** |

## 13.2 Information about interest in direct subsidiaries

The chart below presents a summary of the financial information at subsidiaries as of December 31, 2021. The information below was presented by the percentage of interest held by the Company.

| | Ownership interest percentage in paid-up capital | Paid-in capital | Shareholders' equity (Negative shareholders' equity) proportional to the number of shares held | Profit or loss for the year |
|---|---|---|---|---|
| **December 31, 2021** | | | | |
| DASA Real Estate | 99.99 | 25,667 | 27,480 | 1,404 |
| CientíficaLab | 99.99 | 125,177 | 167,604 | 27,126 |
| Previlab | 99.56 | 29,613 | 47,902 | 9,970 |
| CRMI Petrópolis | 70.00 | 1,080 | 2,123 | 523 |
| Laboratório Gaspar | 99.99 | 4,318 | 50,743 | 24,099 |
| Salomão e Zoppi | 100.00 | 122,213 | 134,259 | (4,893) |
| Laboratório Santa Luzia | 100.00 | 38,218 | 44,714 | 20,157 |
| Laboratório Deliberato | 99.99 | 6,800 | 9,185 | 1,787 |
| Insitus **(d)** | 99.99 | - | - | (839) |
| Padrão Ribeirão | 90.00 | 51 | (3,342) | (1,812) |
| Valeclin | 100.00 | 1,100 | 12,844 | 4,917 |
| Ruggeri | 99.99 | 7,461 | 1,595 | 4,332 |
| Maringá | 99.99 | 15,600 | 25,929 | 279 |
| São Camilo | 99.99 | 872 | 1,915 | (424) |
| Aliança | 99.99 | 1,462 | 239 | (72) |
| DB Genética **(a)** | 75.00 | 10 | (12,864) | (7,736) |
| Itulab **(a)** | 99.99 | 3,153 | (4,447) | (293) |
| Chromatox **(a)** | 100.00 | 2,766 | 26,862 | 21,719 |
| Maipú **(a)** | 100.00 | 2,897 | 135,241 | 16,313 |
| CPCLIN **(a)** | 80.00 | 1 | 2,061 | 1,125 |
| Genia **(a)** | 100.00 | 864 | 3,127 | 1,486 |
| Nobeloy **(a)** | 100.00 | 4,945 | 21,142 | 11,566 |
| Optiren **(a)** | 100.00 | 5,182 | 20,789 | 26,286 |
| Bioclinico MS **(a)** | 80.00 | 16 | 10,610 | 7,306 |
| Ímpar **(a)** | 100.00 | 1,352,545 | 4,159,300 | 31,928 |
| Allbrokers **(b)** | 100.00 | 14,454 | 195,625 | (12,632) |
| Santa Celina **(b)** | 100.00 | 101,439 | 129,453 | 6,229 |
| São Marcos **(b)** | 100.00 | 24,000 | 25,724 | (781) |
| Hemat **(b)** | 80.00 | 3,600 | 6,960 | 4,242 |
| Grupo Exame **(b)** | 90.00 | 15,863 | 1,434 | 16,147 |
| Gesto Saúde **(e)** | 100.00 | 21,270 | 6,214 | (8,169) |
| Centro de Tomografia **(e)** | 100.00 | 150 | 1,990 | (1,268) |
| SALL Participações S.A. **(e)** | 100.00 | 32,000 | 32,932 | - |

The chart below presents a summary of the financial information at subsidiaries as of December 31, 2020. The information below was presented by the percentage of interest held by the Company.

| | Ownership interest percentage in paid-up capital | Paid-in capital | Shareholders 'equity (Negative shareholders' equity) proportional to the number of shares held | Profit or loss for the year |
|---|---|---|---|---|
| **As of December 31, 2020** | | | | |
| DASA Real Estate | 99.99 | 25,667 | 32,210 | 9,446 |
| CientíficaLab | 99.99 | 125,177 | 146,063 | 18,448 |
| Previlab | 99.56 | 29,613 | 44,449 | 6,860 |
| CRMI Petrópolis | 70.00 | 1,080 | 2,493 | 287 |
| Laboratório Gaspar | 99.99 | 4,318 | 47,694 | 21,412 |
| Salomão e Zoppi | 100.00 | 122,213 | 146,115 | (3,992) |
| Laboratório Santa Luzia | 100.00 | 467 | 24,557 | 5,119 |
| Laboratório Deliberato | 99.99 | 6,800 | 7,398 | (43) |
| Insitus **(d)** | 99.99 | 1,842 | 1,939 | (408) |
| Padrão Ribeirão | 90.00 | 51 | (1,530) | (364) |
| Valeclin | 100.00 | 1,100 | 12,415 | 4,598 |
| Ruggeri | 99.99 | 6,461 | (2,672) | 4,762 |
| Maringá | 99.99 | 12,600 | 9,050 | 239 |
| São Camilo | 99.99 | 872 | 839 | (385) |
| Aliança | 99.99 | 1,162 | 311 | (311) |
| DB Genética **(a)** | 75.00 | 10 | (5,129) | (4,354) |
| Itulab **(a)** | 99.99 | 1,153 | (7,654) | 4,479 |
| Chromatox **(a)** | 100.00 | 2,766 | 11,403 | 6,589 |
| Maipú **(a)** | 100.00 | 2,161 | 91,536 | (6,740) |
| CPCLIN **(a)** | 80.00 | 1 | 1,802 | 807 |
| Genia - Genética moléculas **(a)** | 100.00 | - | - | (228) |
| Genia **(a)** | 100.00 | 4,874 | 1,107 | 933 |
| Nobeloy **(a)** | 100.00 | 5,107 | 7,352 | 2,471 |
| Optiren **(a)** | 100.00 | 631 | 1,624 | (10,474) |
| Bioclinico MS **(a)** | 80.00 | 5 | 6,153 | 4,365 |
| Ímpar **(a)** | 100.00 | 547,531 | 1,011,089 | (43,377) |
| Allbrokers **(b)** | 100.00 | 6,454 | (3,843) | (6,997) |
| Nexa **(b) (d)** | 100.00 | - | - | (2,433) |
| Santa Celina **(b)** | 100.00 | 9,975 | 37,471 | (15,639) |
| São Marcos **(b)** | 100.00 | 20,000 | (11,286) | 908 |
| Hemat **(b)** | 80.00 | 3,600 | 3,012 | - |
| Grupo Exame **(b)** | 90.00 | 15,863 | - | - |

## 13.3 Changes in investments / Provision for loss in subsidiaries

Changes in investments as of December 31, 2021 in subsidiaries are as follows:

| | Balance at 12/31/20 | Acquisition of subsidiaries | Merger of subsidiaries | Capital increase (g) | Advances for future capital increase | Transfer between investment and negative shareholders' equity | Equity valuation adjustment (f) | Dividends | Equity in net profit of subsidiaries | Balance at 12/31/2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| **Investments** | | | | | | | | | | |
| DASA Real Estate | 32,210 | - | - | - | - | - | - | (6,134) | 1,404 | 27,480 |
| CientíficaLab | 146,063 | - | - | - | - | - | - | (5,585) | 27,126 | 167,604 |
| Previlab | 44,449 | - | - | - | - | - | - | (6,517) | 9,970 | 47,902 |
| CRMI Petrópolis | 2,493 | - | - | - | - | - | - | (893) | 523 | 2,123 |
| Gaspar | 47,694 | - | - | - | - | - | (70) | (20,980) | 24,099 | 50,743 |
| Salomão e Zoppi | 146,115 | - | - | - | - | - | - | (6,963) | (4,893) | 134,259 |
| Santa Luzia | 24,557 | - | - | - | - | - | - | - | 20,157 | 44,714 |
| Deliberato | 7,398 | - | - | - | - | - | - | - | 1,787 | 9,185 |
| Insitus **(d)** | 1,939 | - | (1,118) | - | - | - | 18 | - | (839) | - |
| Valeclin | 12,415 | - | - | - | - | - | - | (4,488) | 4,917 | 12,844 |
| Ruggeri | - | - | - | - | - | 1,660 | (65) | - | - | 1,595 |
| Maringá | 9,050 | - | - | - | 16,600 | - | - | - | 279 | 25,929 |
| São Camilo | 839 | - | - | - | 1,500 | - | - | - | (424) | 1,915 |
| Aliança | 311 | - | - | - | - | - | - | - | (72) | 239 |
| Chromatox **(a)** | 11,403 | - | - | - | - | - | - | (6,260) | 21,719 | 26,862 |
| Maipú **(a)** | 91,536 | - | - | - | - | - | 27,392 | - | 16,313 | 135,241 |
| CPCLIN **(a)** | 1,802 | - | - | - | - | - | 146 | (1,012) | 1,125 | 2,061 |
| Genia **(a)** | 1,107 | - | - | - | - | - | 534 | - | 1,486 | 3,127 |
| Nobeloy **(a)** | 7,352 | - | - | - | - | - | 2,224 | - | 11,566 | 21,142 |
| Optiren **(a)** | 1,624 | - | - | - | - | - | (7,121) | - | 26,286 | 20,789 |
| Bioclínico MS **(a)** | 6,153 | - | - | - | - | - | - | (2,849) | 7,306 | 10,610 |
| Impar (a) | 1,011,089 | - | - | 805,014 | 1,990,000 | - | 352,127 | (30,858) | 31,927 | 4,159,299 |
| Allbrokers **(b)** | - | - | - | - | 212,100 | (3,843) | - | - | (12,632) | 195,625 |
| Santa Celina **(b)** | 37,471 | (3,089) | - | - | 89,800 | - | (958) | - | 6,229 | 129,453 |
| São Marcos **(b)** | - | - | - | - | 38,600 | (10,975) | (1,120) | - | (781) | 25,724 |
| Hemat **(b)** | 3,012 | - | - | - | - | - | (294) | - | 4,242 | 6,960 |
| Grupo Exame **(b)** | - | - | - | - | - | 1,434 | - | - | - | 1,434 |
| Gesto **(e)** | - | 5,700 | - | - | 10,000 | - | (1,317) | - | (8,169) | 6,214 |
| Centro de Tomografia **(e)** | - | 3,258 | - | - | - | - | - | - | (1,268) | 1,990 |
| SALL Participações S.A. **(e)** | - | 32,932 | - | - | - | - | - | - | - | 32,932 |
| | **1,648,082** | **38,801** | **(1,118)** | **805,014** | **2,358,600** | **(11,724)** | **371,496** | **(92,539)** | **189,383** | **5,305,995** |
| **Provision for loss in subsidiaries:** | | | | | | | | | | |
| Padrão Ribeirão | (1,530) | - | - | - | - | - | - | - | (1,812) | (3,342) |

| | Balance at 12/31/20 | Acquisition of subsidiaries | Merger of subsidiaries | Capital increase (g) | Advances for future capital increase | Transfer between investment and negative shareholders' equity | Equity valuation adjustment (f) | Dividends | Equity in net profit of subsidiaries | Balance at 12/31/2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ruggeri | (2,672) | - | - | - | - | (1,660) | - | - | 4,332 | - |
| Itulab **(b)** | (7,654) | - | - | - | 3,500 | - | - | - | (293) | (4,447) |
| DB Genética **(a)** | (5,128) | - | - | - | - | - | - | - | (7,736) | (12,864) |
| Allbrokers **(b)** | (3,843) | - | - | - | - | 3,843 | - | - | - | - |
| São Marcos (b) | (11,286) | 311 | - | - | - | 10,975 | - | - | - | - |
| Grupo Exame **(b)** | (14,685) | - | - | - | - | (1,434) | (30) | - | 16,149 | - |
| | **(46,798)** | **311** | **-** | **-** | **3,500** | **11,724** | **(30)** | **-** | **10,640** | **(20,653)** |

Changes in investments as of December 31, 2020 in subsidiaries are as follows:

| | Balance at 12/31/2019 | Acquisition of subsidiaries | Merger of subsidiaries | Advances for future capital increase | Transfer between investment and negative shareholders' equity | Equity valuation adjustment (d) | Dividends | Equity in net profit of subsidiaries | Balance at 12/31/20 |
|---|---|---|---|---|---|---|---|---|---|
| **Investments** | | | | | | | | | |
| DASA Real Estate | 22,764 | - | - | - | - | - | - | 9,446 | 32,210 |
| CientíficaLab | 130,458 | - | - | - | - | - | (2,843) | 18,448 | 146,063 |
| Previlab | 42,594 | - | - | - | - | - | (5,005) | 6,860 | 44,449 |
| CRMI Petrópolis | 2,773 | - | - | - | - | - | (567) | 287 | 2,493 |
| Gaspar | 29,390 | - | - | - | - | - | (3,108) | 21,412 | 47,694 |
| Salomão e Zoppi | 155,592 | - | - | - | - | - | (5,485) | (3,992) | 146,115 |
| Santa Luzia | - | (6,638) | - | 37,752 | (11,676) | - | - | 5,119 | 24,557 |
| Deliberato | 8,445 | - | - | - | - | - | (1,004) | (43) | 7,398 |
| Insitus | 1,847 | - | - | 500 | - | - | - | (408) | 1,939 |
| Valeclin | 10,624 | - | - | - | - | - | (2,807) | 4,598 | 12,415 |
| Maringá | 3,611 | - | - | 5,200 | - | - | - | 239 | 9,050 |
| São Camilo | 424 | - | - | 800 | - | - | - | (385) | 839 |
| Aliança | - | - | - | 300 | 11 | - | - | - | 311 |
| DB Genética **(b)** | 1,302 | - | - | - | 3,052 | - | - | (4,354) | - |
| Chromatox **(a)** | 11,752 | (6,938) | - | - | - | - | - | 6,589 | 11,403 |
| Maipú **(a)** | 88,416 | - | - | - | - | 9,860 | - | (6,740) | 91,536 |
| CPCLIN **(a)** | 995 | - | - | - | - | - | - | 807 | 1,802 |
| Genia - GM **(a)** | 510 | (16) | (266) | - | - | - | - | (228) | - |
| Genia **(a)** | 425 | - | - | - | - | (251) | - | 933 | 1,107 |
| Nobeloy **(a)** | 539 | - | - | 4,799 | - | (457) | - | 2,471 | 7,352 |
| Optiren **(a)** | - | 6,451 | - | - | (4,827) | - | - | - | 1,624 |
| Bioclínico MS **(a)** | 4,333 | (2,545) | - | - | - | - | - | 4,365 | 6,153 |
| Ímpar **(a)** | - | 756,056 | - | 335,000 | - | - | (36,590) | (43,377) | 1,011,089 |
| Nexa **(b)** | - | 18,624 | (26,591) | 10,400 | - | - | - | (2,433) | - |

| | Balance at 12/31/2019 | Acquisition of subsidiaries | Merger of subsidiaries | Advances for future capital increase | Transfer between investment and negative shareholders' equity | Equity valuation adjustment (d) | Dividends | Equity in net profit of subsidiaries | Balance at 12/31/20 |
|---|---|---|---|---|---|---|---|---|---|
| Santa Celina **(b)** | - | 5,871 | - | 47,239 | - | - | - | (15,639) | 37,471 |
| São Marcos **(b)** | - | (16,194) | - | 4,000 | 11,286 | - | - | 908 | - |
| Hemat **(b)** | - | 3,012 | - | - | - | - | - | - | 3,012 |
| | **516,794** | **757,683** | **(26,857)** | **445,990** | **(2,154)** | **9,152** | **(57,409)** | **4,883** | **1,648,082** |
| **Provision for loss in subsidiaries:** | | | | | | | | | |
| Santa Luzia | (11,676) | - | - | - | 11,676 | - | - | - | - |
| Padrão Ribeirão | (1,166) | - | - | - | - | - | - | (364) | (1,530) |
| Ruggeri | (10,834) | - | - | 3,400 | - | - | - | 4,762 | (2,672) |
| Aliança | (678) | - | - | 1,000 | (11) | - | - | (311) | - |
| Itulab **(a)** | (13,561) | 428 | - | 1,000 | - | - | - | 4,479 | (7,654) |
| Optiren **(a)** | (510) | - | - | 6,399 | 4,827 | (242) | - | (10,474) | - |
| DB Genética **(a)** | - | (2,077) | - | - | (3,052) | - | - | - | (5,129) |
| Allbrokers **(b)** | - | (4,446) | - | 7,600 | - | - | - | (6,997) | (3,843) |
| São Marcos **(b)** | - | - | - | - | (11,286) | - | - | - | (11,286) |
| Grupo Exame **(b)** | - | (14,685) | - | - | - | - | - | 1 | (14,684) |
| | **(38,425)** | **(20,780)** | **-** | **19,399** | **2,154** | **(242)** | **-** | **(8,904)** | **(46,798)** |

**(a)** Company acquired by the Company in the year 2019.

**(b)** Company acquired by the Company in the year 2020. See details in - 2.

**(c)** Effect in translation of financial statements of foreign subsidiaries and application of CPC 42 / IAS 29 – Hyperinflation (Maipú) and other non-recurring adjustments.

**(d)** Company merged by the Company in the 2020 or 2021.

**(e)** Company acquired by the Company in 2021. See details in - 2.

**(f)** In the equity valuation adjustment of subsidiary Impar, R$ 38,943 is recorded referring to the share-based compensation plan.

**(g)** The capital increase of subsidiary Ímpar Serviços Hospitalares consisted of a cash installment in the amount of R$ 751,000 and payment of shares in the amount of R$ 54,014.

## 13.4 Changes in goodwill and intangible investments of subsidiaries

| Investments - Goodwill and Intangibles | Balance at 12/31/2020 | (+) Additions (-) Write-off | Transf. | Other | Foreign exchange | Merger of subsidiaries | Acquisitions of subsidiaries | Amortization | Balance at 12/31/2021 |
|---|---|---|---|---|---|---|---|---|---|
| Goodwill in the acquisition of interest | **1,207,064** | 40,885 | (66,954) | **(4,351)** | (44,645) | (3,601) | **113,064** | - | **1,241,462** |
| **Intangible asset identified in the acquisition of interest:** | | | | | | | | | |
| Brands | **502,684** | - | 30,982 | - | (20,955) | - | - | (19,577) | **493,134** |
| Relationships with customers and hospitals | **244,547** | - | 21,697 | - | (18,031) | - | 8,259 | (31,506) | **224,966** |
| Competition agreement | **5,623** | - | 14,275 | - | (2,464) | - | 5,243 | (9,540) | **13,137** |
| Surplus of property, plant and equipment | **10,025** | - | - | - | - | - | - | (387) | **9,638** |
| Software | - | - | - | - | - | - | 15,419 | - | 15,419 |
| | **762,879** | **-** | **66,954** | **-** | **(41,450)** | **-** | **28,921** | **(61,010)** | **756,294** |
| **Effect on translation of financial statements of foreign subsidiaries** | **(209,593)** | - | - | - | 35,451 | - | - | - | **(174,143)** |
| **Other investments** | **329** | (7) | - | - | - | - | - | - | **322** |
| | **1,760,679** | **40,878** | **-** | **(4,351)** | **(50,645)** | **(3,601)** | **141,985** | **(61,010)** | **1,823,935** |

# 14 Property, plant and equipment

| | | Parent company | | | |
|---|---|---|---|---|---|
| | | 12/31/2021 | | | 12/31/2020 |
| | | **Cost** | **Accumulated depreciation** | **Net** | **Net** |
| Real estate | 25 | 8,304 | (1,044) | 7,260 | 7,590 |
| Leasehold improvements | 10 | 919,365 | (622,053) | 297,312 | 286,017 |
| Improvements on own real estate | 10 | 4,066 | (3,421) | 645 | 1,052 |
| Machinery and equipment | 10 | 1,382,017 | (780,460) | 601,557 | 587,135 |
| Furniture and fixtures | 10 | 123,130 | (78,258) | 44,872 | 48,445 |
| Facilities | 10 | 186,820 | (97,950) | 88,870 | 78,190 |
| IT equipment | 5 | 275,491 | (181,842) | 93,649 | 77,440 |
| Vehicles | 5 | 2,164 | (2,069) | 95 | 189 |
| Library | 10 | 196 | (194) | 2 | 2 |
| Land | | 180 | - | 180 | 180 |
| Construction in process | | 40,957 | - | 40,957 | 2,252 |
| Impairment | | (4,817) | - | (4,817) | (4,817) |
| | | **2,937,873** | **(1,767,291)** | **1,170,582** | **1,083,675** |

| | | Consolidated | | | |
|---|---|---|---|---|---|
| | | 12/31/2021 | | | 12/31/2020 |
| | | **Cost** | **Accumulated depreciation** | **Net** | **Net** |
| Real estate | 25 | 572,115 | (85,022) | 487,093 | 34,043 |
| Leasehold improvements | 10-20 | 2,320,592 | (1,136,828) | 1,183,764 | 1,135,944 |
| Improvements on own real estate | 10 | 8,647 | (8,002) | 645 | (194) |
| Machinery and equipment | 10 | 2,666,770 | (1,414,585) | 1,252,185 | 1,021,455 |
| Furniture and fixtures | 10 | 260,199 | (143,549) | 116,650 | 94,684 |
| Facilities | 10 | 205,338 | (134,783) | 70,555 | 90,528 |
| IT equipment | 5 | 462,163 | (286,354) | 175,809 | 122,459 |
| Vehicles | 5 | 6,074 | (4,959) | 1,115 | 935 |
| Library | 10 | 203 | (201) | 2 | 3 |
| Land | | 85,660 | - | 85,660 | 4,714 |
| Construction in process | | 410,643 | - | 410,643 | 109,200 |
| Impairment | | (5,150) | - | (5,150) | (4,817) |
| | | **6,993,254** | **(3,214,283)** | **3,778,971** | **2,608,954** |

| **Parent company Property, plant and equipment** | **Balance at 01/01/2020** | **Acquisitions of subsidiaries, net** | **Additions** | **Write-off** | **Transf (b)** | **Depreciation** | **Balance at 12/31/2020** | **Addition by merger of subsidiaries, net** | **Additions (a)** | **Write-off** | **Transf (b)** | **Depreciation** | **Balance at 12/31/2021** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Real estate | **140** | - | - | (71,473) | 78,953 | (30) | **7,590** | - | - | - | - | (330) | **7,260** |
| Leasehold improvements | **277,881** | 39 | - | (303) | 73,193 | (64,793) | **286,017** | 117 | - | (86) | 75,081 | (63,817) | **297,312** |
| Improvements on own real estate | **1,458** | - | - | - | - | (406) | **1,052** | - | - | - | - | (407) | **645** |
| Machinery and equipment | **529,707** | 11 | - | (82) | 168,454 | (110,955) | **587,135** | 552 | - | (817) | 139,778 | (125,091) | **601,557** |
| Furniture and fixtures | **47,321** | 16 | - | (311) | 10,394 | (8,975) | **48,445** | 8 | - | (321) | 6,004 | (9,264) | **44,872** |
| Facilities | **67,297** | 14 | - | (19) | 23,932 | (13,034) | **78,190** | 19 | - | (91) | 23,719 | (12,967) | **88,870** |
| IT equipment | **48,544** | 488 | - | (426) | 47,240 | (18,406) | **77,440** | 21 | - | (388) | 40,645 | (24,069) | **93,649** |
| Vehicles | **312** | - | - | (8) | - | (115) | **189** | - | - | - | - | (94) | **95** |
| Library | **9** | - | - | - | - | (7) | **2** | - | - | - | - | - | **2** |
| Land | **180** | - | - | - | - | - | **180** | - | - | - | - | - | **180** |
| Construction in process | **107,097** | - | 281,011 | - | (385,856) | - | **2,252** | - | 334,103 | - | (295,398) | - | **40,957** |
| Impairment | **(4,817)** | - | - | - | - | - | **(4,817)** | - | - | - | - | - | **(4,817)** |
| | **1,075,129** | **568** | **281,011** | **(72,622)** | **16,310** | **(216,721)** | **1,083,675** | **717** | **334,103** | **(1,703)** | **(10,171)** | **(236,039)** | **1,170,582** |

**(a)** It refers mainly to ongoing investments in appliances, equipment, and leasehold improvements. Of the total additions, R$ 80,874 had no cash effect in the year.

**(b)** The expenses incurred by the Company, classified as construction in process during the construction and installation period, are transferred to the specific group under the property, plant and equipment item when available for use. The depreciation of the related assets starts after the project completion. Additionally, there were transfers from property, plant, and equipment in progress to intangible assets in the software account.

| Consolidated Property, plant and equipment | Balance at 01/01/2020 | Acquisitions of subsidiaries, net (a) | Additions | Write-off | Net FX variation | Net inflation (c) (d) | Transf (b) | Depreciation | Balance at 12/31/2020 | Acquisitions of subsidiaries, net (a) | Additions (e) | Write-off | Net FX variation | Net inflation (c) (d) | Transf (b) | Depreciation | Balance at 12/31/2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Real estate | **15,349** | 9,411 | 3,930 | (72,309) | (3,780) | 2,996 | 78,936 | (490) | **34,043** | 363,780 | 9,188 | 5 | 5,029 | (1,903) | 79,622 | (2,671) | **487,093** |
| Leasehold improvements | **357,751** | 655,903 | 83,828 | (502) | (10,200) | 8,877 | 166,633 | (126,346) | **1,135,944** | 79,216 | 16,783 | (1,096) | 8,238 | (7,410) | 68,757 | (116,668) | **1,183,764** |
| Improvements on own real estate | **472** | 13 | - | (13) | 303 | (266) | - | (703) | **(194)** | - | - | - | - | - | 1,245 | (406) | **645** |
| Machinery and equipment | **609,966** | 345,101 | 99,695 | 440 | 2,163 | (493) | 150,290 | (185,707) | **1,021,455** | 136,668 | 92,998 | (10,389) | 7,823 | (1,949) | 215,969 | (210,390) | **1,252,185** |
| Furniture and fixtures | **54,870** | 41,338 | 8,330 | (521) | (277) | 56 | 6,705 | (15,817) | **94,684** | 6,418 | 11,270 | (1,878) | 1,324 | 861 | 21,603 | (17,632) | **116,650** |
| Facilities | **76,182** | 1,124 | 5,753 | (34) | (972) | 170 | 26,171 | (17,866) | **90,528** | 4,402 | 2,541 | (707) | 2,082 | (486) | (11,034) | (16,771) | **70,555** |
| IT equipment | **51,813** | 4,086 | 18,712 | (601) | (241) | (164) | 76,851 | (27,997) | **122,459** | 19,674 | 41,057 | (1,346) | 831 | (64) | 33,778 | (40,580) | **175,809** |
| Vehicles | **808** | 839 | 75 | (339) | 2 | (13) | - | (437) | **935** | 327 | - | 185 | - | 132 | (65) | (399) | **1,115** |
| Library | **10** | - | - | - | - | - | - | (7) | **3** | - | - | - | - | - | - | (1) | **2** |
| Land | **3,389** | 2,000 | - | (675) | - | - | - | - | **4,714** | 60,970 | 11,018 | - | - | - | 8,958 | - | **85,660** |
| Construction in process | **117,303** | 157,089 | 333,346 | (5,011) | - | - | (493,527) | - | **109,200** | 176,686 | 547,880 | (643) | - | - | (422,480) | - | **410,643** |
| Impairment | **(4,817)** | - | - | - | - | - | - | - | **(4,817)** | - | - | (333) | - | - | - | - | **(5,150)** |
| | **1,283,096** | **1,216,904** | **553,669** | **(79,565)** | **(13,002)** | **11,163** | **12,059** | **(375,370)** | **2,608,954** | **848,141** | **732,735** | **(16,202)** | **25,327** | **(10,819)** | **(3,647)** | **(405,518)** | **3,778,971** |

**(a)** Companies acquired by DASA Group (- 2).

**(b)** The expenses incurred by the Company and its subsidiaries, classified as construction in process during the construction and installation period, are transferred to the specific group under the property, plant and equipment item when available for use. The depreciation of the related assets starts after the project completion. Additionally, there were transfers from property, plant, and equipment in progress to intangible assets in the software account.

**(c)** Application of CPC 42 / IAS 29 - Hyperinflation. Updates are made by applying a general price index between the date of acquisition or occurrence and December 31, 2021.

**(d)** Upon consolidation, property, plant, and equipment from foreign operations is translated into reais (R$) at the exchange rate on the statement of financial position date.

**(e)** It refers mainly to ongoing investments in appliances, equipment, and leasehold improvements. Of the total additions, R$ 84,877 had no cash effect in the year.

The accumulated depreciation additions presented in changes in property, plant and equipment were partly recorded in general and administrative expenses and partially recorded in costs of services rendered. This allocation is linked to the end use of each asset.

For the year ended December 31, 2021, Management concluded that, except for what was recorded in the past, there are no indicators of impairment of property, plant, and equipment.

# 15 Intangible assets

| | Parent company | | | | |
|---|---|---|---|---|---|
| | | 12/31/2021 | | | 12/31/2020 |
| | **Useful life in years** | **Cost** | **Accumulated amortization** | **Net** | **Net** |
| Acquisition of interest - Goodwill | | 2,055,275 | - | 2,055,275 | 2,053,554 |
| **Intangible asset identified in the acquisition of ownership interest:** | | | | | |
| Brands | 20-30 | 312,834 | (100,402) | 212,432 | 219,963 |
| Relationship with customers | 5-10 | 74,473 | (37,410) | 37,063 | 38,094 |
| Software | 8 | 702 | (526) | 176 | - |
| | | 7,680 | - | 7,680 | - |
| **Other intangible assets:** | | | | | |
| IT systems | 5 | 960,957 | (538,565) | 422,392 | 276,253 |
| Commercial rights of use | 5 | 6,523 | (4,098) | 2,425 | 3,474 |
| Patents | 3 | 96 | (70) | 26 | 29 |
| Client exclusivity contract | 7 | 21,368 | (11,597) | 9,771 | 3,592 |
| Goodwill | 14 | 1,243 | (278) | 965 | 1,025 |
| Constructions in progress | - | 1,267 | - | 1,267 | 20,019 |
| | | **3,442,418** | **(692,946)** | **2,749,472** | **2,616,003** |

| | Consolidated | | | | |
|---|---|---|---|---|---|
| | | 12/31/2021 | | | 12/31/2020 |
| | **Useful life in years** | **Cost** | **Accumulated amortization** | **Net** | **Net** |
| Acquisition of interest - Goodwill | | 7,754,731 | - | 7,754,731 | 3,181,278 |
| **Intangible asset identified in the acquisition of ownership interest:** | | | | | |
| Brands | 20-30 | 768,391 | (145,340) | 623,051 | 666,193 |
| Relationship with customers | 5-10 | 401,518 | (104,819) | 296,699 | 232,226 |
| Software | 8 | 24,797 | (17,562) | 7,235 | 11,216 |
| | | 23,099 | (3,083) | 20,016 | 7,680 |
| **Other intangible assets:** | | | | | |
| IT systems | 5 | 1,022,223 | (539,844) | 482,379 | 308,513 |
| Commercial rights of use | 5 | 12,362 | (4,098) | 8,264 | 9,313 |
| Patents | 3 | 599 | (153) | 446 | 3 |
| Client exclusivity contract | 7 | 50,781 | (23,661) | 27,120 | 26,534 |
| Goodwill | 14 | 6,666 | (368) | 6,298 | 6,358 |
| Constructions in progress | - | 5,461 | - | 5,461 | 20,019 |
| | | **10,070,628** | **(838,928)** | **9,231,700** | **4,469,333** |

| **Parent company** | **Balance at 01/01/2020** | **Addition by merger of subsidiaries, net** | **Additions** | **Write-off** | **Transfer** | **Amortization** | **Balance at 12/31/20** | **Addition by merger of subsidiaries, net** | **Additions (a)** | **Write-off** | **Transfer** | **Amortization** | **Balance at 12/31/2021** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acquisition of interest - Goodwill | **2,026,422** | 27,132 | - | - | - | - | **2,053,554** | 3,601 | - | - | (1,880) | - | **2,055,275** |
| | | | | | | | | | | | | | |
| Brands | **230,240** | - | - | - | - | (10,277) | **219,963** | 1,676 | - | - | 1,101 | (10,308) | **212,432** |
| Relationship with customers | **41,355** | - | - | - | - | (3,261) | **38,094** | 855 | - | - | 780 | (2,666) | **37,063** |
| Appreciation of assets | **14,354** | 7,680 | - | - | (19,924) | (2,110) | **-** | - | - | - | 385 | (385) | **-** |
| Non-competition agreement | **-** | - | - | - | - | - | **-** | 246 | - | - | - | (70) | **176** |
| Software | **-** | - | - | - | - | - | **-** | - | - | - | 7,680 | - | **7,680** |
| | | | | | | | | | | | | | |
| IT system | **193,515** | 4 | - | (75) | 154,642 | (71,833) | **276,253** | 80 | 7,744 | (5,282) | 266,603 | (123,006) | **422,392** |
| Commercial rights of use | **4,538** | - | - | - | - | (1,064) | **3,474** | - | - | - | - | (1,049) | **2,425** |
| Patents | **32** | - | - | - | - | (3) | **29** | - | - | - | - | (3) | **26** |
| Client exclusivity contract | **4,438** | - | - | - | - | (846) | **3,592** | - | - | - | 7,698 | (1,519) | **9,771** |
| Goodwill | **1,148** | - | - | | | (123) | **1,025** | - | - | - | 75 | (135) | **965** |
| Constructions in progress | **4,547** | 17,521 | 148,979 | | (151,028) | - | **20,019** | - | 253,519 | - | (272,271) | - | **1,267** |
| | **2,520,589** | **52,337** | **148,979** | **(75)** | **(16,310)** | **(89,517)** | **2,616,003** | **6,458** | **261,263** | **(5,282)** | **10,171** | **(139,141)** | **2,749,472** |

**(a)** It mainly refers to investments in systems development. Of the total additions, R$ 71,894 had no cash effect in the year.

| **Consolidated** | **Balance at 01/01/2020** | **Acquisitions of subsidiaries, net (a)** | **Additions** | **Write-off** | **Net FX (d)** | **Net inflation (c)** | **Transf. (b)** | **Amortization** | **Balance at 12/31/20** | **Acquisitions of subsidiaries, net (a)** | **Additions (e)** | **Write-off** | **Net FX (d)** | **Net inflation (c)** | **Transf. (b)** | **Amortization** | **Balance at 12/31/2021** |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acquisition of interest - Goodwill | **2,995,552** | 199,013 | - | - | 11,280 | - | (24,567) | - | **3,181,278** | 4,561,804 | 40,885 | - | 37,718 | - | (66,954) | - | **7,754,731** |
| Brands | **585,053** | 95,467 | - | - | 2,261 | - | 6,622 | (23,210) | **666,193** | - | 697 | - | (41,620) | - | 23,157 | (25,376) | **623,051** |
| Relationship with customers | **195,182** | 50,798 | - | - | 3,311 | - | 9,837 | (26,902) | **232,226** | 76,204 | 267 | - | (26,956) | - | 28,184 | (13,226) | **296,699** |
| Appreciation of assets | **18,333** | - | - | - | - | - | (15,628) | (2,705) | **-** | - | - | - | - | - | 483 | (483) | **-** |
| Non-competition agreement | **9,397** | - | - | - | 1,211 | - | 6,693 | (6,085) | **11,216** | 5,243 | - | - | (12,486) | - | 13,944 | (10,682) | **7,235** |
| Software | **-** | 7,680 | - | - | - | - | - | - | **7,680** | 15,419 | - | - | - | - | - | (3,083) | **20,016** |
| IT system | **202,243** | 38,338 | 14,176 | (1,269) | (1,400) | 145 | 138,096 | (81,816) | **308,513** | 6,818 | 25,089 | (1,576) | 6,468 | (159) | 274,413 | (137,187) | **482,379** |
| Commercial rights of use | **4,538** | - | 13,590 | (7,751) | - | - | - | (1,064) | **9,313** | - | - | - | - | - | - | (1,049) | **8,264** |
| Patents | **3** | 6 | - | - | - | - | 8 | (14) | **3** | 453 | 140 | (140) | - | - | (2) | (8) | **446** |
| Client exclusivity contract | **6,201** | - | 25,036 | - | 62 | - | 867 | (5,632) | **26,534** | - | 195 | - | (758) | (15) | 7,698 | (6,534) | **27,120** |
| Goodwill | **1,148** | 5,333 | - | - | - | - | - | (123) | **6,358** | - | - | - | - | - | 75 | (135) | **6,298** |
| Constructions in progress | **4,547** | - | 149,262 | - | - | - | (133,790) | - | **20,019** | - | 262,793 | - | - | - | (277,351) | - | **5,461** |
| | **4,022,197** | **396,635** | **202,064** | **(9,020)** | **16,725** | **145** | **(11,862)** | **(147,551)** | **4,469,333** | **4,665,941** | **330,066** | **(1,716)** | **(37,634)** | **(174)** | **3,647** | **(197,763)** | **9,231,700** |

**(a)** Companies acquired by DASA Group. Of the total goodwill of R$ 7,754,731, R$ 4,561,804 refers to companies acquired in 2021, and R$ 40,885 referring to adjustments within the remeasurement period (- 2).

**(b)** The expenses incurred, classified in intangible assets in progress during the development period, are transferred to a specific item in the intangible assets group when they are available for use. The amount of reclassification in the consolidated is spent on software, reclassified from construction in progress to property, plant and equipment. There was also a reclassification of the gain, which must be disclosed according to the assets to which they refer. It was transferred from Intangible assets to Property, plant, and equipment recorded as appliances and equipment.

**(c)** Application of CPC 42 / IAS 29 - Hyperinflation. Updates are made by applying a general price index between the date of acquisition or occurrence and December 31, 2021.

**(d)** Upon consolidation, intangible assets from foreign operations are translated into reais (R$) at the exchange rate on the statement of financial position date.

**(e)** It mainly refers to investments in systems development. Of the total additions, R$ 72,119 had no cash effect in the year.

The additions to accumulated amortization, presented in changes, were recorded partially in general and administrative expenses and partially in costs of services rendered.

## Testing for impairment verification

The goodwill resulting from business combinations is an intangible asset with indefinite useful life and, therefore, it is not amortized, but tested during the year ended December 31, 2021, considering the scenario of COVID-19 outbreak. Despite the second consecutive year of the Covid-19 outbreak (2020 and 2021), there was a significant increase in revenues for the year, and there were no indications for the recognition of an additional provision for these assets.

The goodwill allocated to the Cash Generating Units (CGU), defined in accordance with the accounting practices of the Company and its subsidiaries, are shown below:

| | **12/31/2021** | **12/31/2020** |
|---|---|---|
| Outpatient care and care coordination | 3,317,797 | 3,041,724 |
| Foreign operations | 143,246 | 139,554 |
| Hospital operations (a) | 4,293,688 | - |
| | 7,754,731 | 3,181,278 |

(a) Goodwill from hospital operations fully refers to acquisitions completed in 2021.

The Company assessed the impairment of the goodwill based on its value in use, using the discounted cash flow method for Cash Generating Units (CGU). The estimation process of the value in use involves the use of assumptions, judgments and estimates of future cash flows and represents the Company's best estimate, and these projections were approved by Management. The UGC's recovery test did not identify the need for recognition of loss.

The following assumptions were used for outpatient care services and care coordination:

- The cash flow projection for the first year is based on the budget approved by Management. Management calculated the budgeted gross margin based on its expectations for market development and believes that any type of change in main assumptions that is reasonably possible, on which the recoverable value is based, would not cause the total book value to exceed the total recoverable value of the CGU. The projection covered the period of five years plus the residual value calculated by the perpetuation of the cash balance in the fifth year, discounted to the present value by the Weighted Average Cost of Capital (WACC) of 8.70% (7.33% in 2020);

- Profit: projected from 2022 to 2026 considering historical growth in the volume of services provided and inflation projections based on macroeconomic projections of banks, not considering the opening of new units.

- Expenses: projected over the same billing period, according to business dynamics and EBITDA growth rate;

- CAPEX: considering the historical average percentage of investment in asset maintenance; and

- Growth rate in perpetuity: 3.3% p.a. as of December 31, 2021 and December 31, 2020.

- The following assumptions were used for international operations:

- The cash flow projection for the first year is based on the budget approved by Management. Management calculated the budgeted gross margin based on its expectations for market development and believes that any type of change in main assumptions that is reasonably possible, on which the recoverable value is based, would not cause the total book value to exceed the total recoverable value of the CGU. The projection covered the period of five years plus the residual value calculated by the perpetuation of the cash balance in the fifth year, discounted to the present value by the Weighted Average Cost of Capital (WACC) of 8.70% (7.33% in 2020);

- Profit: projected from 2022 to 2026 considering historical growth in the volume of services provided and inflation projections based on macroeconomic projections of banks, not considering the opening of new units.

- Expenses: projected over the same billing period, according to business dynamics and EBITDA growth rate;

- CAPEX: considering the historical average percentage of investment in asset maintenance; and

- Growth rate in perpetuity: 3.3% p.a. as of December 31, 2021 and December 31, 2020.

# 16 Suppliers

| | **Parent company** | | **Consolidated** | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| Domestic suppliers | 536,367 | 474,316 | 1,144,379 | 814,590 |
| Foreign suppliers | 21,335 | 25,479 | 27,343 | 31,438 |
| Specialized medical services | 54,366 | 49,859 | 71,731 | 62,608 |
| | **612,068** | **549,654** | **1,243,453** | **908,636** |
| Current | 601,993 | 535,942 | 1,230,833 | 893,175 |
| Non-current | 10,075 | 13,712 | 12,620 | 15,461 |

# 17 Loans and financing

| | | | Parent company | | Consolidated | |
|---|---|---|---|---|---|---|
| **Description** | **Average charges** | **Final maturity** | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| BNDES - FINAME PSI **(i) (ii)** | 6% p.a. 9.5% p.a. and TJLP + 3.7% | 12/15/2024 | 3,118 | 4,249 | 3,118 | 4,249 |
| FINEP - **(iv)** | TJLP + 3% | 09/15/2026 | 18,051 | 21,851 | 18,051 | 21,851 |
| Promissory -s **(i)** | CDI + 1.95% | 04/07/2022 | 647,619 | 648,549 | 647,619 | 648,549 |
| Banks - GSM - National | 6.46% p.a. | 05/15/2025 | - | - | 18,977 | 72,809 |
| Banks - GRUPO EXAME - National | 9.38% p.a. and 0.75% p.m. | 10/21/2025 | - | - | - | 25,588 |
| Banks - Maipú – International **(iii) (v)** | ARS+ 39% p.a. | 10/10/2025 | - | - | 55,389 | 22,015 |
| Banks - Ímpar - International | USD/EUR + from 3.76 to 4.45% p.a. | 10/04/2024 | - | - | 151,769 | 144,168 |
| Banks - Ímpar - National | CDI + 1.40% p.a. | 03/08/2022 | | | 152,521 | 236,347 |
| FINAME - Ímpar **(vi)** | 8.92% p.a. | 08/31/2022 | - | - | 893 | 2,930 |
| Banks - Leforte - national **(iii)** | CDI + 3.99% p.a. | 10/20/2025 | - | - | 203,335 | - |
| Banks - Leforte - national **(iii)** | 7.71% p.a. | 12/10/2024 | - | - | 46,845 | - |
| Banks - HBA - national **(iii)** | 10.90% p.a. | 09/16/2025 | - | - | 60,071 | - |
| Banks - HSD - national **(iii)** | CDI + 0.86% p.a. | 06/08/2026 | - | - | 48,930 | - |
| Banks - HSD - national **(iii)** | 9.25% p.a. | 03/30/2026 | - | - | 117,031 | - |
| Banks - HBA - national **(iii)** | 10.90% p.a. | 09/16/2025 | - | - | 22,858 | - |
| Banks - Sall - national **(iii)** | IPCA+ 2.03% | 04/30/2028 | - | - | 18,658 | - |
| Banks - Sall - national | 4.87% p.a. | 09/30/2023 | - | - | 2,835 | - |
| Other | - | - | - | - | 14,669 | 20,212 |
| **Lease:** | | | | | | |
| Financial lease | IGPM | 06/22/2021 | - | 742 | - | 742 |
| Financial lease - Ímpar | 15.85% p.a. | 03/31/2024 | - | - | 1,099 | 2,249 |
| Financial lease - GSM | 14.1% p.a. | 04/30/2022 | - | - | - | 106 |
| Financial lease - Leforte | CDI + 2.55% p.a. | 06/26/2022 | - | - | 618 | - |
| | | | **668,788** | **675,391** | **1,585,286** | **1,201,815** |
| Current | | | 652,611 | 46,211 | 1,090,652 | 200,194 |
| Non-current | | | 16,177 | 629,180 | 494,634 | 1,001,621 |

Changes in loans and financing are as follows:

| | **Parent company** | **Consolidated** |
|---|---|---|
| **Balance at December 31, 2019** | **90,559** | **108,809** |
| Funding | 648,485 | 796,942 |
| Incurred interest and exchange rate change | 24,263 | 114,322 |
| Interest paid | (10,861) | (50,672) |
| Amortization of principal | (77,055) | (338,866) |
| Acquisitions of subsidiaries | - | 571,280 |
| **Balance at December 31, 2020** | **675,391** | **1,201,815** |
| Funding | 499,908 | 557,630 |
| Incurred interest and exchange rate change | 54,412 | 51,795 |
| Interest paid | (15,179) | (41,647) |
| Amortization of principal | (545,744) | (814,638) |
| Acquisition of subsidiary | - | 630,331 |
| **Balance at December 31, 2021** | **668,788** | **1,585,286** |

**Collateral for loans and financing:**

**(i)** Promissory - of 100% of the contractual sum on behalf of the Company.

**(ii)** Well financed

**(iii)** Real estate, surety, assignment of credit receivables

**(iv)** Letter of guarantee

**(v)** Mortgage

**(vi)** Pledge

Except for promissory -s, as detailed in the remark (a), the bank loan and financing contracts do not have covenants. Bank loans and financing, classified in current and non-current liabilities following the contractual maturities will be amortized as shown in - 32 – Financial instruments at liquidity risk.

## Promissory -s

(i) On March 23, 2020, the Company's Board of Directors approved the 6th issuance of 130 promissory -s, in four (4) series, in physical form, with a unit face value of R$ 5.000 million ("Promissory -s"), with a total value of R$ 650,000, on the issuance date; that is, April 07, 2020, for placement through a public distribution offer with restricted placement efforts, pursuant to CVM Instruction nº 476, dated January 16, 2009, as amended. On April 07, 2020, the public distribution offer was closed.

The Issuance was made in 4 series, of which (i) 4 Promissory -s for the first series, (ii) 4 Promissory -s for the second series and (iii) 4 Promissory -s for the third series and (iv) 118 Promissory -s for the third series. The term (i) of the Promissory -s for the first series is up to 185 days from the date of issuance (ii) of the Promissory -s for the second series is of up to 370 days from the date of issuance and (iii) of the Promissory -s for the third series is up to 550 days from the date of issuance and (iv) of the Promissory -s for the fourth series is up to 730 days from the date of issuance.

Promissory - transactions contracted by the Company require compliance with restrictive financial clauses, under penalty of early maturity of the related debts. Failure to comply with obligations or restrictions for two consecutive quarters may lead to the early maturity of the related debts and default in relation to other contractual obligations (cross-default), depending on each loan and financing agreement.

(ii) On March 08, 2021, the Company's Board of Directors approved the 7th issuance of 500 promissory -s, in single series, in physical form, with a unit nominal value of R$ 1.000 million ("Promissory -s"), with a total value of R$ 500,000, on the issuance date; that is, March 11, 2021, for placement through a public distribution offer with restricted placement efforts, pursuant to CVM Instruction nº 476, dated January 16, 2009, as amended. On March 11, 2021, the public distribution offer was closed. The term of the promissory -s is 180 days from the issuance date, and was settled on September 6, 2021.

The promissory - has clauses setting forth maximum levels of indebtedness and leverage, based on the consolidated financial statements:

**1.** Net debt/EBITDA - maximum ratio of 4.00

**2.** EBITDA/Financial result - minimum ratio of 1.50

For reading the above references, the following definitions are considered:

- **Financial net debt for covenants:** Represents: (i) the sum of all consolidated debts of the Company to individuals and/or legal entities, limited to: (a) loans and financing with third parties; (b) debts arising from issuances of fixed-income securities, in circulation in the local and/or international capital markets; (c) net balance of derivative transactions (i.e. liabilities less assets from derivative transactions); (d) the value of redeemable preferred shares issued by the Company; and (e) the balance of credit assignment operations up to the limit of the Company's co-obligation; less (ii) the sum of (a) the amount available in the Company's cash; (b) the net balances of the Company's bank checking accounts; and (c) Company's balances of interest earning bank deposits.

  Specifically for the 15th issuance of debentures, Net Debt for covenant purposes represents: (i) the sum of all consolidated debts of the Company to individuals and/or legal entities, limited to: (a) loans and financing with third parties; (b) debts arising from issuances of fixed-income securities, in circulation in the local and/or international capital markets; (c) net balance of derivative transactions (i.e. liabilities less assets from derivative transactions); (d) the value of redeemable preferred shares issued by the Company;  (e) balance payable related to acquisitions (sellers finance); and (f) the balance of credit assignment operations up to the limit of the Company's co-obligation; less (ii) the sum of (a) the amount available in the Company's cash; (b) the net balances of the Company's bank checking accounts; and (c) Company's balances of interest earning bank deposits.

- **Adjusted EBITDA (Earnings before interest, taxes, depreciation and amortization) for covenants:** Is a non-accounting measure prepared by the Company for the 4 (four) immediately preceding quarters, and corresponds to the Company's net profit before net financial expenses, income tax and social contribution on income, depreciation, amortization, and expenses with the stock option plan (for some contracts the expenses with stock option plan are not foreseen). In case of acquisition(s), the EBITDA generated in the period of twelve (12) months immediately preceding the end of each quarter of the calendar year by the acquiree(s) will be considered for the purposes of calculating the Company's EBITDA. Therefore, the Company included, for purposes of calculating this financial index, the amount of R$ 263,235 corresponding to the sum of earnings before interest, taxes, depreciation, and amortization of the acquirees in 2021 generated by the acquirees from the beginning of 2021 to the business combination date specified in Note 2.

  Financial income (loss) for covenants: it means the difference between the financial revenues and the financial expenses of the Company relating to the 4 (four) quarters of the calendar year immediately prior to the quarter of the calendar year then in progress, relating exclusively to (i) the financial expenses relating to the consolidated debts of the Company before individuals and/or legal entities, limited to (a) loans and financing with third parties; (b) debts arising from issuances of fixed-income securities, in circulation in the local and/or international capital markets; (c) net balance of derivative transactions (i.e. liabilities less assets from derivative transactions); (d) the value of redeemable preferred shares issued by the Company; and (e) the balance of credit assignment operations up to the limit of the Company's co-obligation; and (ii) financial revenues referring to (a) the amount available in the Company's cash; (b) the net balances of the Company's bank checking accounts; and (c) balances of the Company's interest earning bank deposits.

# 18 Leases

## Domestic financial lease

DASA Group leases assets that are recorded in property, plant and equipment, subject to contracts that are: with purchase option, without renewal option, have contingent payments provided for, and do not have covenants related to dividends and interest on own capital or additional debt. The details of these contracts are shown in - 17.

## Right-of-use assets and lease liabilities

DASA Group has property lease operations such as: service units, warehouses, administrative headquarters and technical operational centers. The average term of the contracts varies between 5 and 10 years, but they are negotiated individually.

| | Parent company | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Balance at 12/31/20 | Addition (c) | Amortization | Interest (a) | Payments | Remeasurement (b) | Transfer | Balance at 12/31/2021 |
| **Assets** | | | | | | | | |
| Right of use | 796,876 | 59,414 | (148,562) | - | - | 239,191 | - | 946,919 |
| **Liabilities** | | | | | | | | |
| Leases - rentals | 806,258 | 59,414 | - | 81,836 | (222,988) | 239,191 | - | 963,711 |
| Provision for demobilization cost - non-current | 51,225 | - | - | - | - | - | - | 51,225 |
| | **857,483** | **59,414** | **-** | **81,836** | **(222,988)** | **239,191** | **-** | **1,014,936** |
| | | | | | | | | - |
| Current | 294,843 | 59,414 | - | 81,836 | (222,988) | 239,191 | 72,743 | 525,039 |
| Non-current | 562,640 | - | - | - | - | - | (72,743) | 489,897 |

| | Parent company | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Balance at 12/31/2019 | Addition (c) | Amortization | Interest (a) | Payments | Remeasurement (b) | Transfer | Balance at 12/31/20 |
| **Assets** | | | | | | | | |
| Right of use | **881,965** | **5,672** | **(155,636)** | **-** | **-** | **64,875** | **-** | **796,876** |
| **Liabilities** | | | | | | | | |
| Leases - rentals | 857,592 | 5,672 | - | 85,590 | (207,471) | 64,875 | - | 806,258 |
| Provision for demobilization cost - non-current | 51,225 | - | - | - | - | - | - | 51,225 |
| | **908,817** | **5,672** | **-** | **85,590** | **(207,471)** | **64,875** | **-** | **857,483** |
| Current | 125,820 | 5,672 | - | - | (207,471) | 64,875 | 305,947 | 294,843 |
| Non-current | 782,997 | - | - | 85,590 | - | - | (305,947) | 562,640 |

| | Consolidated | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | **Balance at 12/31/20** | **Acquisition of subsidiaries** | **Addition (c)** | **Amortization** | **Write-off (c)** | **Interest (a)** | **Pay-ments** | **Remeasurement (b)** | **Transfer** | **Balance at 12/31/2021** |
| **Assets** | | | | | | | | | | |
| Right of use | 1,384,934 | 191,485 | 404,518 | (326,481) | (113,505) | - | - | 423,386 | - | 1,964,337 |
| **Liabilities** | | | | | | | | | | |
| Leases - rentals | 1,431,472 | 232,411 | 404,518 | - | (142,005) | 156,246 | (441,032) | 423,386 | - | 2,064,996 |
| Provision for demobilization cost - non-current | 54,041 | - | - | - | | - | - | - | - | 54,041 |
| | **1,485,513** | **232,411** | **404,518** | **-** | **(142,005)** | **156,246** | **(441,032)** | **423,386** | **-** | **2,119,037** |
| Current | 427,238 | 35,699 | 100,872 | - | (142,005) | 156,246 | (441,032) | 163,074 | 399,172 | 699,264 |
| Non-current | 1,058,275 | 196,712 | 303,646 | - | - | - | - | 260,312 | (399,172) | 1,419,773 |

| | Consolidated | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | **Balance at 12/31/2019** | **Acquisition of subsidiaries** | **Addition (c)** | **Amortization** | **Interest (a)** | **Pay-ments** | **Remeasurement (b)** | **Transfer** | **Balance at 12/31/20** |
| **Assets** | | | | | | | | | |
| Right of use | **888,042** | **517,671** | **124,345** | **(242,665)** | **-** | **-** | **97,541** | **-** | **1,384,934** |
| **Liabilities** | | | | | | | | | |
| Leases - rentals | 863,618 | 540,828 | 113,290 | - | 129,239 | (325,049) | 109,546 | - | 1,431,472 |
| Provision for demobilization cost - non-current | 51,807 | - | 1,710 | - | - | - | 524 | - | 54,041 |
| | **915,425** | **540,828** | **115,000** | **-** | **129,239** | **(325,049)** | **110,070** | **-** | **1,485,513** |
| Current | 127,160 | 81,508 | 64,755 | - | - | (325,049) | 69,218 | 409,646 | 427,238 |
| Non-current | 788,265 | 459,320 | 50,245 | - | 129,239 | - | 40,852 | (409,646) | 1,058,275 |

**(a)** Interest is recorded in the profit or loss under financial expenses, using a single discount rate, considering the average funding in the market as shown below:

| **Agreement term** | **Rate** |
|---|---|
| 2 years | 7.37% |
| 4 years | 7.55% |
| 5 years | 7.71% |
| 10 years | 8.18% |
| **Weighted average** | **7.70%** |

**(b)** The remeasurement arises from changes in future lease payments resulting from a change in the rate used to determine these payments (IGP-M). DASA Group has remeasured the lease liability to reflect these revised payments. There was no change in the lease term and there was no need to revise the discount rate. The impact of the remeasurement was R$ 239,191 in the Parent Company and R$ 970,542 in the consolidated, with no immediate effect on the result and no effect on the cash flow statements.

**(c)** The impact of the addition in the Parent Company and in the Consolidated and decrease in Consolidated do not have an immediate effect on the statements of profit or loss and cash flow.

The maturity dates of non-current installments as of December 31, 2021 are as follows:

| | Parent company | Consolidated |
|---|---|---|
| 2023 | 138,518 | 259,268 |
| 2024 | 131,722 | 239,620 |
| 2025 | 122,864 | 216,676 |
| >2026 | 96,793 | 704,209 |
| | **489,897** | **1,419,773** |

Considering that DASA Group has a taxation regime based on the cumulative method, there are no potential PIS and COFINS taxes recoverable in the lease consideration installments.

The following shows how much the balance of the right-of-use assets and the lease liabilities, as well as the depreciation and interest expenses, would be if the projected inflation in the payment flows were considered:

| Analysis of the impact of the statement of financial position difference | | Analysis of the impact of the difference in the statement of profit or loss | |
|---|---|---|---|
| **Lease liabilities** | **12/31/2021** | **Financial expense** | **2021** |
| Flows - check CPC 06 (R2) / IFRS 16 | 2,119,037 | Flows - check CPC 06 (R2) / IFRS 16 | 156,246 |
| Flow without inflation | 2,557,255 | Flow without inflation | 137,159 |
| **Net right-of-use** | **12/31/2021** | **Depreciation expense** | **2021** |
| Flows - check CPC 06 (R2) / IFRS 16 | 1,964,337 | Flows - check CPC 06 (R2) / IFRS 16 | 326,481 |
| Flow without inflation | 2,557,255 | Flow without inflation | 402,152 |

# 19 Debentures

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| Non-convertible debentures | 5,398,333 | 3,531,667 | 6,002,102 | 4,132,758 |
| Remuneration interest | 78,883 | 14,691 | 78,620 | 14,429 |
| Transaction cost | (18,435) | (9,149) | (19,161) | (10,179) |
| | **5,458,781** | **3,537,209** | **6,061,561** | **4,137,008** |
| Current | 801,277 | 145,133 | 1,004,583 | 145,720 |
| Non-current | 4,657,504 | 3,392,076 | 5,056,978 | 3,991,288 |

Changes in debentures are as follows:

| | Parent company | Consolidated |
|---|---|---|
| **Balance at December 31, 2019** | **2,715,986** | **2,715,986** |
| Funding | 965,000 | 965,000 |
| Acquisition of subsidiaries | - | 601,571 |
| Interest accrual | 100,959 | 123,061 |
| Interest paid | (104,719) | (91,391) |
| Amortization of principal | (133,333) | (170,535) |
| Transaction cost | (6,684) | (6,684) |
| **Balance at December 31, 2020** | **3,537,209** | **4,137,008** |
| Funding | 2,000,000 | 2,000,000 |
| Interest accrual | 216,441 | 251,398 |
| Interest paid | (152,262) | (184,238) |
| Amortization of principal | (133,320) | (133,320) |
| Transaction cost | (9,287) | (9,287) |
| **Balance at December 31, 2021** | **5,458,781** | **6,061,561** |

Debentures classified in non-current liabilities have the following amortization term:

| | Parent company | Consolidated |
|---|---|---|
| 2023 | 718,112 | 917,849 |
| 2024 | 784,700 | 984,437 |
| 2025 | 635,331 | 635,331 |
| 2026–2031 | 2,519,361 | 2,519,361 |
| | **4,657,504** | **5,056,978** |

## Debentures - Parent Company

The issuances of debentures not convertible into shares, of unsecured type, were approved by the Company's Board of Directors by means of a public distribution offer with restricted efforts, pursuant to CVM Instruction nº 476, dated January 16, 2009, as amended, shown below:

| Issuance | Series | Approval date | Quantity | Total amount raised | Term (counted as of the issuance) | Remuneration | Amortization of principal |
|---|---|---|---|---|---|---|---|
| 8th | Sole | 08/08/2017 | 40,000 | 400,000 | 5 years | 108.00% of DI Semi-annual payment | 3 installments – 1st on 08/25/2020, 2nd on 25/08/2021 and 3rd on 08/25/2022 |
| 9th | Sole | 02/05/2018 | 60,000 | 600,000 | 5 years | 108.60% of DI | 2 installments – 1st on 26/03/2022 and 2nd on 03/26/2023 |
| 10th | 1st | 11/19/2018 | 10,000 | 100,000 | within 5 years | 107.40% of DI | 2 installments – 1st on 10/12/2022 and 2nd on 12/10/2023 |
| 10th | 2nd | 11/19/2018 | 30,000 | 300,000 | 6 years | 110.50% of DI | 12/10/2024 |
| 10th | 3rd | 11/19/2018 | 40,000 | 400,000 | within 8 years | 112.50% of DI | 2 installments – 1st on 10/12/2025 and 2nd on 12/10/2026 |
| 11th | Sole | 05/17/2019 | 40,000 | 400,000 | within 7 years | 108.50% of DI | 2 installments – 1st on 10/06/2025 and 2nd on 06/10/2026 |
| 12th | Sole | 11/22/2019 | 500,000 | 500,000 | within 5 years | 100% DI + 1.2% p.a. | 2 installments - 1st on 11/25/2023 and 2nd on 11/25/2024 |

| Issuance | Series | Approval date | Quantity | Total amount raised | Term (counted as of the issuance) | Remuneration | Amortization of principal |
|---|---|---|---|---|---|---|---|
| 13th | Sole | 04/08/2020 | 365,000 | 365,000 | within 3 years | 100% DI + 1.95% p.a. | 3 installments – 1st on 04/13/2022, 2nd on 13/10/2022 and 3rd on 04/13/2023 |
| 14th | 1st | 10/20/2020 | 475,650 | 475,650,000 | within 5 years | 100% DI + 2.10% p.a. | 2 installments – 1st on 10/20/2024 and 2nd on 10/20/2025 |
| 14th | 2nd | 10/20/2020 | 124,350 | 124,350,000 | within 7 years | 100% DI + 2.40% p.a. | 2 installments – 1st on 10/20/2026 and 2nd on 10/20/2027 |
| 15th | 1st | 10/15/2021 | 1,000,000 | 1,000,000,000 | 5 years | 100% DI + 1.40% p.a. | 1 installment - 10/30/2026 |
| 15th | 2nd | 10/15/2021 | 285,359 | 285,359,000 | 7 years | 100% DI + 1.50% p.a. | 1 installment - 10/30/2028 |
| 15th | 3rd | 10/15/2021 | 714,641 | 714,641,000 | 10 years | 100% DI + 1.85% p.a. | 1 installment - 10/30/2031 |

The net proceeds obtained by the Company with the issuance of the Debentures were fully used to extend its debt profile and reinforce its working capital, aiming to meet the ordinary management of its businesses.

Debenture transactions contracted by the Company require compliance with restrictive financial clauses, under penalty of early maturity of the related debts. Failure to comply with obligations or restrictions for two consecutive quarters may lead to the early maturity of the related debts and default in relation to other contractual obligations (cross-default), depending on each loan and financing agreement. The compliance rates are the same as mentioned in - 17.

## Debentures of subsidiary Ímpar Serviços Hospitalares S.A.

On October 30, 2019, the Board of Directors of the subsidiary Ímpar Serviços Hospitalares S.A. approved the issuance of 600,000 simple debentures, not convertible into shares, unsecured, with additional collateral, in a single series, with a unit nominal value of R$ 1,000.00, totaling, on the date of issuance (December 10, 2019), the amount of R$ 600,000 for public distribution, with restricted placement efforts as follows:

| Issuance | Series | Approval date | Quantity | Amount raised | Term (counted as of the issuance) | Remuneration | Amortization of principal |
|---|---|---|---|---|---|---|---|
| 1st | Sole | 10/30/2019 | 600 | R$ 600,000 | 5 Years | CDI + 1.40% | 06/10/2022 – 12/12/2022<br>06/12/2023 – 12/11/2023<br>06/10/2024 – 12/10/2024 |

## Financial and non-financial covenants - Early maturities

The debentures issued by the subsidiary Ímpar Serviços Hospitalares S.A. have clauses setting forth maximum levels of indebtedness and leverage, based on its annual consolidated financial statements. Failure to comply with these contractual clauses may lead to the early maturity of the debenture balance, plus interest remuneration for the period.

# 20 Taxes in installments

| | | Parent company | | Consolidated | |
|---|---|---|---|---|---|
| | End of amortization | 12/31/2021 | 12/31/2020 | 12/31/2021 | 12/31/2020 |
| Installment payment of ISS | 2029 | 2,908 | 5,511 | 14,094 | 3,661 |
| Municipal Refis - Ímpar | 2025 | - | - | 6,218 | 18,987 |
| Refis IV - Federal - Ímpar | 2024 | - | - | 33,660 | 48,825 |
| Refis IV - Lab. Gaspar | 2024 | - | - | - | 1,459 |
| Federal tax installment | 2025 | 2,046 | 1,468 | 268,201 | 6,701 |
| Installment payment of solid waste fee - SZD | 2022 | - | - | 305 | 1,005 |
| PERT Installment Payment - Santa Luzia | 2022 | - | - | 348 | 483 |
| Installment payment of federal taxes - Valeclin | 2028 | - | - | 2,078 | 2,346 |
| Installment payment - INSS | 2029 | | - | 58,774 | - |
| Other | 2022 | 114 | 244 | 1,338 | 1,609 |
| | | **5,068** | **7,223** | **385,016** | **85,076** |
| Current | | 2,084 | 2,627 | 116,469 | 23,150 |
| Non-current | | 2,984 | 4,596 | 268,547 | 61,926 |

| | Parent company | Consolidated |
|---|---|---|
| 2023 | 773 | 75,820 |
| 2024 | 759 | 64,600 |
| 2025 | 364 | 63,046 |
| 2026–2029 | 1,088 | 65,081 |
| | **2,984** | **268,547** |

# 21 Accounts payable from acquisition of subsidiaries and options with non-controlling shareholders

Accounts payable from the acquisition of subsidiaries refer to amounts due to the previous owners for the acquisition of shares or quotas representing the capital of acquirees. Debts are updated in accordance with the contractual clauses:

| | | | Parent company | | Consolidated | |
|---|---|---|---|---|---|---|
| | Restatement | Maturity | 12/31/2021 | 12/31/2020 | 12/31/2021 | 12/31/2020 |
| Not collateralized by interest earning bank deposits | IPCA-IGPM-Selic | 06/2025 | 367,332 | 419,203 | 1,700,168 | 431,031 |
| Collateralized by means of interest earning bank deposits | (a) | (a) | 29,353 | 38,386 | 29,477 | 38,505 |
| Earn-out payment | | | 65,322 | 67,267 | 124,466 | 67,267 |
| | | | **462,007** | **524,856** | **1,854,111** | **536,803** |
| Current | | | 383,387 | 116,638 | 1,077,631 | 121,408 |
| Non-current | | | 78,620 | 408,218 | 776,480 | 415,395 |

(a) Both the financial investment and the liabilities are remeasured considering the rate of 102.39% of the CDI as of December 31, 2021 (90.58% as of December 31, 2020). The maturity in up to 6 years from the date of acquisition, or until the discussion on the contingency is concluded. Interest earning bank deposits are recorded and disclosed in a separate caption in non-current assets.

Changes in accounts payable from acquisition of subsidiaries in the parent company are as follows:

| | Not collateralized by interest earning bank deposits | Not collateralized by interest earning bank deposits - International | Collateralized by interest earning bank deposits | Contingent consideration | Total |
|---|---|---|---|---|---|
| **Balance at December 31, 2019** | **117,452** | **204,496** | **41,483** | **40,300** | **403,731** |
| Acquisitions | 164,343 | - | 1,569 | 15,300 | 181,212 |
| Inflation adjustment and exchange-rate change | 4,052 | 48,902 | 877 | 12,667 | 66,498 |
| Payments | (57,345) | (62,696) | (5,544) | (1,000) | (126,585) |
| **Balance at December 31, 2020** | **228,502** | **190,702** | **38,385** | **67,267** | **524,856** |
| Acquisitions | 95,190 | - | - | - | 95,190 |
| Inflation adjustment and exchange-rate change | 622 | 23,302 | 787 | (1,945) | 22,766 |
| Remeasurement of fair value | (3,474) | - | - | - | (3,474) |
| Payments | (111,648) | (55,864) | (9,819) | - | (177,331) |
| **Balance at December 31, 2021** | **209,192** | **158,140** | **29,353** | **65,322** | **462,007** |

Changes in accounts payable from acquisition of subsidiaries in the consolidated are as follows:

| | Not collateralized by interest earning bank deposits | Not collateralized by interest earning bank deposits - International | Collateralized by interest earning bank deposits | Contingent consideration | Total |
|---|---|---|---|---|---|
| **Balance at December 31, 2019** | **117,452** | **204,496** | **41,483** | **40,300** | **403,731** |
| Acquisitions | 164,343 | - | 1,569 | 15,300 | 181,212 |
| Inflation adjustment and exchange-rate change | 4,052 | 48,902 | 877 | 12,667 | 78,325 |
| Payments | (57,345) | (62,696) | (5,424) | (1,000) | (126,465) |
| **Balance at December 31, 2020** | **228,502** | **190,702** | **38,505** | **67,267** | **536,803** |
| Acquisitions | 1,472,648 | - | - | 59,144 | 1,531,792 |
| Balance from acquisition of subsidiaries | 75,728 | | | | 75,728 |
| Inflation adjustment and exchange-rate change | 5,354 | 23,302 | 791 | (1,945) | 27,502 |
| Remeasurement of fair value | (40,795) | - | - | - | (40,795) |
| Payments | (182,092) | (55,864) | (9,819) | (29,144) | (276,919) |
| **Balance at December 31, 2021** | **1,571,172** | **158,140** | **29,477** | **95,322** | **1,854,111** |

The portions classified in non-current assets have the following payment schedule:

| **Year of maturity** | **Parent company** | **Consolidated** |
|---|---|---|
| 2023 | 71,095 | 728,989 |
| 2024 | 2,286 | 16,330 |
| >2025 | 5,239 | 231,794 |
| **Total** | **78,620** | **977,113** |

## Put and call option granted to non-controlling shareholders

As part of the agreement to acquire equity interest, a put option was issued by the Company or its subsidiaries in favor of the non-controlling shareholders and a call option was issued by the sellers in favor of the Company or its subsidiaries, which may result in an acquisition by the Company or its subsidiaries of the remaining shares of non-controlling shareholders, summarized as follows:

Put option granted to non-controlling shareholders:

| | Parent company | Consolidated |
|---|---|---|
| **Balance at December 31, 2019** | - | - |
| Laboratório Nobel S/A | 16,552 | 16,552 |
| Instituto de Hematologia de São José do Rio Preto Ltda. | 5,694 | 5,694 |
| DB Genética Serviços Laboratoriais Ltda. | 5,691 | 5,691 |
| CPCLIN - Centro de Pesquisa Clinicas Ltda. | 1,022 | 1,022 |
| Laboratório Bioclínico MS Ltda. | 10,500 | 10,500 |
| **Balance at December 31, 2020** | **39,459** | **39,459** |
| Laboratório Nobel S/A | 14,762 | 14,762 |
| Instituto de Hematologia de São José do Rio Preto Ltda. | 7,884 | 7,884 |
| DB Genética Serviços Laboratoriais Ltda. | 11,560 | 11,560 |
| CPCLIN - Centro de Pesquisa Clinicas Ltda. | 1,278 | 1,278 |
| Laboratório Bioclínico MS Ltda. | 15,742 | 15,742 |
| Nossa Senhora do Carmo Participações Ltda. | - | 70,092 |
| **Balance at December 31, 2021** | **51,226** | **121,318** |
| Current | 30,504 | 30,504 |
| Non-current | 20,722 | 90,814 |

Call option obtained from non-controlling shareholders:

| | Parent company | Consolidated |
|---|---|---|
| **Balance at December 31, 2019** | - | - |
| Laboratório Nobel S/A | 1,000 | 1,000 |
| Instituto de Hematologia de São José do Rio Preto Ltda. | 1,270 | 1,270 |
| DB Genética Serviços Laboratoriais Ltda. | 1,322 | 1,322 |
| CPCLIN - Centro de Pesquisa Clinicas Ltda. | 1,454 | 1,454 |
| Laboratório Bioclínico MS Ltda. | 2,423 | 2,423 |
| **Balance at December 31, 2020:** | **7,469** | **7,469** |
| Current | 6,147 | 6,147 |
| Non-current | 1,322 | 1,322 |
| Instituto de Hematologia de São José do Rio Preto Ltda. | 610 | 610 |
| DB Genética Serviços Laboratoriais Ltda. | 481 | 481 |
| CPCLIN - Centro de Pesquisa Clinicas Ltda. | 878 | 878 |
| Nossa Senhora do Carmo Participações Ltda. | - | 12,513 |
| **Balance at December 31, 2021** | **1,969** | **14,482** |
| Non-current | 1,969 | 14,482 |

# 22 Provisions for tax, social security, labor and civil claims.

| | Parent company | | | | Consolidated | | | |
|---|---|---|---|---|---|---|---|---|
| | 12/31/2021 | | 12/31/2020 | | 12/31/2021 | | 12/31/2020 | |
| | Provision | Judicial deposit | Provision | Judicial deposit | Provision | Judicial deposit | Provision | Judicial deposit |
| Labor and civil | 37,585 | 15,715 | 53,143 | 16,918 | 142,467 | 40,050 | 107,356 | 30,885 |
| Tax and social security claims | 87,819 | 35,127 | 70,798 | 64,163 | 112,874 | 44,237 | 94,062 | 69,418 |
| | **125,404** | **50,842** | **123,941** | **81,081** | **255,341** | **84,287** | **201,418** | **100,303** |

## Provisions for labor and civil risks

As of December 31, 2021, DASA Group was party to 1,195 labor claims (1,456 as of December 31, 2020) and 1,697 civil lawsuits at administrative and judicial levels (1,761 as of December 31, 2020). The provisions of R$ 37,585 (R$ 53,143 as of December 31, 2020) in the parent company and R$ 142,467 (R$ 107,356 as of December 31, 2020) in the consolidated are based on the history of loss percentage in lawsuits assessed as a probable and possible risk for labor claims and probable risk for civil claims. As of December 31, 2021, the Company and its subsidiaries still had the consolidated amount of R$ 181,392 (R$ 175,104 as of December 31, 2020) referring to civil proceedings classified by their legal advisors as possible loss, for which there is no provision constituted, in accordance with the accounting rule.

Regarding labor claims, we highlight the Public Civil Action pending in the Labor Court of Rio de Janeiro, where the Company and Laboratórios Médicos Dr. Sérgio Franco Ltda., a company merged by the Company on July 1, 2014, were mentioned, questioning in general terms the legality of engaging medical companies specialized in the area of diagnostic imaging support exams, requiring the hiring of physicians linked to said medical companies, under a formal labor contract, as well as indemnity for collective moral damage in the approximate amount of R$ 20,000 on September 10, 2012. On June 26, 2014, the Company released a new Material Fact disclosing that a decision was handed down in the lower court, totally favorable to the Company. On February 24, 2015, the Regional Labor Court partially accepted the Ordinary Appeal filed by the Public Prosecutor's Office and ordered the Company to register the intervening physicians - representing approximately 22 professionals - in addition to reducing the collective moral damage to R$ 500. The decision handed down by the Regional Labor Court (TRT) - 1st Region defined intervening physicians as follows: "(are those professionals) who exercise coordination over the performing physicians who are part of the same specialty." The Company and the Public Prosecutor's Office filed a motion for clarification against the decision. The motions of the Public Prosecutor's Office were rejected and the motions of the Company were accepted; however, without significantly modifying the decision. The Review Appeal presented by the Public Prosecutor's Office was denied. On January 27, 2016, an interlocutory appeal was filed by the Labor Public Prosecutor's Office (MPT). On May 3, 2016, we filed (i) a counter-draft of an interlocutory appeal, (ii) counter-reasons for review appeals and (iii) binding review appeals. The assessment of its legal advisors and of Management is that the loss is probable for the moral damage of approximately 22 professionals in the updated amount of R$ 1,321, and the probability of loss is remote for collective moral damage in the amount of R$ 19,500.

## Provisions for tax and social security claims

The provisions for tax and social security claims in the amount of R$ 87,819 (R$ 70,798 as of December 31, 2020) in the parent company and R$ 112,871 (R$ 94,062 as of December 31, 2020) in the consolidated correspond to (i) challenges for increases in rates (ii) calculation basis and (iii) unconstitutionality of collection. The Company and its subsidiaries still had the consolidated amount of R$ 1,177,958 as of December 31, 2021 (R$ 799,473 as of December 31, 2020) referring to lawsuits classified by its legal advisors as possible losses, for which no provision was recorded, according to the accounting rule applicable for this circumstance, of which R$ 300,632 referring to tax on services of any nature (ISSQN) proceeding mainly discussing the place where clinical analysis services are provided, R$ 105,128 referring to the collection of PIS/COFINS on billing and imports, IRPJ and CSLL credits in the amount of R$ 92,011, IRPJ and CSLL in the amount of R$ 429,178 originated from the deduction of goodwill calculated in the corporate merger.

On March 7, 2016, Management became aware of a Brazilian Federal Revenue Service administrative proceeding related to two tax assessment notices issued requiring PIS and COFINS payment in the total amount of R$ 55,629. On July 15, 2016, the Company filed the Declaratory Action No. 0004053-41.2016.4.03.6144, in progress at the 1st Federal Court of the Judicial Subsection of Barueri-SP, aiming to guarantee in advance the full amount of the tax debts object of the Tax Enforcement by offering a guarantee insurance policy issued on July 13, 2016, in strict compliance with the provisions of Ordinance 164/2014 of the National Treasury Attorney-General's Office (PGFN), as well as of articles 151, item V, and 206 of the National Tax Council (CTN). Tax Enforcement No. 0006303-47.2016.403.6144 was filed on August 10, 2016 for the collection of CDAs 80 6 16 053101-28 and 80 7 16 021700-63, which are subject to PIS and COFINS debts calculated for the year 2011 arising from Federal Administrative Proceeding No. 16004.720192/2015-69 filed by the Brazilian Federal Revenue Service. On May 12, 2017, a decision was issued confirming the urgent relief decision and deemed the declaratory action valid to determine that the tax credits charged due to tax enforcement are guaranteed by means of a suitable guarantee insurance. The Company was summoned to respond to the terms of Tax Enforcement No. 0006303-47.2016.403.6144, which is why it presented a statement in the records of the Declaratory Action with Motion for Injunctive Relief No. 0004053-41.2016.4.03.6144 informing about the existence of this tax enforcement and requiring the transfer of the guarantee. In compliance with the requirements provided for in articles 16, items I and II, of Law nº 6,830/80, 184, head provision and §1, of the CPC, and 62, item I, of Law nº 5,010/66, on September 27, 2017, the Company filed Motions for Stay of Execution, registered in the electronic systems of the 1st Federal Court of the Judicial Subsection of Barueri-SP under No. 0003688-50.2017.403.6144. On April 12, 2018, the decision on the Motions for Stay of Execution was published, determining that evidence be produced, which was met by the Company within the term on April 20, 2018. In November 2018, a decision was published requesting the Company to indicate questions and the technical assistant within 15 days, which were presented in a timely manner. Finally, the assessment by the Company’s external legal advisors as to the chances of losing the merit of said lawsuit is possible, for which there is no provision recorded.

The Company filed Declaratory Action No. 1005652-68.2018.4.01.3400 before the Federal Government, aiming at granting urgent provisional protection to ensure the Company the deduction, in the IRPJ and CSLL calculation bases, of the amortization of goodwill arising from the corporate merger, thus suspending the payment of the disputed amount. On April 16, 2018, a decision was handed down granting the provisional emergency relief claimed to suspend the enforceability of the disputed amount provided that the guarantee insurance is accepted by the Federal Government. On May 4, 2018, the Federal Government filed motions for clarification questioning the acceptance of the guarantee insurance policy as a way of suspending the credit payment. In view of the impossibility of proceeding with the guarantee insurance, the Company deposited the amount of R$ 33,350 in court until October 2018, including fine and interest on late payment, which corresponds to the amounts of IRPJ and CSLL calculated on the deduction of these taxes in the calculation basis. The assessment by the Company's external legal advisors as to the chances of losing the merit of said lawsuit is possible, for which there is no provision recorded. On May 28, 2020, the Brazilian Federal Revenue ended the inspection procedure on the deductibility of said goodwill, showing the sufficiency of the judicial deposits and, at the same time, disallowing the IRPJ tax loss and negative calculation basis of social contribution in the extent of the goodwill used for tax purposes. The Company understands that there are legal grounds for the tax enjoyment of goodwill and will challenge the tax assessment notices in the administrative sphere. At the same time, the lawsuit will have a regular course, and the Company may thus deduct the aforementioned amounts after the final and unappealable decision, if the final decision is favorable. The assessment by the Company's external legal advisors as to the risk of losing the merit of litigation is possible, for which there is no provision recorded, since there is no tax exposure.

## Changes in the provisions for contingencies as of December 31, 2021

| | Parent company | | | | |
|---|---|---|---|---|---|
| | | Changes for the year | | | |
| | **12/31/2020** | **Addition to provision** | **Usage** | **Update / (update reversal)** | **12/31/2021** |
| Labor and civil | 53,143 | 31,919 | (47,477) | - | 37,585 |
| Tax and social security claims | 70,798 | 20,220 | (5,841) | 2,642 | 87,819 |
| | **123,941** | **52,139** | **(53,318)** | **2,642** | **125,404** |

| | Consolidated | | | | | |
|---|---|---|---|---|---|---|
| | | Changes for the year | | | | |
| | **12/31/2020** | **Addition to provision** | **Addition for acquisition of subsidiaries** | **Usage** | **Update / (update reversal)** | **12/31/2021** |
| Labor and civil | 107,356 | 26,205 | 58,982 | (55,138) | 5,062 | 142,467 |
| Tax and social security claims | 94,062 | 3,763 | 18,293 | (6,506) | 3,262 | 112,874 |
| | **201,418** | **29,968** | **77,275** | **(61,644)** | **8,324** | **255,341** |

## Changes in the provisions for contingencies as of December 31, 2020

| | Parent company | | | | |
|---|---|---|---|---|---|
| | **12/31/2019** | **Addition to provision** | **Usage** | **Update / (update reversal)** | **12/31/2020** |
| Labor and civil | 44,566 | 24,212 | (15,630) | (5) | 53,143 |
| Tax and social security claims | 62,592 | 10,592 | (5,317) | 2,931 | 70,798 |
| | **107,158** | **34,804** | **(20,947)** | **2,926** | **123,941** |

| | Consolidated | | | | | |
|---|---|---|---|---|---|---|
| | | Changes for the year | | | | |
| | **12/31/2019** | **Addition to provision** | **Addition for acquisition of subsidiaries** | **Usage** | **Update / (update reversal)** | **12/31/2020** |
| Labor and civil | 50,865 | 25,676 | 52,171 | (17,022) | (4,334) | 107,356 |
| Tax and social security claims | 89,715 | 16,559 | 2,047 | (17,355) | 3,096 | 94,062 |
| | **140,580** | **42,235** | **54,218** | **(34,377)** | **(1,238)** | **201,418** |

# 23 Share-based payments

The Company offers to executives a share-based remuneration plan, and currently two plans are in force, "2018 Plan" for the period from 2016 to 2019, duly approved at the Extraordinary General Meeting held on April 25, 2016 and subsequently amended at the Extraordinary General Meeting held on May 25, 2017 and the "2020 Plan" for the period from 2020 to 2024 approved at the Extraordinary General Meeting on November 30, 2020.

These plans have the following characteristics/objectives:

(a) Its purpose is to establish a share-based remuneration plan, which will allow the Company to align its interests with those of its shareholders and beneficiaries, attract and retain talent, mitigate agency conflicts, increase the generation of sustainable results and reinforce long-term guidance in decision making by the Company's executives and employees.

(b) The Beneficiaries will be chosen and elected by the Board of Directors, at is sole discretion.

(c) It will be managed by the Board of Directors, which may rely on a committee to assist it in this regard, and will have, to the extent permitted by law and by the Company's bylaws, broad powers to take all necessary and appropriate measures for the management of these plans.

(d) Regarding the "2018 Plan", the maximum number of Shares that may be effectively used as a basis for the exercise of premiums granted may not exceed 19,902,320 Shares, representing, on the creation date of the 2018 Plan, approximately 6% of the Company's capital. For the "2020 Plan", the Board of Directors may approve the partial or total settlement of the Options exercised in cash; the Options that may be granted under the "2020 Plan" may not exceed the amount of 28,848,825 (twenty-eight million, eight hundred and forty-eight thousand, eight hundred and twenty-five) of Representative Options, on the date of approval of the "2020 Plan", of approximately 6% (six percent) of the Company's capital.

(e) The strike price is defined based on the fair value of the shares on the grant date and it is monetarily adjusted by an inflation index, while the vesting period (service condition) is 3 years. Premiums must be fully exercised at the end of the grace period.

(f) The determination of settlement amounts considers the unit price of the Company's shares on the stock exchange corresponding to the weighted average of the last 30 (thirty) trading sessions immediately prior to the expiration date of the Grace Period in question ("Quotation Price"). The settlement of options referring to the "2018 Plan" determines the payment of 20% in cash and 80% in shares. The "2020 Plan" determines the settlement of 100% in shares.

(g) The fair value of options is measured using the Black-Scholes method. Expected volatility was based on an assessment of the historical volatility of the share price of similar entities, particularly over the historical period proportional to the expected term.

Under the 2018 Plan, the following grants were approved:

| **Year of approval** | **Approval** | **Number of issued shares** | **Number of remaining options** |
|---|---|---|---|
| 2018 | Board of Directors | 4,663,274 | 4,156,206 |
| 2019 | Board of Directors | 5,215,000 | 3,982,500 |

Under the 2020 Plan, the following grants were approved:

| **Year of approval** | **Approval** | **Number of issued shares** | **Number of remaining options** |
|---|---|---|---|
| 2020 | Board of Directors | 7,181,250 | 6,631,250 |
| 2021 | Board of Directors | 6,413,500 | 6,001,000 |

## Settlement in shares

| | 2018 Plan Grants | | | | 2020 Plan Grants | | |
|---|---|---|---|---|---|---|---|
| | **1st** | **2nd** | **3rd** | **4th** | **1st** | **2nd** | **Total** |
| Life | 2016<br>Settled | 2017<br>Settled | 2018<br>3 years | 2019<br>3 years | 2020<br>3 years | 2021<br>3 years | |
| Share price | 58.00 | 58.00 | 58.00 | 58.00 | 58.00 | 58.00 | - |
| Fair value | 46.27 | 33.12 | 29.90 | 32.88 | 33.34 | 21.37 | - |
| Strike price | 11.73 | 24.88 | 28.10 | 25.10 | 24.66 | 36.63 | - |
| Expected volatility | 0.5 | 0.5 | 0.65 | 0.65 | 0.65 | 0.65 | - |
| Risk-free rate | 5.25% | 5.25% | 6.25% | 6.25% | 6.25% | 6.25% | - |
| **Balance of the Shareholders' equity** | **78,794** | **150,048** | **101,223** | **73,363** | **64,086** | **14,707** | **482,221** |

## Settlement in cash:

| | 2018 Plan Grants | | | | 2020 Plan Grants | | |
|---|---|---|---|---|---|---|---|
| | **1st** | **2nd** | **3rd** | **4th** | **1st** | **2nd** | **Total** |
| Life | 2016<br>Settled | 2017<br>Settled | 2018<br>3 years | 2019<br>3 years | 2020<br>N/A | 2021<br>N/A | |
| Share price | 58.00 | 58.00 | 34.14 | 33.94 | - | - | - |
| Fair value | 46.27 | 33.12 | 30.68 | 6.85 | - | - | - |
| Strike price | 11.73 | 24.88 | 3.46 | 27.09 | - | - | - |
| Expected volatility | 0.5 | 0.5 | 0.39 | 0.39 | - | - | - |
| Risk-free rate | 5.25% | 5.25% | 6.25% | 6.25% | - | - | - |
| **Liability balance** | **-** | **-** | **2,876** | **3,820** | **-** | **-** | **6,696** |
| Withholding Income Tax - IRRF (Payment in shares and cash) | | | | | | | 58,106 |
| **Total** | | | | | | | **64,802** |
| Balance of current liabilities | | | | | | | 25,889 |
| Balance of non-current liabilities | | | | | | | 38,913 |

Provision for share-based payment is as follows:

| | **Plan** | **Taxes and charges** | **Total Consolidated** |
|---|---|---|---|
| **Balance at December 31, 2019** | **150,287** | **61,317** | **211,604** |
| Provision | 29,447 | 7,361 | 36,808 |
| Reversal of provision | (78,122) | (46,549) | (124,671) |
| Payments | (69,803) | (14,176) | (83,979) |
| **Balance at December 31, 2020** | **31,809** | **7,953** | **39,762** |
| Stock option plan expense (i) (- 27) | 568,377 | 126,865 | 695,242 |
| Payments | (111,270) | (76,711) | (187,981) |
| **Balance at December 31, 2021** | **488,916** | **58,107** | **547,023** |
| | - | - | - |
| Current | 2,876 | 23,013 | 25,889 |
| Non-current | 3,819 | 35,094 | 38,913 |
| Shareholders' equity (f) (ii) | 482,221 | - | 482,221 |

(i) Of the amount of R$ 695,242 of expenses with the stock option plan, the amount of R$ 656,299 refers to the parent company and the amount of R$ 38,943 refers to the granting of the share-based payment plan to executives of subsidiaries dedicated to DASA Group.

(ii) Of the amount of R$ 482,221 in stock options, R$ 228,842 has already been settled.

# 24 Shareholders' equity

## Capital

As of December 31, 2021, the Company's capital totals R$ 16,359,199 (R$ 12,326,706 as of December 31, 2020), represented by 560,510,880 common shares, all nominative, book-entry and with no par value, presented in the statement of shareholders' equity in the amount of R$ 16,302,238, net of costs with issuance of shares in the amount of R$ 56,961, net of taxes.

The authorized limit for the capital increase, independently of statutory reform, through the issuance of new shares, provided that the capital will not exceed 1,000,000,000 (one billion) common shares.

As mentioned in - 1, on April 6, 2021, the Company completed its initial public offering of shares - "IPO". As a result of the offer, at the Board of Directors' Meeting, the capital increase was approved, with the issuance of 57,010,786 new common shares, in the total amount of R$ 3,306,626.

At a meeting of the Board of Directors held on May 6, 2021, the ratification of the capital increase was approved with the issuance of 3,937,827 new common shares, due to the exercise of share-based payment options (- 23).

At the Board of Directors' Meeting held on May 10, 2021, the capital increase was approved, with the issuance of 6,200,817 new common shares, in the total amount of R$ 359,647 due to the partial exercise of option for supplementary shares in the scope of the offer.

At the Extraordinary General Meeting held on December 27, 2021, the Company's capital increase was approved, with the issuance of 12,547,692 new common, nominative and book-entry shares with no par value of the Company, in the amount of R$ 366,220. The capital increase was recorded against the Company's investment, due to the exchange of shares with its subsidiary - Hospital Impar, for payment of part of the acquisition price of the São Domingos Group (- 2).

## Equity valuation adjustment

As a result of the transaction carried out with Ímpar as of January 23, 2020, since it is a transaction between an entity under common control and no goodwill should be recognized as an increase in shareholders' equity, after the acquisition, aiming at adapting all corporate procedures carried out in accordance with the provisions of the Brazilian Corporation Law in accounting terms, the amount of R$ 9,243,943 was recorded as an equity valuation adjustment, reducing shareholders' equity and equalizing the effects at cost.

This account also recognizes the effects of shareholders' transactions, translating the presentation currency of subsidiaries abroad and of hyperinflation in the Argentine subsidiary.

## Treasury shares

In the year ended December 31, 2021, there was no change in treasury shares, as shown below:

| Descriptions | Number of shares | Average price per share in Reais | Shares in reais |
|---|---|---|---|
| **Balance at December 31, 2019** | 109,199 | 22.20 | 2,424 |
| Acquisitions | 1 | 10.36 | - |
| Disposals (a) | (17,534) | 65.00 | (1,140) |
| **Balances at December 31, 2021 and December 31, 2020** | **91,666** | **14.01** | **1,284** |

(a) Disposal of treasury shares for the purpose of exercising the call options for the shareholding in Laboratório Santa Luiza, quoted market value at the time of acquisition.

## Loss per share (basic and diluted)

Basic losses per share are calculated by dividing loss attributable to Company's controlling shareholders by the weighted average number of common shares issued during the year, less the common shares purchased by the Company and held as treasury shares.

| | 01/01/2021– 12/31/2021 | 01/01/2020– 12/31/2020 |
|---|---|---|
| Loss attributable to Company's controlling shareholders | (226,569) | (150,802) |
| Weighted average value of common shares issued (in thousands) | 560,511 | 480,814 |
| Weighted average of treasury shares (In thousands) | (92) | (92) |
| Weighted average value of outstanding common shares (in thousands) | 560,419 | 480,722 |
| Basic loss per share - (in R$) | **(0.40429)** | **(0.31370)** |

Diluted losses per share are calculated by adjusting to weighted average quantity of outstanding common shares, assuming conversion of all common shares that would possibly provoke dilution. The Company has only one category of potential common shares that would cause dilution, which are the options in the stock option plan.

| | 01/01/2021– 12/31/2021 | 01/01/2020– 12/31/2020 |
|---|---|---|
| Loss attributable to Company's controlling shareholders | (226,569) | (150,802) |
| Weighted average value of outstanding common shares (in thousands) | 560,419 | 480,722 |
| Adjustment by stock options (in thousands) (a) | 23,473 | 19,902 |
| Weighted average quantity of common shares for diluted losses per share (in thousands) | 583,892 | 500,624 |
| Diluted loss per share - (in R$) | **(0.38803)** | **(0.30123)** |

(a) They result in the issuance of common shares for less than the average market price of common shares during the year and therefore act as a diluter. Details are described in - 23).

### Dividends and interest on own capital

According to the Company's by-laws, net profit for the year is allocated as follows: (i) 5% for formation of legal reserve, until reaches 20% of subscribed capital; and (ii) at least 25% of the remaining balance adjusted, pursuant to article nº 202 of Law nº 6,404/76, for the payment of mandatory dividends.

On December 31, 2020, the Board of Directors approved *ad referendum* of the General Meeting that resolved on interest on own capital in the total gross amount of R$ 137,197 (R$ 0.28539720219 per share) on the financial statements for the year ended December 31, 2020.

On December 31, 2021, the Board of Directors approved *ad referendum* of the General Meeting that resolved on interest on own capital in the total gross amount of R$ 165,044 (R$ 0.30124582748 per share) on the financial statements for the year ended December 31, 2021.

Changes in interest on own capital are as follows:

| **Description** | **Parent company** | **Consolidated** |
|---|---|---|
| **Balance at December 31, 2019** | **151,032** | **165,124** |
| (+) Interest on own capital distributed (a) | 137,197 | 263,701 |
| (-) Payment of interest on own capital | (151,202) | (165,124) |
| (-) Withholding income tax | (20,400) | (39,555) |
| **Balance at December 31, 2020** | **116,627** | **224,146** |
| (+) Interest on own capital distributed (a) | 165,044 | 208,450 |
| (-) Payment of interest on own capital | (116,613) | (207,519) |
| (-) Withholding income tax | (5,817) | (12,731) |
| **Balance at December 31, 2021** | **159,241** | **212,346** |

(a) The minimum mandatory dividends are already included in interest on own capital distributed.

## 25 Net operating revenue

The reconciliation between gross revenue for tax purposes and the net operating revenue presented in the statement of profit or loss for the year is presented below:

| | **Parent company** | | **Consolidated** | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| Operating revenue per sector: | | | | |
| National private | 5,059,736 | 3,879,855 | 6,311,889 | 4,518,368 |
| Foreign privately-held companies | - | - | 453,319 | 205,540 |
| Government | - | - | 279,171 | 227,617 |
| Hospital | - | - | 4,186,945 | 2,690,793 |
| | **5,059,736** | **3,879,855** | **11,231,324** | **7,642,318** |
| Deductions: | | | | |
| Taxes on billing | (303,286) | (228,557) | (654,051) | (445,099) |
| Expected losses from variable consideration (disallowance) | (39,152) | (73,989) | (126,138) | (129,626) |

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | 12/31/2021 | 12/31/2020 | 12/31/2021 | 12/31/2020 |
| Commercial discounts | (30,626) | (26,439) | (32,461) | (28,262) |
| Net operating revenue | **4,686,672** | **3,550,870** | **10,418,674** | **7,039,331** |

DASA Group has a certain degree of concentration in their client portfolios. As of December 31, 2021 and 2020, the consolidated concentration of the five main customers was as follows:

| | 12/31/2021 | 12/31/2020 |
|---|---|---|
| CLIENT A | 13% | 8% |
| CLIENT B | 11% | 7% |
| CLIENT C | 10% | 6% |
| CLIENT D | 6% | 5% |
| CLIENT E | 3% | 4% |

# 26 Cost of services rendered

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | 12/31/2021 | 12/31/2020 | 12/31/2021 | 12/31/2020 |
| Personnel cost | (797,017) | (647,752) | (1,934,957) | (1,493,731) |
| Cost with material | (963,676) | (713,957) | (2,189,873) | (1,496,478) |
| Cost with services and utilities | (939,779) | (753,515) | (2,272,207) | (1,636,591) |
| Depreciation and amortization cost | (355,872) | (344,235) | (637,363) | (548,454) |
| General expenses | (60,485) | (55,339) | (267,451) | (108,369) |
| | **(3,116,829)** | **(2,514,798)** | **(7,301,851)** | **(5,283,623)** |

# 27 General and administrative expenses

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | 12/31/2021 | 12/31/2020 | 12/31/2021 | 12/31/2020 |
| Personnel expenses | (428,230) | (373,921) | (878,535) | (625,651) |
| Provision for profit sharing and bonus | (35,275) | (96,749) | (68,625) | (149,571) |
| Stock option plan (- 23) | (656,299) | 87,863 | (695,242) | 87,863 |
| Services and utilities | (386,980) | (257,428) | (693,143) | (450,135) |
| Advertising and publicity | (64,901) | (30,411) | (85,717) | (48,624) |
| Transportation expenses | (57,095) | (65,096) | (62,607) | (72,933) |
| Depreciation and amortization | (228,880) | (160,664) | (292,398) | (217,132) |
| Taxes and rates | (11,694) | (2,355) | (52,875) | (15,198) |
| Sundry provisions | (28,132) | (11,931) | (69,017) | (21,319) |
| Other | (68,289) | (64,219) | (168,089) | (121,845) |
| | **(1,965,775)** | **(974,911)** | **(3,066,248)** | **(1,634,545)** |

# 28 Other revenues (expenses)

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| **Other income** | | | | |
| Income from the sale of property, plant and equipment | 614 | 16,316 | 4,706 | 29,022 |
| Revenues from rental of properties | 365 | 1,238 | 14,130 | 10,305 |
| Recovery of third party credits (a) | 2,388 | - | 28,262 | 12,883 |
| Operating commissions | 4,200 | - | 4,200 | - |
| Recovery of taxes | - | - | 2,212 | - |
| Other revenues | 2,925 | 1,929 | 4,810 | 2,298 |
| | **10,492** | **19,483** | **58,320** | **54,508** |
| **Other expenses** | | | | |
| Provision for inventory devaluation | (254) | (3,273) | (808) | (4,901) |
| Loss of receivables | - | - | (10,538) | - |
| Social Integration Program - PIS and Contribution to social Security Financing - COFINS on interest on equity | (3,356) | - | (3,356) | - |
| Other expenses | (360) | (1,012) | (5,678) | (4,220) |
| | **(3,970)** | **(4,285)** | **(20,380)** | **(9,121)** |

(a) It refers to revenue from administrative process services provided by Maipú to local companies in Argentina.

# 29 Net financial income

| | Parent company | | Consolidated | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| **Financial expenses** | | | | |
| Interest | (285,316) | (134,057) | (366,847) | (185,517) |
| Exchange rate change and inflation adjustment costs | (18,965) | (85,885) | (57,820) | (203,513) |
| Adjustment to present value – APV | (415) | (3,071) | (415) | (3,071) |
| Interest on right-of-use lease | (81,836) | (85,590) | (156,302) | (129,239) |
| Other | (43,449) | (25,156) | (87,808) | (40,957) |
| | **(429,981)** | **(333,759)** | **(669,192)** | **(562,297)** |
| **Financial revenues** | | | | |
| Interest | 121,790 | 28,309 | 155,596 | 50,406 |
| Derivative financial instruments | - | - | 23,931 | 57,500 |
| Exchange rate change and inflation adjustments in assets | 9,790 | 9,379 | 22,024 | 63,026 |
| Other | 544 | 719 | 4,899 | 5,373 |
| | **132,124** | **38,407** | **206,450** | **176,305** |
| | **(297,857)** | **(295,352)** | **(462,742)** | **(385,992)** |

# 30 Income tax and social contribution

DASA Group forms a provision on a monthly basis for installments of income tax and social contribution on net income, complying with the accrual basis.

The reconciliation between the tax expense as calculated by the combined statutory rates and the income tax and social contribution expense charged to net profit is presented below:

| | **Parent company** | | **Consolidated** | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| **Loss before income tax and social contribution** | (487,244) | (223,015) | (374,227) | (219,442) |
| Combined statutory rate | 34% | 34% | 34% | 34% |
| **Income tax and social contribution:** | | | | |
| Calculated at combined statutory rate | 165,663 | 75,825 | 127,237 | 74,610 |
| Effect of tax rates in foreign jurisdictions (30%) | - | (4,197) | (27,975) | (9,132) |
| **Permanent (additions) exclusions** | | | | |
| Equity in net profit of subsidiaries | 68,008 | 1,367 | - | - |
| Interest on own capital | 41,357 | 31,420 | 48,319 | 31,420 |
| Non-deductible expenses (i) | (43,119) | (4,462) | (43,607) | (4,333) |
| Merger of subsidiaries with less than a year of acquisition | - | (14,210) | - | (14,210) |
| **Other adjustments** | | | | |
| Deemed profit (ii) | - | - | 8,921 | 4,144 |
| Formation of tax loss and negative basis (iii) | 28,703 | - | 28,703 | - |
| Other | 63 | (13,530) | 15,692 | (10,796) |
| | 260,675 | 72,213 | 157,290 | 71,703 |
| Current income tax and social contribution | - | (32,554) | (144,864) | (82,644) |
| Deferred taxes | 260,675 | 104,767 | 302,154 | 154,347 |
| **Total** | 260,675 | 72,213 | 157,290 | 71,703 |
| Effective rate (iv) | (53%) | (32%) | (42%) | (33%) |

(i) These are expenses that cannot be deducted for tax purposes, under the terms of the applicable tax legislation, such as: expenses with fines, donations, gifts and certain provisions;

(ii) Brazilian tax legislation provides for an alternative method of taxation for companies that earned gross revenue of up to R$ 78 million in their previous fiscal year, called deemed income. Some of the Company's subsidiaries have adopted this alternative taxation, according to which the IRPJ and CSLL were calculated on a basis equal to 8% of revenues from operations, and not calculated based on the actual taxable income of these subsidiaries. The deemed income adjustment represents the difference between taxation under this alternative method and what would have been due based on the official tax rate applied to the taxable income of these subsidiaries;

(iii) This refers to the constitution of deferred income tax and social contribution on a share-based payment plan from the previous year.

(iv) The effective tax rate reconciliation is based on its domestic rates, with a reconciliation item against tax rates applied by companies in another jurisdiction. Effective tax rate reconciliation is based on an applicable tax rate that provides the most meaningful information to users.

The combined tax rate used in the calculations of December 31, 2021 and 2020 is 34%, payable by legal entities in Brazil on taxable income, as provided by the tax legislation of the country.

## Deferred taxes on tax losses and temporary provisions

The deferred income tax and social contribution are recognized to reflect future tax effects attributable to temporary differences between the tax bases of assets and liabilities and their book values.

According to CPC 32 / IAS 12, DASA Group, based on the expectation of generating future taxable income, through technical study approved by management, recognizes the tax credits and debits on deductible temporary differences and tax losses and contribution of accumulated carryforwards social, that no statutory limitation period and whose offset is limited to 30% of annual taxable income. The book value of the deferred tax asset and liabilities is reviewed monthly and the projections are reviewed annually.

Breakdown of balances of deferred income tax and social contribution, assets and liabilities is as follows:

| | Statement of financial position - Parent company | | Profit or loss Parent company | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| Tax loss and negative basis | 784,474 | 544,147 | 240,327 | 53,705 |
| Provision for expected losses due to bad debt | 49,242 | 35,720 | 13,522 | 12,573 |
| Provision for disallowance | 9,875 | 15,308 | (5,433) | 2,830 |
| Provision for specialized medical services | (13,617) | (765) | (12,852) | (6,863) |
| Provision for profit sharing/bonus | 5,964 | 31,807 | (25,843) | 21,287 |
| Provision for stock option plan | 94,941 | 13,370 | 81,571 | (58,576) |
| Depreciation IFRS 16 - Leases | 23,125 | 20,605 | 2,520 | 11,477 |
| Sundry provisions | 14,665 | 9,841 | 4,824 | 1,309 |
| Provision for obsolescence | 3,665 | 2,687 | 978 | (853) |
| Adjustment to present value – APV | 4,635 | 5,589 | (954) | (37) |
| Provision for contingencies | 27,096 | 32,326 | (5,230) | 4,920 |
| Review of useful lives of property, plant and equipment | 23,265 | 25,983 | (2,718) | 1,598 |
| Other | 922 | 808 | 114 | 126 |
| Deferred in downstream merger of subsidiary | 314,184 | 301,202 | 12,982 | 75,549 |
| Surplus in the acquisition of subsidiary | (7,698) | - | (7,698) | - |
| Amortization of goodwill | (672,756) | (655,545) | (17,211) | (17,513) |
| Intangible assets identified in acquisitions of equity interests | (55,924) | (59,345) | 3,421 | 3,421 |
| Other | (3,937) | (3,939) | 2 | (177) |
| **Deferred income tax and social contribution** | **602,121** | **319,799** | **282,322** | **104,776** |
| **Changes in equity not affecting profit or loss** | | | | |
| Capital gains effect on acquisition of subsidiaries | - | - | 7,698 | - |
| Expenses from expenditures with issuance of shares | - | - | (29,343) | - |
| Other | - | - | (2) | (9) |
| | **-** | **-** | **260,675** | **104,767** |
| **Reflected in the statement of financial position as follows:** | | | | |
| Deferred tax assets | 602,121 | - | - | - |
| Deferred tax liabilities | - | - | - | - |
| | **602,121** | **-** | **-** | **-** |
| **Reconciliation of deferred tax assets (liabilities)** | | | | |
| Opening balance - December 31, 2020 | 319,799 | - | - | - |
| Tax revenue recognized in profit or loss | 260,675 | - | - | - |
| Capital gains effect on acquisition of subsidiaries | (7,698) | - | - | - |
| Expenses from expenditures with issuance of shares | 29,343 | - | - | - |
| Other | 3 | - | - | - |
| **Balance at December 31, 2021** | **602,121** | **-** | **-** | **-** |

| | Statement of financial position - Consolidated | | Consolidated profit or loss | |
|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| Tax loss and negative basis | 933,533 | 612,049 | 321,484 | 121,489 |
| Provision for expected losses due to bad debt | 29,030 | 42,672 | (13,642) | 12,668 |
| Provision for disallowance | 42,352 | 20,081 | 22,271 | 6,369 |
| Provision for specialized medical services | (13,617) | (765) | (12,852) | (6,863) |
| Provision for profit sharing/bonus | 6,397 | 33,157 | (26,760) | 21,287 |
| Provision for stock option plan | 108,181 | 13,370 | 94,811 | (58,576) |
| Depreciation IFRS 16 - Leases | 23,776 | 20,778 | 2,998 | 11,477 |
| Sundry provisions | 14,974 | 8,957 | 6,017 | 1,663 |
| Provision for obsolescence | 3,665 | 2,687 | 978 | (853) |
| Adjustment to present value – APV | 4,635 | 5,589 | (954) | (37) |
| Provision for contingencies | 27,153 | 32,432 | (5,279) | 4,982 |
| Review of useful lives of property, plant and equipment | 23,265 | 25,983 | (2,718) | 1,598 |
| Other | 61,928 | 43,122 | 18,806 | 48,668 |
| Deferred in downstream merger of subsidiary | 314,184 | 301,202 | 12,982 | 75,549 |
| Surplus in the acquisition of subsidiary | (7,698) | - | (7,698) | - |
| Amortization of goodwill | (673,387) | (656,175) | (17,212) | (17,512) |
| Intangible assets identified on acquisitions that are not deductible for tax purposes | (57,046) | (60,551) | 3,505 | 3,504 |
| Other | (3,174) | (4,300) | 1,126 | (539) |
| **Deferred income tax and social contribution** | **838,151** | **440,288** | **397,863** | **224,874** |
| **Changes in equity not affecting profit or loss** | | | | |
| Surplus in the acquisition of subsidiary | - | - | 7,698 | - |
| Acquisitions of subsidiaries | - | - | (86,009) | (66,590) |
| Expenses from expenditures with issuance of shares | - | - | (29,343) | - |
| Other | - | - | 11,945 | (3,937) |
| | - | - | **302,154** | **154,347** |
| **Reflected in the statement of financial position as follows:** | | | | |
| Deferred tax assets | 859,478 | - | - | - |
| Deferred tax liabilities | (21,327) | - | - | - |
| | **838,151** | - | - | - |
| **Reconciliation of deferred tax assets (liabilities)** | | | | |
| Opening balance - December 31, 2020 | 440,288 | - | - | - |
| Tax revenue recognized in profit or loss | 302,154 | - | - | - |
| Surplus in the acquisition of subsidiaries | (7,698) | - | - | - |
| Acquisitions of subsidiaries | 86,009 | - | - | - |
| Expenses from expenditures with issuance of shares | 29,343 | - | - | - |
| Other | (11,945) | - | - | - |
| **Balance at December 31, 2021** | **838,151** | - | - | - |

DASA Group's management considers that the balances of deferred income tax and social contribution assets arising from temporary differences will be realized in proportion to the contingencies and realization of the events that gave rise to the provision for losses.
DASA Group did not identify non-recovery indicators for deferred taxes during the year ended December 31, 2021.

Regarding the tax assets resulting from tax losses and negative basis, Management estimates to recover the tax credits, as shown in the table below:

| | **Parent company** | **Consolidated** |
|---|---|---|
| 2022 | 11,602 | 13,549 |
| 2023 | 20,788 | 24,276 |
| 2024 | 37,644 | 43,961 |
| 2025–2036 | 714,440 | 851,747 |
| | **784,474** | **933,533** |

# 31 Information per business segment

For the purposes of Management's analysis and decision-making, as of December 31, 2019, DASA Group's operations were managed only by the outpatient care and care coordination services segments. With the acquisition of Ímpar Serviços Hospitalares S.A. in January 2020 and the growth of international operations, DASA Group now has the following 3 strategic divisions, which are its reportable segments: (i) outpatient care services and care coordination, (ii) hospitals and oncology - through Ímpar Serviços Hospitalares S.A. and (iii) International operations - auxiliary support services located in Argentina, Uruguay, Chile and Colombia. The operating segment is reported consistently with management reports used by the main operating decision maker (President) to assess segment performance and resource allocation. The President of DASA Group analyzes the internal management reports of each division at least quarterly. The following summary describes the operations of each reportable segment:

| **Segments** | **Operations** | **Geographic region** |
|---|---|---|
| Outpatient care services and care coordination | Diagnosis and health management | Brazil |
| Hospital and Oncology | Medical and hospital services | Brazil |
| Foreign operations | Diagnosis | South America (Argentina, Uruguay, Chile and Colombia) |

The segment performance was assessed based on net operating revenues, net profit or loss and employed capital (total assets less current and non-current liabilities) in each segment.

Information for the year ended December 31, 2021 and 2020 is as follows:

| | Outpatient care services and care coordination | | Hospital and Oncology | | Foreign operations | | Total | |
|---|---|---|---|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| **Net revenue:** | | | | | | | | |
| Revenue per segment | 5,893,243 | 4,212,057 | 3,874,828 | 2,470,256 | 447,825 | 202,567 | 10,215,896 | 6,884,880 |
| Intra-segment revenue | 202,778 | 154,451 | - | - | - | - | 202,778 | 154,451 |
| | **6,096,021** | **4,366,508** | **3,874,828** | **2,470,256** | **447,825** | **202,567** | **10,418,674** | **7,039,331** |
| **Cost:** | | | | | | | | |
| Reportable segment cost | (3,858,109) | (2,941,737) | (2,964,324) | (2,031,402) | (276,640) | (156,033) | (7,099,073) | (5,129,172) |
| Intra-segment cost | (129,700) | (82,132) | (73,078) | (72,319) | - | - | (202,778) | (154,451) |
| | **(3,987,809)** | **(3,023,869)** | **(3,037,402)** | **(2,103,721)** | **(276,640)** | **(156,033)** | **(7,301,851)** | **(5,283,623)** |
| **Results by reportable segments:** | | | | | | | | |
| Operating income (expenses), net | (2,038,487) | (1,114,887) | (713,181) | (433,298) | (276,640) | (40,973) | (3,028,308) | (1,589,158) |
| Financial revenues | 128,110 | 58,246 | 70,482 | 117,309 | 7,858 | 750 | 206,450 | 176,305 |
| Financial expenses | (446,144) | (350,698) | (196,528) | (197,100) | (26,520) | (14,499) | (669,192) | (562,297) |
| Income tax and social contribution | 216,040 | 46,470 | (32,124) | 30,856 | (26,626) | (5,623) | 157,290 | 71,703 |
| Non-controlling shareholders | (2,408) | (3,063) | (7,224) | - | - | - | (9,632) | (3,063) |
| **Loss per segment** | **(34,677)** | **(21,293)** | **(41,149)** | **(115,698)** | **(150,743)** | **(13,811)** | **(226,569)** | **(150,802)** |
| Assets of reportable segments | 12,859,600 | 9,860,195 | 10,016,524 | 3,292,694 | 373,780 | 190,607 | 23,249,904 | 13,343,496 |
| Investment - MEP | 200,023 | (4,022) | - | - | - | - | 200,023 | (4,022) |
| Liabilities of reportable segments | 9,655,577 | 7,436,651 | 5,852,328 | 2,281,606 | 193,481 | 88,711 | 15,701,386 | 9,806,968 |

# 32 Financial instruments

## Accounting classification and fair values

The following table shows the book and fair values of financial assets and liabilities, including their fair value hierarchy. It does not include information on the fair value of financial assets and liabilities not measured at fair value if the book value is a reasonable approximation of fair value.

## Parent company's assets and liabilities

| Parent company | | | | | |
|---|---|---|---|---|---|
| | | | | Book balance | |
| **Financial liabilities measured at fair value** | **-** | **Classification per category** | **Hierarchy** | **12/31/2021** | **12/31/2020** |
| Interest earning bank deposits | 7 | Fair value through profit or loss | Level 2 | 148,205 | 111,985 |
| Collateralized by means of interest earning bank deposits | 21 | Fair value through profit or loss | Level 2 | 29,353 | 38,386 |
| Call option obtained from non-controlling shareholders | 21 | Fair value through profit or loss | Level 3 | 1,969 | 7,469 |
| Interest earning bank deposits | 8 | Fair value through profit or loss | Level 2 | 2,434,350 | 740,916 |
| | | | | **2,613,877** | **898,756** |
| **Financial assets not measured at fair value** | | | | | |
| Cash and cash equivalents | 7 | Financial assets at amortized cost | - | 45,557 | 31,060 |
| Trade accounts receivable | 9 | Financial assets at amortized cost | - | 714,608 | 904,609 |
| | | | | **760,165** | **935,669** |
| | | | | **3,374,042** | **1,834,425** |
| **Financial liabilities not measured at fair value** | | | | | |
| Loans and financing | 17 | Financial liability at amortized cost | - | 668,788 | 675,391 |
| Debentures | 19 | Financial liability at amortized cost | - | 5,458,781 | 3,537,209 |
| Suppliers | 16 | Financial liability at amortized cost | - | 612,068 | 549,654 |
| Accounts payable from acquisition of subsidiaries | 21 | Financial liability at amortized cost | - | 396,685 | 524,856 |
| Lease liabilities | 18 | Financial liability at amortized cost | - | 1,014,936 | 857,483 |
| | | | | **8,151,258** | **6,144,593** |
| **Financial liabilities measured at fair value** | | | | | |
| Put option granted to non-controlling shareholders | 21 | Fair value through profit or loss | Level 3 | 51,226 | 39,459 |
| Contingent consideration (a) | 21 | Fair value through profit or loss | Level 3 | 65,322 | 67,267 |
| | | | | **116,548** | **106,726** |
| | | | | **8,336,351** | **6,223,814** |

**Consolidated**

| | | | | Book balance | |
|---|---|---|---|---|---|
| **Financial liabilities measured at fair value** | **-** | **Classification per category** | **Hierarchy** | **12/31/2021** | **12/31/2020** |
| Interest earning bank deposits | 7 | Fair value through profit or loss | Level 2 | 832,689 | 673,268 |
| Collateralized by means of interest earning bank deposits | 21 | Fair value through profit or loss | Level 2 | 29,477 | 38,505 |
| Call option obtained from non-controlling shareholders | 21 | Fair value through profit or loss | Level 3 | 14,482 | 7,469 |
| Derivative financial instruments | 31 | Fair value through profit or loss | Level 2 | 64,303 | 65,404 |
| Interest earning bank deposits | 8 | Fair value through profit or loss | Level 2 | 2,471,032 | 760,816 |
| | | | | **3,411,983** | **1,545,462** |
| **Financial assets not measured at fair value** | | | | | |
| Cash and cash equivalents | 7 | Financial assets at amortized cost | - | 310,337 | 80,339 |
| Trade accounts receivable | 9 | Financial assets at amortized cost | - | 2,312,277 | 1,745,886 |
| | | | | **2,622,614** | **1,826,225** |
| | | | | **6,034,597** | **3,371,687** |
| **Financial liabilities not measured at fair value** | | | | | |
| Loans and financing | 17 | Financial liability at amortized cost | - | 1,585,286 | 1,201,815 |
| Debentures | 19 | Financial liability at amortized cost | - | 6,061,561 | 4,137,008 |
| Suppliers | 16 | Financial liability at amortized cost | - | 1,243,453 | 908,636 |
| Accounts payable from acquisition of subsidiaries | 21 | Financial liability at amortized cost | - | 1,630,278 | 536,803 |
| Lease liabilities | 18 | Financial liability at amortized cost | - | 2,119,037 | 1,485,513 |
| | | | | **12,639,615** | **8,269,775** |
| **Financial liabilities measured at fair value** | | | | | |
| Put option granted to non-controlling shareholders | 21 | Fair value through profit or loss | Level 3 | 121,318 | 39,459 |
| Contingent consideration (a) | 21 | Fair value through profit or loss | Level 3 | 424,466 | 67,267 |
| | | | | **545,784** | **106,726** |
| | | | | **13,250,202** | **8,416,263** |

(b) This amount is linked to the fulfillment of certain performance conditions related to Diagnóstico Maipú por Imágenes S.A, Laboratório Nobel S.A, and Grupo Case (i) Maípu: 2021 revenue of Diagnóstico Maipú por Imágenes S.A., which, through the results and projections based on discounted cash flows, DASA Group believes that will be achieved, therefore, it recorded the fair value based on the maximum value, if the value did not meet these conditions, the amount would be less than US$ 10 million, equivalent to R$ 50,019 (R$ 51,967 as of December 31, 2020), resulting in US$ 27,275 instead of US$ 37,275. This amount will be paid in 2022. (ii) Laboratório Nobel: On the acquisition date, the fair value of the contingent consideration was estimated at R$ 15,300 (December 31, 2020, and December 31, 2021) based on the maximum amount. As of December 31, 2020, the main performance indicators of Laboratório Nobel S.A. evidenced the fulfillment of the stipulated goal; Grupo Case: Achievement of 160,000 lives by companies as of December 31, 2023, and achievement of EBITDA change provided for in the Corporate Business Plan, calculated on an accumulated basis, as of December 31, 2021, the main performance indicators evidenced compliance with the stipulated target.

Different levels are defined as follows:

- **Level 1 -** Prices quoted (not adjusted) in active markets for identical assets and liabilities.
- **Level 2 -** Inputs, except for quoted prices, included in Level 1 which are observable for assets or liabilities, directly (prices) or indirectly (derived from prices).

- **Level 3 -** Assumptions, for assets or liabilities, which are not based on observable market data (non-observable data).

DASA Group, in general, is exposed to the following risks arising from its operations and that may affect, to a greater or lesser degree, their strategic and financial objectives:

- Market risk
- Liquidity risk
- Credit risk
- Operating risk

The DASA Group manages the risks to which it is exposed through the definition of conservative strategies,
aiming at liquidity, profitability and security, in accordance with objective criteria for risk diversification.

Additionally, there were no transfers between the measurement levels in fair value hierarchy in the year ended December 31, 2021 for these assets and liabilities.

## Measurement of fair value

Valuation techniques and significant non-observable inputs:

The tables below present the valuation techniques used to measure the fair values of levels 2 and 3 for financial instruments measured at fair value in the statement of financial position, as well as the significant unobservable inputs used. The evaluation processes are:

| **Type** | **Valuation techniques** | **Significant unobservable inputs** | **Relationship between significant unobservable inputs and fair value measurement** |
|---|---|---|---|
| Financial investment and interest earning bank deposits | Bank deposits remunerated in CDBs [Bank Deposit Certificates] by changes in the CDI rate, with effective remuneration ranging from 89.76% to 102.39%. They are not sold and are settled directly with the counterparty so that the book value presented is a reasonable approximation of the fair value | Not applicable | Not applicable |
| Put option granted to non-controlling shareholders and expected gain in relation to the acquisition (included in "accounts payable from the acquisition of subsidiaries") | Discounted cash flows: the valuation model considers the present value of the expected future payments, discounted at a discount rate adjusted by the risk. | Risk-adjusted discount | The estimated fair values would increase (decrease) in case the risk-adjusted discount rate is lower (higher) |
| Derivative financial instrument (foreign exchange swap) | The most frequently applied techniques include a pricing model with present value calculations on forward exchange rates quoted in the market. | Not applicable | Not applicable |

## Financial instrument not measured at fair value

| Type | Valuation techniques | Significant unobservable inputs |
|---|---|---|
| Amortized cost | Discounted cash flows: The valuation model considers the present value of the payment expected, discounted by a risk-adjusted discount rate. | Discount rate |

The fair values of cash and bank balances, trade accounts receivable, suppliers, and accounts payable are equivalent to their book values, mainly due to the short-term maturity of these instruments.

## Risk management structure

In line with the current regulations and DASA Group's corporate policies, the system is based on the integrated management of each of the business processes and on the adaptation of the risk level to the strategic objectives established. The risk management process has a corporate governance framework that covers from senior management and institutional committees, which are responsible, among other duties, for supervising the effectiveness and integrity of the internal control and risk management processes, to the various areas of DASA Group in the identification, handling and monitoring of these risks.

DASA Group has an internal control environment designed to support the nature, risk and complexity of its operations, based on formalized policies and procedures and disclosed to the entire organization, as well as dedicated areas and specific risk monitoring tools.

The management of all risks inherent to activities in an integrated manner is addressed within a process supported by the Internal Controls and Compliance frameworks (regarding regulations, internal policies and policies) that provide for the continuous improvement of risk management models and minimize the existence of gaps that could compromise the correct risk identification and measurement. Based on the identification, assessment and monitoring of the main risks, specific action plans are prepared, ensuring that improvements are implemented.

Historically, the financial instruments contracted by the DASA Group presented adequate results to mitigate risks. Moreover, DASA Group does not carry out transactions involving exotic or speculative derivatives.

## Market risks

These are risks related to assets and liabilities which cash flows or present values are exposed to:

## Currency risk

(a) DASA Group has accounts payable from the acquisition of subsidiaries in Dollar and considered the scenarios below for the volatility of Real/US Dollar exchange rate.

- **Scenario 1**: (25% valuation of the Real) R$/US$ foreign exchange rate of 4.19
- **Scenario 2**: (50% valuation of the Real) R$/US$ foreign exchange rate of 2.79
- **Scenario 3**: (25% devaluation of the Real) R$/US$ foreign exchange rate of 6.98
- **Scenario 4**: (50% depreciation of the Real) R$/US$ foreign exchange rate of 8.37.

| | | | **Revenue (expense) on exchange rate (in reais)** | | | |
|---|---|---|---|---|---|---|
| | **Balance (R$)** | **Reference value, USD** | **Scenario 1** | **Scenario 2** | **Scenario 3** | **Scenario 4** |
| **USD rate** | | 5.5805 | 4.19 | 2.79 | 6.98 | 8.37 |
| Accounts payable from acquisition of subsidiaries | 213,219 | 39,199 | 159,932 | 106,621 | 266,553 | 319,864 |
| Loans in USD | 158,531 | 29,145 | 118,912 | 79,274 | 198,186 | 237,823 |
| Financial income (loss) - revenue (expense) | | | **92,906** | **185,855** | **(92,989)** | **(185,937)** |

(b) Due to the acquisition of subsidiary Ímpar, as shown in - 2, DASA Group assumed loans contracted for in foreign currency (US Dollar) that have derivative financial instruments contracted for protection against changes in interest rate in the acquisition of services in foreign currency.

Derivative instruments as of December 31, 2021:

| **Swap** | **Current** | **Non-current** | **Total** |
|---|---|---|---|
| Assets | 22,626 | 41,677 | 64,303 |
| Liabilities | (12,364) | (7,934) | (20,298) |
| | 10,262 | 33,743 | 44,005 |

Derivative instruments as of December 31, 2020:

| Swap | Current | Non-current | Total |
|---|---|---|---|
| Assets | 26,201 | 39,203 | 62,705 |
| Liabilities | (1,856) | (5,603) | (6,415) |
| | 24,377 | 31,913 | 56,290 |

As of December 31, 2021, DASA Group had derivative contracts to hedge the exchange rate fluctuation for all outstanding foreign currency loans. Summaries of the contracts in force are as follows:

| | | | Percentage | | Validity | | |
|---|---|---|---|---|---|---|---|
| **Interest rate swap (fixed CDI rate)** | **Nominal value (US$)** | **Balance of loans in foreign currency as of 12/31/2021** | **Original indexes** | **Swap** | **Beginning** | **Maturity** | **Unrealized gains (losses) from derivative instruments on 12/31/2021** |
| Santander | 27,027 | 248,086 | 4.45% | CDI + 1.35% p.a. | 12/12/2019 | 04/19/2024 | 41,762 |

## Interest market risk

(a) Risk of interest rate fluctuation that will incur an increase in expenses or decrease in financial revenue. Fixed interest held to maturity allows cash flow certainty. Floating interest rates bring volatility to future interest payments. The main tool for controlling interest rate risk will be the daily treasury position, which will be based on reports provided by B3 to control interest rates involved in our operations.

The main market risks for DASA Group are the possible fluctuations in interest and exchange rates. As a result, DASA Group seeks protection against liquidity risks, through financial instruments such as interest earning bank deposits, borrowings for working capital, fundraising through the issuance of debentures, all of them under normal market conditions.

Every financial transaction is submitted to the DASA Group’s Executive Committee and subsequently for validation by the Board of Directors and/or its auxiliary advisory bodies. In the case of currency exposure and interest exposure, the guidelines are defined by the Board of Directors and operationalized by the treasury department, as it depends on the variables that compose the economic scenario. The Treasury department provides the Executive Committee with an updated position of its exposure of DASA Group to market risks on a monthly basis, through the presentation of reports, documents and contracts, which allows verification of compliance with the Policy.

Furthermore, for the market risks to which DASA Group is exposed, the preparation of a monthly sensitivity analysis (stress test) by the Treasury department is mandatory, at rates of 25% and 50% of change from the original rates, aiming to assess the elasticity of these positions when subjected to large changes in the rates involved in these transactions and their impact on DASA Group's results and cash positions.

## Liquidity risk

Liquidity risk is the risk of occurring an unpredictable event or error in calculation of liquidity need which will affect DASA Group's investment decisions or on daily basis.

DASA Group manages liquidity risk by maintaining proper reserves, bank credit facilities and credit facilities to raise loans as it considers adequate, through continuous monitoring of foreseen and actual cash flows and through combination of financial assets and liabilities' maturity profiles by allocating:

(a) Short-term cash management - Management of liquid assets and credit facilities to cover immediate needs. Periodicity: Daily. Term: D+1 (in business days);

(b) Long-term cash management - Ongoing process to guarantee long-term funds, by analyzing the cash budget on a monthly basis, updating the budgeted assumptions according to the needs of the business, and comparing the actual versus budgeted amounts. Periodicity: Monthly. Term: $5^{th}$ working day of the month following the base date of the report;

(c) Maintenance of a minimum cash - Refers to the cash balance that DASA Group covers in a very short period of time to meet its urgent needs. Furthermore, the Company adopts as a criterion that the cash must have sufficient funds to cover the five worst daily flows of a particular month, without considering receipts; and

(d) Exposure limits and risk mitigators - The treasury area maintains, in short-term lines, between cash investments with immediate liquidity and working capital facilities, a volume of funds sufficient to guarantee at least the amount equal to the five largest consecutive days of cash disbursements in the last 12 months.

For medium-term and long-term facilities, the treasury department credit facilities compatible with DASA Group's strategic planning, always with the goal of guaranteeing the availability of funds to fulfill the expected cash flow.

The table below shows the maturity of consolidated non-current financial liabilities contracted as of December 31, 2021:

| Operation | 2023 | 2024–2025 | >2026 | Total |
|---|---|---|---|---|
| Derivative financial instruments | 5,352 | 2,582 | - | 7,934 |
| Suppliers | 12,620 | - | - | 12,620 |
| Bank loans and financing | 272,679 | 210,122 | 11,833 | 494,634 |
| Debentures | 917,849 | 1,619,768 | 2,519,361 | 5,056,978 |
| Taxes in installments | 75,820 | 127,646 | 65,081 | 268,547 |
| Leases | 259,268 | 456,296 | 704,209 | 1,419,773 |
| Put options granted to non-controlling shareholders | 77,976 | 12,838 | - | 90,814 |
| Share-based payment | 35,605 | 3,309 | - | 38,914 |
| Accounts payable from acquisition of subsidiaries | 728,989 | 207,542 | 40,582 | 977,113 |
| | **2,386,158** | **2,640,103** | **3,341,066** | **8,367,326** |

DASA Group recognized a loss of R$ 226,569 as of December 31, 2021, and, on that date, its net working capital was positive in the parent company at R$ 211,180 (positive at R$ 323,206 as of December 31, 2020), and negative in the consolidated at R$ 82,134 (positive at R$ 1,197,759 as of December 31, 2020). Management believes that this position in the consolidated occurs in a scenario where the Company and its subsidiaries are going through a cycle of growth and expansion through the acquisition of subsidiaries (- 2), which will contribute to the increase in their operating cash flow.

Therefore, Management anticipates that any current liability obligations arising substantially from suppliers, loans and financing, debentures, social and labor obligations, accounts payable from the acquisition of subsidiaries, and lease liabilities will be met with operating cash flows, receipt of dividends from its subsidiaries or alternative fundraising, such as issuing bonds in a private offering or alternative fundraising.

## Credit risk

Refers to the risk of loss resulting from the counterparty's inability to comply with its contractual payment obligations to DASA Group, as assumed in the contract. The main mitigator of this risk will be through the credit analysis process, and the measurement of this risk over time will be mainly based on the calculation of expected losses for doubtful accounts and expected losses on variable consideration (disallowance).

DASA Group is governed by the credit policy determined by its management, and is aimed at minimizing possible problems resulting from default by disallowances of health care plans. DASA Group also has a provision for expected loss for doubtful accounts due to default, disallowances and checks returned at the parent company, which represent 8.89% as of December 31, 2021 (7.57% as of December 31, 2020) of the balance of outstanding accounts receivable and 11% in the consolidated (7.80% as of December 31, 2020) of the balance of outstanding accounts receivable to cover the credit risk.

As of December 31, 2021, maximum exposure in consolidated was R$ 2,636,647 (R$ 2,459,044 as of December 31, 2020) referring to cash and cash equivalents and accounts receivable.

## Operating risk

Operating risk is the risk of direct or indirect losses arising from different causes related to DASA Group's processes, personnel, technology and infrastructure and external factors, except credit, market and liquidity risks, as those arising from legal and regulatory requirements and from generally accepted standards. Operating risks are associated to all operations of DASA Group.

DASA Group's goal is to manage the operational risk to avoid the occurrence of financial losses and damage to its reputation, and to pursue cost effectiveness and avoid control procedures that restrict initiative and creativeness.

Top Management of each business unit is responsible for developing and implementing controls to address operating risks. The responsibility is supported by the development of general standards of DASA Group regarding operating risk management.

## The amounts shown are net of transaction costs.

DASA Group may change its capital structure, according to economic and financial, strategic or operational conditions, with a view to improving debt management. At the same time, DASA Group seeks to improve its return on invested capital (ROIC) through the implementation of working capital management and an efficient investment program.

## Sensitivity analysis for financial assets and liabilities

Main risks related to DASA Group’s operations are linked to CDI (Interbank Deposit Certificate) change for promissory -s, debentures and interest earning bank deposits and those linked to Dollar change for bank loans, financing and interest earning bank deposits.

CDI investments are recorded at market value according to quotations disclosed by respective financial institutions, and other investments mostly refer to bank deposit certificates and purchase and sale commitments; accordingly, these securities’ recorded values do not differ from market value.

In order to check the sensitivity of the indexer of consolidated interest earning bank deposits to which DASA Group was exposed to at December 31, 2021, scenarios based on projection and were defined and changes of 25% and 50% were calculated.

For each scenario the financial expense / gross (financial revenue) was calculated, not taking into account the taxes levied and the flow of maturities for each contract scheduled for 2021. As it does not generate financial results, investments that guarantee the payments of contingencies that may be required from acquired companies (R$ 29,477 as of December 31, 2021) were not considered in this projection.

| Operation | Balance at 12/31/2021 | Risk (a) | Scenario I (Probable) | Scenario II | Scenario III |
|---|---|---|---|---|---|
| Interest earning bank deposit | 3,303,721 | CDI | 388,187 | 291,140 | 194,094 |
| | | | 11.75% | 8.81% | 5.88% |

In order to check the sensitivity of the indexer of consolidated debts to which DASA Group was exposed to at December 31, 2021, three scenarios based on projection and were defined and changes of 25% and 50% were calculated.

For each scenario the gross financial expense was calculated, not taking into account the taxes levied and the flow of maturities for each contract scheduled for 2021. The base date used for financings was December 31, 2021, projecting indices for one year and verifying their sensitivity in each scenario.

| Operation | Balance at 12/31/2021 | Risk (a) | Scenario I (Probable) | Scenario II | Scenario III |
|---|---|---|---|---|---|
| Debentures | 6,080,722 | CDI | 714,485 | 893,106 | 1,071,727 |
| Promissory -s | 647,619 | CDI | 76,095 | 95,119 | 114,143 |
| | | | 11.75% | 14.69% | 17.63% |

# 33 Related parties

The Company maintained operations with related parties, as follows:

## Operations subsidiaries to the provision of services carried out between the Company and its subsidiaries

| | Current assets - Clients | | Current liabilities – Other accounts payable | | Revenue from services | | Cost of services rendered | |
|---|---|---|---|---|---|---|---|---|
| | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** | **12/31/2021** | **12/31/2020** |
| CientificaLab | 3,871 | 5,635 | - | - | 9,232 | 7,854 | - | - |
| Previlab | 758 | 1,463 | - | - | 11,279 | 9,519 | - | - |
| Gaspar | 299 | 569 | - | - | 5,911 | 4,423 | - | - |
| Salomão Zoppi | 12,715 | 22,926 | - | - | 18,954 | 22,843 | - | - |
| Santa Luzia | 1,075 | 2,325 | - | - | 8,110 | 6,210 | - | - |
| Deliberato | - | - | - | - | 2,898 | 3,372 | - | - |
| Padrão Ribeirão | 304 | 304 | - | - | - | 386 | - | - |
| Valeclin | - | 1 | - | - | 98 | 825 | - | - |
| Insitus | - | 17 | - | - | 48 | 216 | - | - |
| Ruggeri | 147 | 247 | - | - | 1,514 | 1,923 | - | - |
| Itulab | - | 406 | - | - | 380 | 1,917 | - | - |
| Dresch | - | 10 | - | - | - | - | - | - |
| CPCLIN | 11 | 9 | - | - | 63 | 42 | - | - |
| CRMI Petrópolis | - | - | - | - | - | 78 | - | 744 |
| DASA RE (i) | - | - | - | 69 | - | - | 765 | 1,036 |
| Ímpar | 9,974 | 16,687 | - | - | 73,078 | 72,319 | - | - |
| HSP | - | 3,384 | - | - | 61 | 20,608 | - | - |
| Genia - MOL | 130 | 130 | - | - | - | 167 | - | - |
| Bioclinico | 337 | 351 | - | - | 2,218 | 1,005 | - | - |
| São Marcos | 662 | - | - | - | 4,152 | | - | - |
| Hemat | 106 | - | - | - | 443 | | - | - |
| Exame | 1,060 | - | - | - | 2,621 | | - | - |
| | **31,449** | **54,464** | **-** | **69** | **141,060** | **153,707** | **765** | **1,780** |

(i) Amounts corresponding to property rental transactions.

Related party transactions, as presented above, are carried out at cost and are eliminated in the consolidated financial statements.

## Related parties - Loan agreements between the Company and its subsidiaries as of December 31, 2021 and December 31, 2020

| | Remuneration fee | Maturity | 12/31/2021 | 12/31/2020 |
|---|---|---|---|---|
| **Loan agreement** | | | | |
| Padrão Ribeirão | 120% CDI | 08/20/2022 | 2,656 | 1,543 |
| DB Genética | 120% CDI | 12/31/2023 | 16,830 | 12,043 |
| Exame | 120% CDI | 12/31/2023 | 20,586 | - |
| | | | **40,072** | **13,586** |

The loan agreements between the Company and its subsidiaries generated an eliminated financial revenue of R$ 1,612 for the year ended December 31, 2021.

## Related parties - Dividends and interest on own capital receivable by the Company from its subsidiaries as of December 31, 2021 and 2020 are shown below (- 12)

| | 12/31/2021 | 12/31/2020 |
|---|---|---|
| DASA RE | 6,134 | 1,533 |
| Cientifica Lab | 4,748 | 2,416 |
| CRMI Petrópolis | - | 1,739 |
| Previlab | 6,538 | 3,373 |
| Gaspar | 20,980 | 3,108 |
| Salomão Zoppi | 5,918 | 4,662 |
| Deliberato | - | 1,004 |
| DB Genera | - | 265 |
| Valeclin | 4,488 | 1,387 |
| Cromatox | 6,260 | 1,565 |
| Impar Serviços Hospitalares | 26,228 | 30,990 |
| | **81,294** | **52,042** |

## Other receivables

Specialized medical services shared between the Company and its subsidiary Salomão and Zoppi, recorded under other receivables in the amount of R$ 40,515 (R$ 5,603 as of December 31, 2020).

## Management remuneration

Management's total remuneration was R$ 33,893 in 2021 (R$ 20,974 in 2020), including fixed remuneration and bonuses, of which R$ 5,964 in 2021 (R$ 4,875 in 2020) for members of the Board of Directors (6 members in 2021 and 6 in 2020), and R$ 27,929 in 2021 (R$ 16,099 in 2020) for statutory directors (19 statutory directors in the year 2021 and 14 statutory directors in 2020). The changes in share-based remuneration are disclosed in - 23.

As per - 23, Management is entitled to share-based payment and the book value of the program is R$ 488,916 as of December 31, 2021 (R$ 31,809 as of December 31, 2020). The cash disbursement/payment as of December 31, 2021, was R$ 111,270 (R$ 69,803 as of December 31, 2020).

There are no additional benefits for the Company's managers.

## Operations carried out between the Company and other related parties

Operations carried out between related parties are carried out at usual market values, terms and rates agreed among the parties, in effect on the respective dates and in continuity conditions.

The related parties included in the individual financial statements are as follows:

- **Link Consultoria em Medicina Diagnóstica Ltda.**: Company controlled by Ms. Alcione Moya Aprilante, quotaholder of Previlab Análises Clínicas Ltda., a subsidiary of the Company, which provides regional consulting services specialized in business management in the medical field, with market knowledge, relationships with physicians within the region where Previlab operates and recognition of potential health professionals and clients.

- **Amar Administradora de Bens Próprios Ltda.**: company owned by Dr. Alcione Moya Aprilante and his wife, Melania Angelieri Cunha Aprilante. Dr. Alcione is a quotaholder of Previlab (a corporation controlled by the Company), which rents the properties owned by AMAR that belonged to Ms. Melania Angelieri Cunha Aprilante.

- **César Antonio Biazio Sanches**: Quotaholder of Previlab Análises Clínicas Ltda., owner of the property leased by Previlab, a corporation controlled by the Company.

- **A e C Consultores Ltda.**: Company controlled by Mr. Cezar Antonio Biazio Sanches, quotaholder of Previlab Análises Clínicas Ltda., a subsidiary of the Company, which provides consulting and business advisory services in the area of Previlab's activities and consulting, instruction, training and evaluation services for Previlab's employees and its service providers.

- **Pesmed - Pesquisas e Serviços Médicos Ltda.**: Company that has as partner Mr. Emerson Leandro Gasparetto, executive medical director of the Company (elected on March 26, 2012) and his wife, also a medical professional, Dr. Taisa Pallu Davaus Gasparetto, both remunerated for providing consultancy services in medical studies and research for the Company. The amounts are calculated based on the number of reports actually produced by Pesmed, observing the corresponding value for each type of report, according to the Company's table and pursuant to the same system adopted for the other service providers of the Company.

- **RMR Ressonância Magnética Ltda.**: Company whose partners jointly hold 80% of its equity capital, brothers of Mr. Romeu Cortês Domingues, chairman of the Company's Board of Directors (elected on April 26, 2011), which provides medical services in the area of magnetic resonance imaging for the Company. The amounts are calculated based on the revenue from the magnetic resonance imaging service and the number of reports produced by RMR, observing the corresponding value for each type of report, according to the Company's table and pursuant to the same system adopted for the other service providers of the Company.

- **Ultrascan Serviços de imagem Ltda.**: Company having as partner Mr. Eduardo Luiz Primo de Siqueira, who also owns 7.5% of Clínica de Ressonância Multi-Imagem Petrópolis Ltda., which provides medical services in the imaging area to the subsidiary Clinica de Ressonância Multi-Imagem Petrópolis Ltda. The amounts are calculated based on the revenue from the imaging service and the number of reports produced by Ultrascan, observing the corresponding value for each type of report, according to the table of the subsidiary and observing the same system adopted for the other service providers of the subsidiary.

- **ECRD - Serviços Médicos de Radiologia Ltda.:** Company whose partner is Mr. Roberto Cortes Domingues, brother of Mr. Romeu Cortês Domingues, chairman of the Company's Board of Directors, which provides medical services in the area of magnetic resonance and radiology to the Company.

- **PTR 7 Investimentos Imobiliários Ltda.:** A company that has properties leased with the Company and its subsidiaries, having as direct shareholder Mr. Pedro de Godoy Bueno, shareholder of the Company and Chief Executive Office, and having as indirect shareholders, Ms. Camilla de Godoy Bueno Grossi and Ms. Dulce Pugliese de Godoy Bueno, shareholders of the Company.

- **Ecolimp Sistemas de Serviços Ltda.:** Company that provides cleaning and conservation services for the Company, controlled by Mr. Rodolpho Ricci, cousin of the Company's CEO, Mr. Pedro de Godoy Bueno.

- **Conexa Saúde Serviços Médicos Ltda.:** The service provider company has Mr. Fernando Domingues as its controlling shareholder, son of Mr. Romeu Cortês Domingues, chairman of the Company's Board of Directors.

- **BFL Empreendimentos Imobiliários Ltda.:** Company controlled by Mr. Romeu Cortês Domingues, chairman of the Company's Board of Directors, which has a property lease agreement with the Company.

- **Seven Seas Partner - Saúde e Prevenção Ltda.-ME:** Franchisee of the Company, controlled by Mr. Romeu Cortês Domingues, chairman of the Board of Directors of the Company, which maintains a service contract

- **VIDA - Posto de Coleta Ltda.:** Franchisee of the Company, controlled by Dr. Natasha Slhessarenko Fraife Barreto, medical director of the Company, which maintains a franchise agreement.

- **Localiza Rent a Car S.A.**: Company that provides car rental services to the Company, having Mr. Pedro de Godoy Bueno as Board Member, shareholder and Chief Executive Officer.

- **EDAN Serviços De Coleta Ltda.**: Franchisee of the Company, controlled by Mr. Danilo Rodrigues, husband of Dr. Claudia Cohn, director of the Company, which maintains a franchise agreement.

- **Essijota Serviços de Coleta e Diagnósticos Ltda.**: Franchisee of the Company, controlled by Mr. Sérgio Jr, cousin of Mr. Pedro de Godoy Bueno, CEO, who has a franchise agreement.

- **Signo Properties Investimentos Imobiliários Ltda.:** A company that has properties leased with the Company and its subsidiaries, having as direct shareholder Mr. Pedro de Godoy Bueno, shareholder of the Company and Chief Executive Office, and having as indirect shareholders, Ms. Camilla de Godoy Bueno Grossi and Ms. Dulce Pugliese de Godoy Bueno, shareholders of the Company.

- **Patrys Investimentos Imobiliários Ltda.:** A company that has properties leased with the Company and its subsidiaries, having as direct shareholder Mr. Pedro de Godoy Bueno, shareholder of the Company and Chief Executive Office, and having as indirect shareholders, Ms. Camilla de Godoy Bueno Grossi and Ms. Dulce Pugliese de Godoy Bueno, shareholders of the Company.

- **Fundo de Investimento em Participações Genoma III - Multiestratégia:** Controlling shareholder of the Company's subsidiary until January 2020.

- **Socec Serviços Médicos SS Ltda.:** A company which has properties leased with the Company and its subsidiaries, having Mr. George Schahin as shareholder and board member of the subsidiary of the Company.

- **José de Oliveira Domingos**: Estate of Mr. José, represented in the form of Mr. Romeu Cortês Domingues, Chairman of the Board of Directors of the Company, owns property leased to the Company.

- **CM Hospitalar S.A.**: Company that provides hospital services to the Company and its subsidiaries, having Mr. Pedro de Godoy Bueno as the Company's shareholder and Chief Executive Officer.

The following are the amounts of the operations carried out with the above companies:

| | Assets (Liabilities) Balances on 12/31/2021 | | | Assets (Liabilities) Balances on 12/31/2020 | | |
|---|---|---|---|---|---|---|
| | Services | Rentals | Other | Services | Rentals | Other |
| Link Consult. em Medicina Diag. Ltda. | (16) | - | - | (16) | - | - |
| Amar Admin. de Bens Próprios Ltda. | - | (37) | - | - | (33) | - |
| César Antonio Biazio Sanches | - | (8) | - | - | (8) | - |
| A e C Consultores Ltda. | (16) | - | - | (23) | - | - |
| PTR7 Investimentos Imobiliários Ltda. | - | (1,718) | - | - | (1,374) | - |
| Ecolimp Sistemas de Serviços Ltda. | (3,923) | - | - | (4,638) | - | - |
| Fundo de Invest. em Particip. Genoma - Dividends | - | - | (4,897) | - | - | (46,761) |
| Patrys Investimentos Imobiliários Ltda. | - | (3,474) | - | - | (6,378) | - |
| Socec Empreendimentos Imobiliários Ltda. | - | (392) | - | - | - | - |
| BFL Empreendimentos Imobiliários Ltda. | - | (183) | - | - | (175) | - |
| Seven Seas Partner Saúde e Prev. Ltda. | (92) | - | - | (121) | - | - |
| VIDA - Posto de Coleta Ltda. | - | - | - | (83) | - | - |
| Conexa Saúde Serviços Médicos Ltda. | (242) | - | - | (100) | - | - |
| Localiza Rent a Car S.A. | - | - | - | (3) | - | - |
| José de Oliveira Domingues | - | (19) | - | - | (15) | - |
| CM Hospitalar | (8,594) | - | - | (7,860) | - | - |

| | Revenues (expenses) - 12/31/2021 | | | Revenues (expenses) - 12/31/2020 | | |
|---|---|---|---|---|---|---|
| | **Services** | **Rentals** | **Other** | **Services** | **Rentals** | **Other** |
| Link Consult. em Medicina Diag. Ltda. | (256) | - | - | (256) | - | - |
| Amar Admin. de Bens Próprios Ltda. | - | (422) | - | - | (389) | - |
| César Antonio Biazio Sanches | - | (94) | - | - | (104) | - |
| A e C Consultores Ltda. | 276 | - | - | (328) | - | - |
| Pesmed - Pesq. e Serv. Médicos Ltda. | (599) | - | - | (698) | - | - |
| RMR Ressonância Magnética Ltda. | (2,250) | - | - | (2,158) | - | - |
| Ultrascan Serviços de imagem Ltda. | (68) | - | - | (110) | - | - |
| ECRD Serv. Médicos de Radiologia Ltda. | (2,605) | - | - | (2,475) | - | - |
| PTR7 Investimentos Imobiliários Ltda. | - | (21,123) | - | - | (16,749) | - |
| Patrys Investimentos Imobiliários Ltda. | - | (91,821) | - | - | (79,767) | - |
| Ecolimp Sistemas de Serviços Ltda. | (47,057) | - | - | (87,542) | - | - |
| Esho Empresa de Serviços | - | - | - | (130) | - | - |
| Socec Empreendimentos Imobiliários Ltda. | - | (3,516) | - | - | - | - |
| Signo Properties Invest. Imobiliários Ltda. | (103) | - | - | (375) | - | - |
| BFL Empreendimentos Imobiliários Ltda. | - | (2,190) | - | - | (2,088) | - |
| Seven Seas Partner Saúde e Prev. Ltda. | (1,097) | - | - | (946) | - | - |
| VIDA - Posto de Coleta Ltda. | (1,286) | - | - | (1,203) | - | - |
| Conexa Saúde Serviços Médicos Ltda. | (1,994) | - | - | (514) | - | - |
| Localiza Rent a Car S.A. | (34) | - | - | (254) | - | - |
| EDAN Serviços de Coleta Ltda. | (2,320) | - | - | (1,608) | - | - |
| Essijota Serv. de Coleta e Diag. Ltda. | (607) | - | - | (463) | - | - |
| José de Oliveira Domingues | - | (220) | - | - | (181) | - |
| CM Hospitalar | (50,355) | - | - | (34,057) | - | - |

# 34 Insurance coverage

As of December 31, 2021, the total insurance coverage was R$ 8,765,900, and R$ 2,118,114 for loss of profits, R$ 6,484,186 for property damage and R$ 13,600 for professional civil liability and R$ 150,000 for Directors & Officers (D&O).

# 35 Subsequent events

## Acquisition of subsidiary - Clínica AMO

The acquisition of 100% of the capital of Paquetá Participações S.A. and 100% of the capital of AMO Participações S.A., legitimate holders and sole holders, jointly, of the voting capital of GEM Assistência Médica Especializada S.A. was approved at the Board of Directors' meeting held on June 30, 2021, for R$ 750,000. The company's corporate purpose is to act in the provision of oncology services (chemotherapy treatment, including outpatient procedures and examinations, medical consultations related to oncology care lines, oncology outpatient treatment, and oncology surgeries) in the States of Bahia, Sergipe, and Rio Grande do Norte.

On January 3, 2022, the Acquisition of Clínica AMO was completed, through the implementation of the closing acts provided for in the Agreement. As consideration for the closing of the Acquisition, the Company reinforces the obligation to pay the sellers the amount of approximately R$ 760,000, which represents the market value of all the shares of the Companies, plus their indebtedness, discounting the value of their cash and financial investments, and the total indicative amount of the business was updated in accordance with the terms of the Agreement.

### Acquisition of subsidiary - Marimed Serviços Médicos ("Hospital Paraná")

On July 9, 2021, the acquisition of up to 100% (one hundred percent) of the shares representing the total capital of Marimed Serviços Médicos S.A. ("Hospital Paraná"), a joint-stock company, was approved.

On March 15, 2022, the Acquisition of Hospital Paraná was completed, through the implementation of the closing acts provided for in the Agreement. As a result of the closing of the Transaction, Ímpar undertook to pay, in cash, the amount of R$ 208,000, of which 70% (seventy percent) will be paid upon closing of the Transaction, while the remaining 30% (thirty percent) will make up the withheld portion.

The Company also informs that the price of the Transaction is subject to adjustment based on the change in the net debt of Hospital Paraná and that the payment of the remaining portion of the price (withheld portion) is subject to other conditions usual in this type of transaction, among which, the absence of indemnifiable losses, under the terms of the Share Purchase Agreement and Other Covenants.

Pursuant to the CVM/SEP Annual Circular Letter 2022, of February 24, 2022, the Company clarifies to its shareholders and the market in general that article nº 256 of Law nº 6,404/76 does not apply to the Transaction.

Finally, the Company emphasizes that the Transaction is in line with its expansion plans, as well as reiterates its commitment to keep shareholders and the market in general informed about the progress of the Transaction and any other matter of interest to the market.

### Acquisition of MO Holding and Mantris

On November 18, 2021, Dasa Group announced the acquisition, carried out by the Company, of shares representing 100% of the total capital of MO Holding S.A., a joint-stock company, and shares representing 100% of the total capital of Matris – Gestão em Saúde Corporativa Ltda., a limited liability company. Mantris develops services related to occupational medicine and integrated health management, while MO Holding is a pure holding company that holds a majority stake in Mantris' total capital.

The conclusion of the Acquisition is subject, among other conditions established in accordance with market practices for similar operations, to approval by Brazilian antitrust authorities.

The Company clarifies that after compliance with the precedent conditions and applicable approvals, if the appraisal report concludes that the Acquisition must be submitted for ratification by the shareholders, the General Meeting will be convened in due course by the Company's management, pursuant to article nº 256 of Law nº 6,404 /76.

Finally, the Company emphasizes that the Acquisition is in line with its expansion plans, as well as reiterating its commitment to keep shareholders and the market in general informed about the progress of this matter.

## Capital increase

On January 31, 2022, Dasa Group communicated to its shareholders and the market in general the approval by the Board, unanimously and without any qualifications or restrictions, of the capital increase, within the limit of the authorized capital, in the total amount of R$ 1.03, with the consequent issuance of 67,384 new registered book-entry common shares with no par value, fully subscribed and paid in on this date, in accordance with the subscription bulletins that are filed at the Company's headquarters. In view of the aforementioned capital increase, the Company's capital stock increased from R$ 16,359,198,783.91, divided by 560,510,880 common shares, all nominative, book-entry and with no par value, to R$ 16,359,198,784.94, divided into 560,578,264 common shares, all nominative, book-entry and with no par value.

## Issuance of commercial -

On February 15, 2022, the Dasa Group announced to its shareholders and to the market in general that it had raised funds through the 1st issuance for public distribution with restricted placement efforts of single-series Registered Commercial -s in the total amount of R$ 2,000,000,000.00, pursuant to Law nº 14,195 and the Brazilian Securities and Exchange Commission ("CVM") Instruction nº 476, of January 16, 2009, as amended ("Offer" and "CVM Instruction nº 476", respectively).

Compensatory interest will be levied on the Unit Par Value, corresponding to accumulated change of 100% (one hundred percent) of average daily rate of DI - Interbank Deposits of one day, "over extra group", expressed as a percentage per year, with basis of 252 (two hundred and fifty-two) Business Days, calculated and published by B3 S.A. – Brasil, Bolsa, Balcão, in the Daily Newsletter available on its website (http://www.b3.com.br) ("DI Rate") plus a surcharge ("Spread") of 1.50% per annum, calculated exponentially and cumulatively on a pro rata temporis basis per elapsed Business Days, from Issuance Date or from Remuneration Payment Date.

Due remuneration will be paid in 4 (four) installments according to dates provided for in the Issuance Term (each, a "Remuneration Payment Date"), except in the cases of early redemption and early maturity of Registered Commercial -s to be provided for in the Issuance Term.

Net funds obtained through the Issuance will be exclusively and fully used by the Company for the ordinary management of the Company’s business and to strengthen working capital.

*        *        *

| | |
|---|---|
| Pedro de Godoy Bueno<br>President | Felipe da Silva Guimarães<br>Chief Financial and Administrative Officer |

Alexandre de Castro Custódio
Controllership Manager
CRC 1SP224538/O-0

## Audit Committee Opinion

DASA's Audit Committee, exercising its legal duties and responsibilities, as provided for in its own Internal Regulations and in compliance with legal provisions, reviewed individual and consolidated Financial Statements as of December 31, 2021, accompanied by the Management Report and unqualified Independent Auditors' Report of KPMG Auditores Independentes.

Based on reviewed documents and on information provided by the Company's Management and Independent Auditors, the Audit Committee Members consider that such documents properly reflect, in all material respects, the financial position of DASA and its subsidiaries for year ended December 31, 2021. In this sense, the Audit Committee decided to recommend to the Board of Directors to approve the aforementioned Financial Statements and their submission to the Shareholders' Annual Meeting, in accordance with the Brazilian Corporate Law.

Barueri, March 25, 2022.

José Ronaldo Vilela Rezende

Viviane Pinto Mendes

Romeu Cortes Domingues

* * *

## Statement of the Executive Officers on the Financial Statements

In compliance with the provisions found in article 25 of CVM Instruction 480/09 dated December 7, 2009, Senior Management represents that it has reviewed, discussed and agreed with the Financial Statements (Parent company and Consolidated) for the year ended December 31, 2021.

Barueri, March 28, 2022

President - Pedro de Godoy Bueno

Chief Financial and Administrative Officer - Felipe da Silva Guimarães

* * *

## Statement of the Executive Officers on the Independent Auditor's Report

In compliance with the provisions found in article 25 of CVM Instruction 480/09 dated December 7, 2009, Senior Management represents that it has discussed, reviewed, and agreed with the opinion by the Independent Auditors dated March 28, 2022 related to the Financial Statements (Parent Company and Consolidated) for the year ended December 31, 2021.

Barueri, March 28, 2022.

President - Pedro de Godoy Bueno

Felipe da Silva Guimarães - Chief Financial and Administrative Officer

* * *